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Towards the design and synthesis of small molecule antagonists of nuclear 
receptor liver receptor homologue-1 
             Jullien Rey 
Abstract 
 
Nuclear receptors (NRs) are a large family of mammalian transcription factors that 
have the particularity of binding directly to DNA and regulating the expression of 
adjacent genes. Liver receptor homologue-1 (LRH-1) is a NR from the subfamily 5 
(steroidogenic factor-like) and plays a prominent role in development, reverse 
cholesterol transport, bile-acid homeostasis and steroidogenesis, as well as being 
implicated in the control of aromatase expression. In addition, Ali et al. showed that 
LRH-1 acts as a key regulator of the estrogen response in breast cancer cells through 
the regulation of estrogen receptor-α (ERα) expression.  
 
As a crystal structure of LRH-1 was available, the design of new potential LRH-1 
antagonists was based on a computer-aided drug design (CADD) approach. It was 
believed that virtual agonist and antagonist analogues would bind at the same site 
within the core of the ligand-binding domain (LBD) but demonstrate different binding 
modes. Binding of an antagonist would induce a conformational change within the 
LBD of LRH-1, involving a rotation of helix 12 (H12) by direct steric clashes between 
this helix and the ligand and as a consequence, prevent co-activator recruitment. The 
LRH-1 LBD was identified as mainly hydrophobic and as one of the largest in the NR 
family. Three series of analogues have been designed. Steroid-based compounds 
bearing a challenging C-2 ether linkage were initially synthesized followed by 
analogues structurally related to anti-estrogen agents tamoxifen and 
raloxifene (Scheme 0). 
 
 
Scheme 0 – Three series of virtual LRH-1 antagonists from our CADD approach 
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FDA   Food and Drug Administration 
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g   gram 
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HAT   Histone acetyl-transferase 
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m   Multiplet 
M   Molar 
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Introduction 
 
Cancer can be viewed as a group of diseases characterized by uncontrolled cell 
division leading to growth of abnormal tissue. Global cancer rates have been 
increasing primarily due to an aging population (most people who are diagnosed with 
invasive cancer are over the age of 65) and lifestyle changes in the western world. In 
fact, 5-10% of all diagnosed cancers are due to genetic defects, whereas 90-95% can 
be attributed to the environment and lifestyle.1 The key lifestyle factors that are 
responsible for cancer are diet, tobacco, alcohol, environmental pollutants and 
radiation. 
 
Despite the enormous amount of research and rapid developments observed over the 
past 15 years, cancer continues to be the leading cause of death in economically 
developed countries and the second leading cause of death in developing countries.2 
In 2002, an estimated 6.7 million people died from cancer worldwide and more than 
10.9 million cases were diagnosed.3 A more recent study showed that an estimated 
12.7 million new cancer cases and 7.6 million cancer deaths occurred in 2008 which 
corresponds to an increase of 15% of the global mortality in a period of only 6 years.4 
Considering these statistics, there is an obvious need for vast improvements in cancer 
treatment in order to win the “war on cancer”. However, the complex nature of this 
disease and its multiple variations makes it difficult not only to detect and treat but 
also to understand.  
 
1. The hallmarks of cancer 	  
In 2000, Hanahan and Weinberg suggested that six changes at the cellular level were 
responsible for malignant growth: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death (apoptosis), enabling replicative immortality, 
inducing angiogenesis, activating invasion and metastasis (Figure 1).5 Recently, an 
updated version of this paper has been published with two new hallmarks: 
reprogramming of energy metabolism and evading immune destruction.6 
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Figure 1 - The hallmarks of cancer6 
 
1.1. Sustaining proliferative signaling 	  
Growth factors, generally identified as proteins or steroid hormones, have the 
particularity to bind to transmembrane receptors, leading to cell growth, proliferation 
and cell division. In order to enter an active proliferative state, every normal cell has 
to be stimulated by growth factors. Cancerous cells have the particularity to show 
reduced dependence on exogenous growth stimulation. In fact, tumor cells can 
synthesize their own growth factor and respond via the expression of cognate 
receptors causing cells to proliferate.7 
 
1.2. Evading growth suppressors 
 
Normal cells have the particularity to respond to antiproliferative signals such as 
soluble growth inhibitors and immobilized inhibitors attached both to the 
extracellular matrix and on the surfaces of nearby cells. Anti-growth signals can force 
cells to enter a post mitotic or quiescent state (G0) corresponding to a non-dividing 
phase, outside of the cell cycle. By ignoring anti-growth signals, cancer cells 
maintain their replicative potential leading to the formation of tumors. 
 
number and thus maintenance of normal tissue architecture and
function. Cancer cells, by deregulating these signals, become
masters of their own destinies. The enabling signals are
conveyed in large part by growth factors that bind cell-surface
receptors, typically containing intracellular tyrosine kinase
domains. The latter proceed to emit signals via branched intra-
cellular signaling pathways that regulate progression through
the cell cycle as well as cell growth (that is, increases in cell
size); often these signals influence yet other cell-biological prop-
erties, such as cell survival and energy metabolism.
Remarkably, the precise identities and sources of the prolifer-
ative signals operating within normal tissues were poorly under-
stood a decade ago and in general remain so. Moreover, we still
know relatively little about the mechanisms controlling the
release of these mitogenic signals. In part, the understanding
of these mechanisms is complicated by the fact that the growth
factor signals controlling cell number and position within tissues
are thought to be transmitted in a temporally and spatially regu-
lated fashion from one cell to its neighbors; such paracrine
signaling is difficult to access experimentally. In addition, the
bioavailability of growth factors is regulated by equestration in
the pericellular space and extracellular matrix, and by the actions
of a complex network f proteases, sulfatases, and possibly
other enzymes that liberate and activate them, apparently in
a highly specific and localized fashion.
The mitogenic signaling in cancer cells is, in contrast, better
understood (Lemmon and Schlessinger, 2010; Witsch et al.,
2010; Hynes and MacDonald, 2009; Perona, 2006). Cancer cells
can acquire the capability to sustain proliferative signaling in
a number of alternative ways: They may produce growth factor
ligands themselves, to which they can respond via the expres-
sion of cognate receptors, resulting in autocrine proliferative
stimulation. Alternatively, cancer cells may send signals to stim-
ulate normal cells within the supporting tumor-associated
stroma, which reciprocate by supplying the cancer cells with
various growth factors (Cheng et al., 2008; Bhowmick et al.,
2004). Receptor signaling can also be deregulated by elevating
the levels of receptor proteins displayed at the cancer cell
Figure 1. The Hallmarks of Cancer
This illustration encompasses the six hallmark
capabilities originally proposed in our 2000 per-
spective. The past decade has witnessed
remarkable progress toward understanding the
mechanistic underpinnings of each hallmark.
surface, rendering such cells hyperre-
sponsive to otherwise-limiting amounts
of growth factor ligand; the same
outcome can result from structural alter-
ations in the receptor molecules that
facilitate ligand-independent firing.
Growth factor independence may also
derive from the constitutive activation of
components of signaling pathways oper-
ating downstream of these receptors,
obviating the need to stimulate these
pathways by ligand-mediated receptor
activation. Given that a number of distinct downstream signaling
pathways radiate from a ligand-stimulated receptor, the activa-
tion of one or another of these downstream pathways, for
example, the one responding to the Ras signal transducer,
may only recapitulate a subset of the regulatory instructions
transmitted by an activated receptor.
Somatic Mutations Activate Additional Downstream
Pathways
High-throughput DNA sequencing analyses of cancer cell
genomes have revealed somatic mutations in certain human
tumors that predict constitutive activation of signaling circuits
usually triggered by activated growth factor receptors. Thus,
we now know that !40% of human melanomas contain
activating mutations affecting the structure of the B-Raf protein,
resulting in constitutive signaling through the Raf to mitogen-
activated protein (MAP)-kinase pathway (Davies and Samuels
2010). Similarly, mutations in the catalytic subunit of phosphoi-
nositide 3-kinase (PI3-kinase) isoforms are being detected in
an array of tumor types, which serve to hyperactivate the PI3-
kinase signaling circuitry, including its key Akt/PKB signal
transducer (Jiang and Liu, 2009; Yuan and Cantley, 2008). The
advantages to tumor cells of activating upstream (receptor)
versus downstream (transducer) signaling remain obscure, as
does the functional impact of crosstalk between the multiple
pathways radiating from growth factor receptors.
Disruptions of Negative-Feedback Mechanisms that
Attenuate Proliferative Signaling
Recent results have highlighted the importance of negative-
feedback loops that normally operate to dampen various types
of signaling and thereby ensure homeostatic regulation of the
flux of signals coursing through the intracellular circuitry (Wertz
and Dixit, 2010; Cabrita and Christofori, 2008; Amit et al.,
2007; Mosesson et al., 2008). Defects in these feedback mech-
anisms are capable of enhancing proliferative signaling. The
prototype of this type of regulation involves the Ras oncoprotein:
the oncogenic effects of Ras do not result from a hyperactivation
of its signaling powers; i stead, the oncogenic mutations
affecting ras genes compromise Ras GTPase activity, which
Cell 144, March 4, 2011 ª2011 Elsevier Inc. 647
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1.3. Resisting cell death 
 
Our immune system can detect and eliminate cells that are considered as non-self. 
Abnormalities such as DNA damage, signaling imbalance, survival factor 
insufficiency or hypoxia are generally detected by intracellular sensors that can send 
signals to initiate apoptosis (programmed cell death).8 Resistance to apoptosis by 
cancer cells can be acquired by two main pathways: cells must disable the effectors of 
apoptosis or the receptors that trigger them. For example, a mutation of the p53 tumor 
suppressor gene, a key component in DNA damage detection, has been observed in 
more than 50% of human cancers. This mutation causes cancer cells to ignore 
apoptosis signals.9 
 
1.4. Enabling replicative immortality 
 
Hayflick et al. showed that, in culture, human cells are limited to 60-70 divisions 
before they stop growing, a process named senescence.10 Then cells either age or self-
destruct. This arises from the inability of DNA polymerase to replicate chromosomes 
completely. During the duplication step, loss of telomeric DNA from the end of every 
chromosome leads to generation of unprotected DNA that can fuse together. Under 
these end-to-end chromosomal fusion conditions, the cell dies quickly.11 However, 
cancer cells could acquire limitless replicative potential, making them “immortal”. In 
cancerous cells, the upregulation of the telomerase enzyme expression can lead to an 
extension at the end of telomeric DNA.12a Telomeres can also be lengthened through 
recombination.12b 
 
1.5. Inducing angiogenesis 
 
Angiogenesis, which consists of the growth of new blood vessels from pre-existing 
vessels, is a vital process in growth and development. Its importance in tumorigenenis 
has been well studied in the past and led to the development of new angiogenesis 
inhibitors.13 In fact, cells cannot survive at distances greater than 100 µm from blood 
supply. Angiogenesis is regulated by a large number of signaling proteins that can 
either stimulate (vascular endothelial growth factor (VEGF)) or inhibit 
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(thrombospondin (TSP)) cell-surface receptors of vascular endothelial cells.14 Cancer 
cells have the particularity of over-producing inducers and/or lacking inhibitors. 
 
1.6. Activating invasion and metastasis 
 
Cancer cells can escape the primary tumor mass and spread to new locations in the 
body. Sporn et al. showed that metastases are responsible for around 90% of all 
human cancer deaths.15 Once cancer cells have decoupled themselves from 
surrounding tissue, they can circulate through the body via blood and lymphatic 
vessels. With the apparition of secondary tumors, it then becomes very difficult to 
treat multiple cancers. 
 
With these two reviews, Hanahan and Weinberg have published an amazing piece of 
work regarding the causes of cancer at the cellular level. It has been widely used and 
referenced in other research papers. It gives us a better understanding of the different 
pathways leading to cancer even though there is still a lot to learn about this disease.  
 
Many pharmaceutical companies and academic groups are working together to 
identify and develop new drugs. However, their task is becoming more and more 
difficult as druggable targets represent only 5% of the human genome.16 In addition, 
working on a druggable target doesn’t necessarily mean that a new drug will be 
designed and synthesized. New problems are generally emerging along the way: 
capital/economics, toxicology, potency etc. It has been extensively documented that 
Nature, especially plant products, plays an important role in the health care systems 
of many tribes as well as in developed countries. For instance, the World Health 
Organization has estimated that approximately 65% of the world’s population relies 
mainly on plant-derived medicines for their primary health care.17 Considering this, 
many researchers are focusing on the design of plant derived natural products for the 
development of new drug candidates such as anti-cancer agents. 
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2. Natural products and the development of new anti-cancer agents 	  
Plants have a long history of therapeutic use against cancer and a wide spectrum of 
diseases. Throughout the ages, many civilizations have developed sophisticated 
medicine systems based on plants and plants extracts.18 With the techniques and 
screening assays that we now have at our disposal, many anti-cancer agents have 
been identified through the screening of these traditional medicines. 
  
2.1. Plant-derived traditional medicine and anti-cancer agents 	  
Alkaloids vinblastine (1) and vincristine (2) were the first two plant-derived 
compounds to advance to clinical use (Scheme 1). These two natural products were 
isolated from the Madagascar periwinkle plant, which was used as a diabetes 
treatment by many cultures.19 Additional studies showed that this plant could also 
decrease the number of white blood cells. This finding led to the isolation of 1 and 2, 
which are effective against cancers of the white blood cells such as lymphoma. 	  
Extensive studies also led to the discovery of etoposide (3), a semi-synthetic anti-
cancer agent derived from podophyllotoxin (4). The latter was identified as the active 
component of the Podophyllum peltatum Linnaeus used for the treatment of skin 
cancers and warts.20  
 
Finally, flavopiridol (5) has been designed from the natural product rohitukine (6), 
isolated in the early 1990s and proved to be responsible for anti-inflammatory 
and immunomodulatory activity. Flavopiridol has tyrosine kinase activity associated 
with a potent growth inhibitory activity against many breast and lung cancer cell 
lines.21 
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Scheme 1 – Anti-cancer agents derived from natural products found in traditional 
plant medicine treatment 
 
2.2. Role of nature in drug discovery 
 
With the rapid development of techniques such as high-throughput screening (HTS) 
and computer-aided drug design (CADD) in the 1990s and early 2000s, many 
pharmaceutical companies have been focusing on the development of nature-derived 
and inspired molecules as potential leads for a wide range of cancer targets. In 2007, 
Newman and Cragg published an interesting paper covering the different sources of 
drugs for the period 1981 to 2006.22 In this analysis, 974 small molecule drugs were 
taken into account and these compounds were classified as N (unmodified natural 
product); ND (modified natural product); S (synthetic compound with no natural 
product conception); S/NM (synthetic compound showing competitive inhibition of 
the natural product substrate); S* (synthetic compound with a natural product 
pharmacophore); and S*/NM (synthetic compound with a natural product 
pharmacophore showing competitive inhibition of the natural product substrate) 
(Figure 2). The proportion of compounds unrelated to natural products was 37%. 
However, in considering only the cancer treatment area, this figure drops to 20.2% 
meaning that Nature is an important source of new anti-cancer drug agents. 
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Figure 2 – Classification of small molecule drugs between 1981 and 200622 
 
Some people still believe that focusing on natural products for cancer treatment is a 
risky challenge as these compounds are very often produced in trace quantities 
making their availability limited. Their structural complexity can also be a major 
issue. However, advances in genomic mining and the engineering of biosynthetic 
pathways have revolutionized the discovery of novel natural products. These methods 
can also enable large-scale synthesis of natural products in the native or engineered 
organisms. In addition, the isolated natural product won’t necessary be the actual 
drug candidate used for the treatment of the targeted disease. Recent advances in 
combinatorial chemistry/biosynthesis and synthetic methodology have allowed 
chemists to extensively modify the natural product via structure-activity relationships 
(SARs) and design nature-derived compounds with optimized pharmacological 
properties. 
 
2.3. Total synthesis and ways to access complex natural products and analogues 	  
Many academic research groups are working on the development of new 
methodologies and synthetic routes that could aid the total synthesis of natural 
products. These natural products are generally carefully chosen, not only because of 
their great biological properties but also because the supply of these compounds can 
be a limiting factor in their preclinical or clinical development. The top priority of 
these synthetic groups is to focus on economically feasible synthetic strategies to 
access sufficient quantities of these natural products with excellent purity for clinical 
use. A recent example is the natural product discodermolide (7), first isolated in 1990 
from the Caribbean marine sponge Discodermia dissoluta (Scheme 2).23 The sponge 
species. For plants, this process is known as allelopathy.18,19
Similarly, microorganisms produc and excr te antimicrobial
toxins as a means of killing sensitive strains of the same or
r lated spec es.20
The cell-to-cell signaling mechanism, known as quorum-
sensing, exerted by bacteria to control their density of
population growth and biofilm formation, involves the
excretion of so-called quorum-sensing compounds. The best
studied are the acyl homoserine lactones (AHLs), with
compounds, including N-3-oxohexanoyl-l-homoserine lactone
(9; Scheme 2) and a previously unidentified furanone
boronate diester that appears to be a universal signal (10;
Scheme 2), from Vibrio fisheri being examples. These
compounds signal the activation of genes promoting viru-
lence, spore formation, biofilm formation, and other
phenomena.21,22 Very recently, another variation on inter-
ruption of Gram-negative aggregates by Gram-positive
nontoxic secondary metabolites (phenylethylamides 11 and
12; Scheme 2), by interfering with quorum-sensing, was
reported by Teasdale et al.23 This is the first time that such
compounds had been identified. In addition to such actions,
microbes can also produce simple molecules that will
disperse biofilms, as demonstrated by Davies and Marques
in late 2008 when they demonstrated that the pseudomonad
metabolite cis-2-decenoic acid was a nanomolar disrupter
of cross-kingdom biofilms.24 In addition to simple signaling
in normal settings in soils, quorum-sensing may also be one
of the causes of significant infection in long-term patients
due to the recruitment of many different microbes and the
subsequent production of resistant biofilms on in-dwelling
catheters and prosthetic devices.
Species of the cone snail genus, Conus, inject venom
composed of combinatorial libraries of several hundred
peptides to stun their prey prior to capture,25 and the venom
may also be used for defense against predators. One
component of this combinatorial mixture has been developed
as Ziconotide, a non-narcotic analgesic, currently marketed
as Prialt.26
3.2. Classical Nonmicrobial Natural Sources:
Untapped Potential
The classification and documenting of terrestrial flora have
been intensively investigated, with estimates of the number
of higher plant species ranging from 300 000 to as high as
500 000. In t rms of pharmacological and phytochemical
investigation, however, estimates are as low as 6% and 15%,
respectively.8,27,28 Furthermore, the marine environment
remains virtually unexplored as a potential source of novel
drugs,29,30 and until recently, the investigation had largely
been restricted to tropical and subtropical regions. Explora-
tion, however, has expanded to colder regions, and a recent
Scheme 1. Anti-Cancer Agents Derived from Plants Used in Traditional Medicine
Chart 1. Small Molecule New Chemical Entities 01/
1981-10/2008, By Source (N ) 1024)
Scheme 2. Secondary Metabolites in Chemical Defense and
Quorum Sensing
Impact of Natural Products on Anti-Cancer Agents Chemical Reviews, 2009, Vol. 109, No. 7 3015
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contained 0.002% of discodermolide which corresponds to 7 mg/434 g of sponge. 
After its isolation, many total syntheses have been reported in the literature providing 
enough material for clinical trials.24 
 
 
 
Scheme 2 – Discodermolide (7), a complex natural product obtained by total 
synthesis 
 
Sometimes, quantities of natural products available from total synthesis are 
insufficient for clinical trial or drug development. This is generally due to the 
compound’s challenging structure, which makes its direct access by total synthesis, 
possible but complicated (low quantities isolated at the end, high cost of the synthesis 
etc). An important example is taclitaxel (9) commonly named taxol, isolated from the 
bark of the Pacific yew tree, Taxus brevifolia. The development of this extremely 
challenging natural product has been solved by semi-synthesis from 10-
deacetylbaccatin III (8). This intermediate, available from a renewable source 
(needles of Taxus species) bears the general scaffold of taxol with many stereocenters 
already in place (Scheme 3).25 
 
 
 
Scheme 3 – Semi-synthesis of taxol (9) from key natural product 8 
 
Finally, very often, only a small part of the lead natural product may be involved in 
the appropriate drug/receptor interactions. The relevant core of the molecule that 
directly interacts with the corresponding receptor and is responsible for the 
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compound’s activity is known as the pharmacophore. The other atoms in the lead 
molecule sometimes referred to as the auxophore may be interfering with the binding 
of the pharmacophore or may just add molecular complexity to the natural product. 
Recently, the term “diverted total synthesis” (DTS) was introduced to the drug 
discovery world. This concept consists of identifying the pharmacophore of a desired 
natural product and then design and synthesis of new analogues containing this 
pharmacophore.26 This method allows medicinal chemists to access a wide range of 
compounds bearing various molecular complexity with generally improved potency 
compared to the lead natural product. One important example is the marine-derived 
anti-tumor agent halichondrin B (10) which exhibits an extremely complex chemical 
structure. However, studies have shown that only the right-hand half of this natural 
product was responsible for the potency of the molecule. DTS studies led to the 
discovery of eribulin (11), a less complex analogue of 10 with equivalent bioactivity 
but improved in vivo stability and lower toxicity (Scheme 4). This compound is 
currently in phase III clinical trials.27 
 
 
 
Scheme 4 – Discovery of eribulin (11) by diverted total synthesis 
 
It is clear that many marketed drugs and compounds on clinical trials have been 
designed and synthesized from natural sources. Considering the fact that the marine 
environment hasn’t been fully explored yet, the probability to identify new natural 
anti-tumor agents is very high. Even though many academic groups are still working 
on the total synthesis of some of these structurally complex molecules, many 
pharmaceutical companies have now decided to focus mainly on small molecules 
with low molecular weight and accessible by large-scale synthesis for the 
development and biological assessment of new drug candidates. 
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In fact, these companies have large libraries of compounds (millions for the top-
ranked companies) and the recent progresses made on HTS makes this technique 
extremely useful for the rapid identification of hit molecules regarding a desired 
target. HTS is a unique tool in drug discovery for the treatment of many diseases 
including cancer. These in vitro screens were initially developed between 1989 and 
1991 and are now carried out on 1536- or 3456-well titer plates on small amounts of 
compound. It is now possible to screen around 100,000 compounds in a day whereas 
the number of compounds assayed in a large pharmaceutical company in the early 
1990s was about 200,000 a year.28  
 
As explained earlier, cancer can potentially affect every individual and multiple 
mechanisms of action as well as possible treatments can be postulated (drug-receptor 
interaction, enzyme inhibition and inactivation, DNA-interactive agents, 
agonist/antagonist small molecules etc). In this thesis, we are going to be mainly 
focusing on the development of a potential breast cancer treatment. 
 
3. Breast cancer and anti-estrogen agents 	  
After lung cancer, female breast cancer is the second most common cancer in the 
world with an estimated 1,152,161 new cases diagnosed every year.29 Much progress 
has been made in the fight against breast cancer but it is still the leading cause of 
cancer-related deaths in women resulting in more than 410,000 deaths annually. 
Although many risk factors have been pointed out over the years, the greatest risk for 
developing female breast cancer is aging. Over the past 30 years, breast cancer 
mortality has declined in many developed countries. It is now easier to detect breast 
cancer and it is highly recommended to healthy women that screening is performed 
regularly. The assumption is that early detection can greatly improve the chances of 
recovery and survival. Screening methods include clinical and self breast exams, 
mammography, magnetic resonance imaging (MRI). Of course, many factors such as 
size of the tumor, stage etc will determine the required therapy but the most common 
treatments are surgery, drugs, radiation and immunotherapy. One particularity of this 
disease is that many breast cancers are sensitive to hormones, especially estrogen. 
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This led to the development of anti-estrogens as therapeutic agents for breast cancer 
treatment. 
 
3.1. The role of estrogen in breast cancer 
 
Although estrogen is not required for prenatal development, it plays an important role 
in postnatal development in mammals. It has been linked with the female 
reproductive organs, fertility, pregnancy, maintenance of bone density and 
cardiovascular protection. Estrogen action in different tissues is primarily regulated 
by two estrogen receptors (ERs) named ERα and ERβ. In 1998, Fisher et al. showed 
the importance of estrogen and ERs via a study based on a mouse gene knockout 
model, the aromatase gene cyp19.30 This gene encodes for the cytochrome P450 
enzyme required for estrogen biosynthesis. This resulted in animals surviving to 
adulthood but facing multiple problems such as infertility or ovarian dysfunction. 
 
In humans, mammary gland growth occurs during puberty and is dependent on high 
levels of estrogen and progesterone produced by the ovaries. Post-pubertal 
development results in cyclical increases in ductal branching, resulting in extensive 
branching in the fat pad. The ducts consist of a continuous layer of epithelial cells 
that synthesize and secrete milk components into the lumen. A second layer of 
contractile myoepithelial cells surrounds the epithelial cells and contacts the 
basement membrane. These two cell layers, together with the fibroblasts surrounding 
them, compose the ducts. Estrogen maintains the ducts and promote the dynamic 
changes in side branching that occur during the menstrual cycle.31 Most breast cancer 
types, invasive ductal carcinoma (corresponding to 80% of all breast cancer) and 
invasive lobular carcinoma (5% to 15%), come from an initial hyper proliferative 
stage. It then leads to a precancerous, in situ carcinoma stage and finally to an 
invasive breast cancer.  
 
ERα is only expressed in around 20% of mammary epithelial cells. In the presence of 
estrogen, these non-dividing cells can stimulate the growth of adjacent ERα-negative 
epithelial cells.32 Interestingly, in the vast majority (70% to 80%) of primary breast 
cancer tumors, ERα is expressed at a very high level. The growth of these tumors is 
	   24	  
also regulated by estrogen, meaning that these cancerous cells present an alteration in 
the ERα function. Considering these findings, it has been postulated that the design 
of estrogen antagonists could effectively treat breast cancer. 
 
3.2. Introduction to the Nuclear Receptor (NR) superfamily 
 
ERs were first identified in the 1960s and are members of the NR superfamily. NRs 
are a large family of mammalian transcription factors that have the particularity of 
binding directly to DNA and regulating the expression of adjacent genes. NRs 
function as molecular targets for various small lipophilic ligands including hormones 
and synthetic therapeutic agents. Many NRs have no natural ligand and are therefore, 
known as “orphan nuclear receptors”. 
 
NR activity can be controlled by three mechanisms (Figure 3): 
- Binding of a small lipophilic ligand by the receptor; 
- Covalent modification such as phosphorylation (by activation of cell-surface 
receptors or cyclin-dependent kinases); 
- Protein-protein interactions (direct contact with other transcription factors 
including NRs). 
 
 
 
Figure 3 – Three different signaling pathways that control NR activity33 
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NRs structures consist of four independent parts: the modulator domain, the DNA-
binding domain (DBD), the hinge region and the ligand-binding domain (LBD) 
(Figure 4). The modulator domain generally referred to as the A/B domain is variable 
in sequence between different NRs. It also contains a transcriptional activation 
function called AF-1, which can synergize with AF-2 to generate a more robust 
upregulation of gene expression. The DBD is the most conserved domain. It consists 
of two zinc-finger motifs unique to NRs, that target specific DNA sequences called 
hormone response elements (HRE). Like the modulator domain, the hinge region is 
also variable in length and sequence between NRs. Its primary role is to confer 
structural flexibility to the receptor. The LBD is a multifunctional domain that is 
responsible for ligand recognition, receptor dimerization and cofactor interaction. The 
LBD generally consists of 12 helices, the last one being called the C-terminal AF-2 
helix or helix 12 (H12). H12 is highly variable in sequence between various nuclear 
receptors.  
 
 
 
Figure 4 – Schematic structure of a nuclear receptor34 
 
In some cases, H12 is fixed in an active conformation, resulting in constitutive 
receptor activation. If H12 is flexible, conformational changes of this helix can be 
induced by ligand binding within the LBD. In the absence of ligand, the NR forms a 
repressive complex with histone deacetylases (HDAC) via binding of co-repressors 
(CoRs). In the case of ligand binding activation of the NR, dissociation of CoRs is 
observed, followed by recruitment of co-activators (CoAs) including histone acetyl-
transferases (HAT) and chromatin remodeling complexes (Figure 5). 
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Figure 5 – Nuclear receptor repression and activation mechanism34 
 
3.3. The development of anti-estrogens and their application in breast cancer 
treament 	  
3.3.1. Estrogen receptors: structure and action 
 
As described in the two paragraphs above, ERs are members of the NR superfamily 
and can regulate gene expression by the direct binding of estrogen. Human ERα and 
ERβ share a similar structure with other NRs. Both ERα and ERβ DBDs are highly 
conserved with a percentage homology of 97% between these two NRs. However, 
this percentage drops to 60% when we compare their LBDs. Considering this, 
different ligands may differ in their affinity for the α and β isoforms of the ER 
resulting in a different mode of action for these two receptors (Figure 6). 
 
 
Figure 6 – Schematic structures of ERα and ERβ35 
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ERs are recruited as homodimers or heterodimers (ERα/ERβ) in order to regulate 
gene expression.36 We have already talked about the fact that ERα was expressed at a 
very high level in breast cancer tumors. Estrogen binding to ERα LBD can promote a 
conformational change that leads to CoA recruitment and gene expression. If the NR 
is not activated by hormone binding, the unliganded ER stays inactive regarding gene 
expression (Figure 7). Finally, in order to “block” the undesirable effect of estrogen 
in breast cancer cells, people started to believe that estrogen antagonists could be 
designed. These compounds would have the particularity of competing with estrogen 
binding within the LBD of ERα. Inactivation of this NR with an antagonist would 
provide a powerful tool for the treatment of breast cancer. However, estrogen also 
plays an important role in many other parts of the body. It helps maintain bone 
density, lowers cholesterol leading to a reduced risk of atherosclerosis and heart 
attacks and improves the cognitive function within the brain. Considering that, the 
development of anti-estrogens might also lead to undesirable side effects. That is 
why, the term “selective estrogen receptor modulator” (SERM) has been introduced 
to describe an anti-estrogen and its action. The ideal SERM would antagonize any 
undesirable effects of estrogen (for example in the breast) but at the same time 
preserve the estrogen action in other tissues, where it is beneficial (bone, 
cardiovascular system, brain). This led to the discovery of selective anti-estrogen 
agents such as tamoxifen and raloxifene. 
 
	   	   	  
 
 
Figure 7 – ER action or inaction35 
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3.3.2. Anti-estrogen agents and their action 
 
Tamoxifen (12), also referred to as ICI 46474 or Nolvadex, is a non-steroidal 
triphenylethylene agent used for the treatment of all stages of estrogen receptor 
positive breast cancer.37 It was discovered by ICI Pharmaceuticals, now known as 
AstraZeneca. Tamoxifen can be considered as a prodrug as it only shows little 
affinity for its target, ER. However, tamoxifen is extensively metabolized in the 
gastrointestinal tract and the liver, generating the active specie 4-hydroxytamoxifen 
(13) that exhibits excellent affinity for ER (Scheme 5). 4-Hydroxytamoxifen binds to 
the LBD of ER and competes with estrogen. Unlike estrogen that activates ER 
leading to CoA recruitment, DNA binding and gene expression, 4-hydroxytamoxifen 
acts as an antagonist of this NR and inhibit estrogen’s normal effects. Tamoxifen 
causes cells to remain in the G0 and G1 phases of the cell cycle, meaning that breast 
cancer cell growth is blocked. The World Health Organization lists tamoxifen as an 
essential drug for the treatment of breast cancer considering the fact that an estimated 
400,000 women are still alive today due to tamoxifen therapy and millions have 
benefited from this anti-cancer treatment. However, this story could have been totally 
different, as back in the 1960s, tamoxifen had initially been developed as a 
contraceptive agent. 
 
 
 
Scheme 5 – Tamoxifen (12) and its active metabolites 
 
In the 1950s, pharmaceutical companies were mainly focusing on the development of 
contraceptives and drugs capable of targeting coronary heart disease (CHD). Estrogen 
has been linked in the reduced risk of CHD in premenopausal women. After the 
menopause, estrogen is no longer synthesized in the ovary, leading to an increased 
risk of CHD. This led to the discovery of trianisylchlorethylene (15), an orally active 
estrogen agent, and triparanol (16), a lipid-lowering drug (Scheme 6). However, 
triparanol was rapidly linked to acute cataract formation and this led to the 
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withdrawal of the medicine.38 Considering their structural similarities to triparanol 
and trianisylchlorethylene, ethamoxytriphetol (17) and clomiphene (18) were also 
tested in cardiovascular and endocrinology programs. Interestingly, 
ethamoxytriphetol showed no estrogenic activity but was reported as the first non-
steroidal anti-estrogen agent.39 At that time, the link between ovarian hormones 
(estrogen) and the development of breast cancer was already known but these 
compounds proved to be too toxic for clinical use and the market for the treatment of 
breast cancer was relatively modest. 
 
 
 
Scheme 6 – Triphenylethylene compounds and analogues 
 
Despite this toxicity issue, ICI Pharmaceuticals was still interested in the 
development and pharmacology of triphenylethylene analogues as potential 
contraceptive agents. In the 1960s, tamoxifen was discovered. At that time, members 
of ICI Pharmaceuticals showed an interest in oncology and included coverage of the 
“control of hormone-dependent tumors” in the patent on tamoxifen. Clinical studies 
from the early 1970s associated to low toxicity compared to compounds such as 
triparanol, ethamoxytriphetol and clomiphene presented tamoxifen as a potential anti-
cancer agent.  
 
Over the years, V. Craig Jordan published extensive work on tamoxifen and he also 
developed ER assays and dimethylbenzanthracene (DMBA)-induced rat mammary 
cancer model of estrogen-regulated breast cancer. He showed that 4-
hydroxytamoxifen has a high affinity for ERα and that it inhibits the growth of ERα-
positive breast cancer cell lines by competing with estradiol binding.40,41 In addition, 
it displays antitumor properties in the DMBA assay.42 Tamoxifen was also evaluated 
for its effectiveness as an adjuvant. One-year treatment showed a reduction in 
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recurrence and improved survival, five-year treatment led to a 50% reduction of 
recurrence and the breast cancer mortality rate was divided by three. Treatment for 
more than five years did not improve the rate of survival or recurrence but an increase 
of side effects started to appear (endometrial cancer). Clinical trials were also 
initiated in order to assess the potential of tamoxifen in prevention, for women at high 
risk of breast cancer. This showed a 38% reduction in breast cancer incidence and 
continued protection seven years following the end of treatment.43,44 
 
Tamoxifen is classified as an anti-estrogen agent and people started to believe that it 
could enhance the chance of women developing osteoporosis and increase the risk of 
CHD. However, tamoxifen behaves as a SERM. On one hand, it acts as an anti-
estrogen in breast and mammary tissue and on the other hand, it lowers the 
circulation of cholesterol and acts as an estrogenic compound in bone.45 Although 
tamoxifen has been the drug of choice for many years in endocrine therapy for breast 
cancer, pharmaceutical companies have been searching for better drugs with 
improved clinical efficacy but more importantly less side effects. In fact, due to 
tamoxifen’s partial agonist effects, women under this treatment can develop 
endometrial cancer. 
 
Raloxifene (20) is a SERM and its chemical structure clearly differs from tamoxifen 
and estradiol (19). It is used in the prevention of osteoporosis in postmenopausal 
women. In 1997, Brzozowski compared the binding mode of raloxifene and estradiol 
in ERα. Thanks to their hydroxyl groups that can make key hydrogen bonding 
interactions, both raloxifene and estradiol bind within the same region of the LBD of 
ERα but demonstrate different binding modes. Upon binding of raloxifene, ERα 
adopts an inactive conformation also referred to as the antagonist conformation 
(Figure 8).46 Under these conditions, raloxifene blocks the estrogen-induced DNA 
transcription both in the breast and endometrium.47 This finding was a clear 
improvement compared to tamoxifen treatment as a major adverse effect of 
tamoxifen was uterine cancer (endometrial cancer). In 2007, the Food and Drug 
Administration (FDA) approved raloxifene as a drug for the treatment of invasive 
breast cancer in postmenopausal women with osteoporosis and in postmenopausal 
women at high risk for invasive breast cancer. A five-year comparison treatment with 
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tamoxifen and raloxifene for women at high risk of developing breast cancer showed 
that raloxifene could reduce the incidence of breast cancer but it was not as effective 
as tamoxifen.48 However, considering the fact that raloxifene was responsible for 
fewer side effects than tamoxifen, it appeared to be a good alternative treatment 
especially to women who did not respond to tamoxifen. 
 
  
 
 
Figure 8 – Raloxifene (20) and its binding mode in ERα leading to an antagonist 
conformation of the NR (left)46 
 
Tamoxifen and raloxifene are two SERMs used in breast cancer therapy and 
prevention and they can both act as an agonist or antagonist depending on the tissue 
they are targeting. With that in mind, pharmaceutical companies became interested in 
developing new class of compounds capable of completely blocking all ER signaling 
pathways. Under these conditions, all partial agonist effects would be avoided. This 
led to the synthesis of a series of estradiol analogues, substituted at position 7 of the 
steroidal core. The first pure estrogen antagonist is referred as ICI 164,384 (21) and 
showed complete blocking of the uterotrophic action of both estradiol and tamoxifen 
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in rats.49 A new generation of analogues was then synthesized and an even more 
potent antagonist, ICI 182,780 (22) (also known as fulvestrant or faslodex), was 
discovered (Scheme 7). Faslodex exhibits a high affinity for ER and inhibits its 
activity through a specific mode of action. It blocks dimerisation and involves ER 
nuclear export and degradation. Unlike anti-estrogens structurally related to 
tamoxifen, faslodex can help get around resistance to tamoxifen treatment. For 
instance, in phase III clinical trials, faslodex has shown partial to complete response 
in 19% of women with advanced breast cancer whose tumors showed no response to 
tamoxifen.50 In postmenopausal women with advanced breast cancer, faslodex 
represents a good alternative option when cancer progresses following anti-estrogen 
therapy. 
 
 
 
Scheme 7 – Pure estrogen antagonists 
 
In this section, we have shown that ERα was generally over expressed in the majority 
of breast cancer cells. For many years, pharmaceutical companies have tried to design 
anti-estrogen agents capable of inhibiting the ER action, leading to the development 
of breast cancer drug treatments. Back in the 1960s, tamoxifen was first synthesized 
as a contraceptive agent. However, its unique anti-estrogenic properties were pointed 
out in many clinical trials and considering the fact that at the beginning of the 1980s, 
there was a real need for breast cancer drug development, tamoxifen rapidly became a 
successful drug for breast cancer treatment. Tamoxifen also possesses “estrogen-like” 
properties and with long-term use, it is responsible for the formation of undesired 
side effects including development of endometrial cancer. In order to tackle this, new 
SERMs such as raloxifene were discovered. The main goal was the design of 
compounds as effective as tamoxifen but with fewer side effects. Tamoxifen and 
raloxifene both bind to the LBD of ERα and disrupt H12, involving a conformation 
change of this NR. Under these conditions, ERα takes an inactive conformation, 
preventing CoA recruitment. Pure anti-estrogen agents such as the steroidal agent 
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faslodex were also developed. This compound is an ER antagonist that downregulates 
ER via a different mode of action compared to tamoxifen and has no agonist effects. 
However, resistance to all these therapies is common and people started to work on 
the identification of new molecular targets for breast cancer treatment. Recently, Ali 
et al. identified the NR liver receptor homolog-1 (LRH-1) as a key regulator of the 
estrogen response in breast cancer cells through the regulation of ER expression.51 
 
4. Liver receptor homologue-1 and its possible role in breast cancer 
therapy 	  
LRH-1 is a NR that belongs to the NR5A subfamily (also referred as Ftz-F1), which 
includes four different categories (NR5A1 to NR5A4). LRH-1 orthologs have been 
identified in several species including human (Figure 9).52 LRH-1 shows structure 
similarities with the NR steroidogenic factor-1 (SF-1) that is expressed in steroigenic 
tissues and the hypothalamo-pituitary-adrenal axis. This NR has been well studied in 
the past and is implicated in the control and differentiation of steroidogenic tissues, 
steroidogenesis and sexual determination.53 
 
 
 
Figure 9 – The NR5A subfamily of NRs54 
q32.11 [8,9]. In mice, in which an LRH-1 pseudogene has
been identified, LRH-1 maps to band E4 of chromosome 1
[14]. The human gene encoding LRH-1 gives rise to two
bands on a northern blot of 3.8 and 5.2 kb, derived from the
use of two different polyadenylation signals [13]. The region
between these 30 polyadenylation signals contains a repeti-
tiveAUUUAmotif that negatively affectsmRNAstability of
the 5.2-kb transcript. The 5.2-kb transcript is the only form
observed inadult liver [1,9,10],whereasanadditional3.8-kb
transcript is expressed in the hepatoma cell line HepG2 [9].
Figure 1. Liver receptor homolog-1 (LRH-1) and the NR5A subfamily of nuclear receptor (NRs). (a) Canonical structure of a generic NR (top) and amino acid alignment of
selected members of the NR5A NR subfamily (bottom). The location of the Ftz-F1 box between the C and DE domains and the percentage identity are indicated. Abbrevi-
ation: SF1, steroidogenic factor-1. (b) Phylogenetic tree of the NR5A subgroup of NRs. The complete amino acid sequences of NR5A family members were aligned and phy-
logenetic analyses were carried out using the CLUSTAL X program [83]. GenBank accession numbers of Ftz-F1 members are indicated between brackets: zebrafish LRH-1
(GenBank accession number AAC60274), Xenopus LRH-1 (A56543), chick LRH-1 (O42101), mouse LRH-1 (S27874), rat LRH-1 (NP068510), horse LRH-1 (AAG35649), human
LRH-1 (AAD03155), frog SF-1 (BAA36789), turtle SF-1 (AAD01975), Taeniopygia guttata SF-1 (AAK97659), chick SF-1 (BAA22839), tammar wallaby SF-1 (AAK94918), human
SF-1 (AAH32501), rat SF-1 (P50569), mouse SF-1 (A40716), horse SF-1 (AAG35648), bovine SF-1 (Q04752), pig SF-1 (AAC64209), orange-spotter grouper ftz-f1 (AAQ72771),
zebrafish ff1b (AAF43283), African catfish ftz-f1b (AAG49005), African catfish ftz-f1a (AAG49004), goldfish ftz-f1 (AAM89250), Tilapia nilotica SF-1 (BAC75890), medaka
NR5A4 (BAA32394), sand shrimp ftz-f1 (AAD41899), yellow-fever mosquito ftz-f1 (AAF83207), fruitfly ftz-f1 (AAA28542), tobacco hornworm bftz-f1 (AAL50351), silk moth
ftz-f1 (BAA01745). Retinoid X receptor a (RXRa) from four different species was used as an outgroup and collapsed for simplification.
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4.1. Structure and activity of LRH-1 	  
Like other NR, the structure of LRH-1 consists of a modulator domain, a DBD, a 
hinge region and a LBD. We have previously shown that most NRs, including ERs 
(see figure 7) were binding to DNA as homodimers or heterodimers. That is not the 
case for LRH-1 and the members of the NR5A subfamily that bind DNA as 
monomers. At the end of their DBD, a specific stretch of 26 amino acids called Ftz-
F1 box is responsible for the specific DNA binding with high affinity of these NR as 
monomers (Figure 10). 
 
 
 
 
Figure 10 – Structure of LRH-1 and its specific Ftz-F1 box54 
 
The LBD of LRH-1 consists of twelve α–helical regions and contains a ligand-
binding pocket that was identified as mainly hydrophobic, with a greater surface area 
compared to other NRs such as ERα and SF-1. LRH-1 is considered as an orphan NR 
with no identified natural ligand. However, LRH-1 is constitutively active meaning 
that it doesn’t need ligand binding to be activated. Binding of bulky ligands such as 
phospholipids does not affect LRH-1 activity. In order to explain this constitutive 
activity, structural and molecular studies of LRH-1 LBD have been done. The N-
terminal region (H1, H2 and H3) of the NR5A subgroup LBD shares limited 
similarity with other NR subfamilies. In this region, LRH-1 possesses an extended 
rigid helix (H2) that confers constitutive activity by stabilizing H12 in its active 
conformation (Figure 11). Sablin et al. showed that mutation of a conserved arginine 
from H2 of LRH-1, led to a destabilization of H12 and a reduced activity of this 
NR.55 
 
q32.11 [8,9]. In mice, in which an LRH-1 pseudogene has
been identified, LRH-1 maps to band E4 of chromosome 1
[14]. The human gene encoding LRH-1 gives rise to two
bands on a northern blot of 3.8 and 5.2 kb, derived from the
use of two different polyadenylation signals [13]. The region
between these 30 polyadenylation signals contains a repeti-
tiveAUUUAmotif that negatively affectsmRNAstability of
the 5.2-kb transcript. The 5.2-kb transcript is the only form
observed inadult liver [1,9,10],whereasanadditional3.8-kb
transcript is expressed in the hepatoma cell line HepG2 [9].
Figure 1. Liver receptor homolog-1 (LRH-1) and the NR5A subfamily of nuclear receptor (NRs). (a) Canonical structure of a generic NR (top) and amino acid alignment of
selected members of the NR5A NR subfamily (bottom). The location of the Ftz-F1 box between the C and DE domains and the percentage identity are indicated. Abbrevi-
ation: SF1, steroidogenic factor-1. (b) Phylogenetic tree of the NR5A subgroup of NRs. The complete amino acid sequences of NR5A family members were aligned and phy-
logenetic analyses were carried out using the CLUSTAL X program [83]. GenBank accession numbers of Ftz-F1 members are indicated between brackets: zebrafish LRH-1
(GenBank accession number AAC60274), Xenopus LRH-1 (A56543), chick LRH-1 (O42101), mouse LRH-1 (S27874), rat LRH-1 (NP068510), horse LRH-1 (AAG35649), human
LRH-1 (AAD03155), frog SF-1 (BAA36789), turtle SF-1 (AAD01975), Taeniopygia guttata SF-1 (AAK97659), chick SF-1 (BAA22839), tammar wallaby SF-1 (AAK94918), human
SF-1 (AAH32501), rat SF-1 (P50569), mouse SF-1 (A40716), horse SF-1 (AAG35648), bovine SF-1 (Q04752), pig SF-1 (AAC64209), orange-spotter grouper ftz-f1 (AAQ72771),
zebrafish ff1b (AAF43283), African catfish ftz-f1b (AAG49005), African catfish ftz-f1a (AAG49004), goldfish ftz-f1 (AAM89250), Tilapia nilotica SF-1 (BAC75890), medaka
NR5A4 (BAA32394), sand shrimp ftz-f1 (AAD41899), yellow-fever mosquito ftz-f1 (AAF83207), fruitfly ftz-f1 (AAA28542), tobacco hornworm bftz-f1 (AAL50351), silk moth
ftz-f1 (BAA01745). Retinoid X receptor a (RXRa) from four different species was used as an outgroup and collapsed for simplification.
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Figure 11 – Structure of the LBD of mouse LRH-1 with its rigid H2 (blue) and 
H12 (green) in its active conformation55 
 
In adult mammals, LRH-1 is expressed in endodermal tissues such as the liver, 
pancreas and intestine as well as in the ovary. It plays an important role in 
development, metabolism, lipid and cholesterol absorption, bile acid homeostatis and 
steroidogenesis.54 LRH-1 has also previously been implicated in the control of 
aromatase expression leading to a regulation of estrogen biosynthesis.56 Finally, 
Annicotte et al. studied the expression and regulation of LRH-1 in several breast 
cancer cell lines. They observed an increase of LRH-1 expression in ERα expressing 
cell lines. For instance, in MCF7 cells, treatment with estradiol led to high expression 
of LRH-1. This clearly showed that LRH-1 is an estrogen-regulated gene in breast 
cancer cells.57 
 
In 2005, the structure of the LBD of LRH-1 was solved and this NR displayed 
prominent functions within the body. However, there were still many things to learn 
about this target and people started to believe that identification of synthetic ligands 
for LRH-1 would help explore even further the biology of this NR. 
 
 
been unsuccessful so far, with the exception of one report
suggesting that oxysterols could activate SF-1 [31] – a
finding that could not be confirmed in most cellular
contexts [32]. However, structural and molecular studies
of the LBD of SF-1 and LRH-1 have helped to explain their
constitutive activity. The N-terminal region of the LBD,
including H1, H2 and H3, is conserved among members of
the NR5A subgroup and shares limited sequence simi-
larity with other NR subfamilies. In contrast to ligand-
activated NRs, interaction of this N-terminal region with
the remaining part of the LBD is ligand-independent in
NR5A NRs [33]. Unequivocal evidence that ligands are
dispensable for activity has come from the crystal struc-
ture of the mouse LRH-1 LBD, which shows a stable
monomer with a large, but empty, ligand-binding pocket
[34] (Figure 3). This study showed that, despite the
presence of this large hydrophobic ligand-binding pocket,
activation is probably independent of ligands because
disruption of the size and shape of the cavity by bulky side
chains does not affect LRH-1 activity.
Although these findings do not exclude the existence of
ligands for LRH-1, they do demonstrate that they are
dispensable for basal activity. How can the absence of a
ligand, a coactivator peptide or a dimeric-receptor partner
be compatible with a stabilized active conformation of the
LBD? The crystal structure of the LRH-1 LBD, which
displays features that are strikingly different from other
LBDs, might provide an explanation. The structural
differences involve the NR5A-specific N-terminal region
of the LBD, in which the extended rigid structure of H2
forms an additional fourth layer in the canonical fold of the
receptor LBD. This additional structure confers constitu-
tive activity by stabilizing indirectly (through the exten-
sion of H2) the active position of H12, which contains AF-2
(Figure 3). This was also reflected in the reduced activity
and co-regulator recruitment seen following the mutation
of the conserved arginine (R352E) in H2 of LRH-1, which
destabilized H12 [34]. This finding is consistent with the
partial loss-of-function phenotype observed previously in
an analogous human SF-1 mutant [35], and illustrates an
alternative structural strategy for the stabilization of an
active LBD.
LRH-1 contains an intact and functional AF-2 domain.
This consists of the hexameric motif LLIEML, which is
found in most NRs and is important for stabilization of
coactivator binding. Thus, an AF-2-truncated form of
LRH-1 functions as a dominant negative protein [1,16,36].
In contrast to other NRs, no ligand-independent AF-1
function has been identified in the A/B domain of LRH-1.
Interestingly in SF-1, a potential AF-1 region has been
mapped to a domain spanning the hinge and H1 of the
LBD. This region contains a mitogen-activated protein
kinase (MAPK)-phosphorylation site at S203 [37,38]. SF-1
activation by MAPK phosphorylation involves protein
stabilization [33] and stimulates the recruitment of the
transcriptional intermediary factor 2 (TIF2 or GRIP1)
co-regulator [37]. The corresponding potential MAPK-
phosphorylation site is conserved in the hinge of LRH-1
[33], although its impact on LRH-1 activity is not yet
known. The primary sequence of LRH-1 contains several
potential consensus protein kinase (PK)A- and PKC-
phosphorylation sites, but further studies are required to
determine whether LRH-1 activity is regulated by PKA- or
PKC-signaling pathways.
Co-regulators of LRH-1
Although it seems that the binding of coactivators,
through their LXXLL motif, to the LBD of SF-1 and
LRH-1 is ligand-independent in vitro, binding affinities
are generally lower compared with ligand-dependent NRs
[34,37]. LRH-1 interacts with members of the p160
coactivator family – SRC-1 [39] and SRC-3 [40] – and
Figure 3. 3D structure of the ligand-binding domain (LBD) of mouse liver receptor homolog-1 (LRH-1). Helix (H) 12, the position of which determines the active state of a
nuclear receptor, is highlighted in green. The extended NR5A-specific H2 (blue) provides an additional layer to the canonical LBD fold and stabilizes the active position of
H12 in the LRH-1 crystal structure. The empty ligand-binding pocket is shown in gray. Figure based on the d ta from Sablin et al. [34]. Views from two opposite angles (a,b)
are shown.
(a) (b)
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4.2. Identification of small molecule agonists of LRH-1 	  
In 2006, Whitby et al. developed a series of substituted cis-bicyclo[3.3.0]oct-2-enes 
as small molecule agonists of LRH-1 and SF-1.58 Compound 27 was first identified 
from a HTS using a fluorescence resonance energy transfer (FRET)-based assay. The 
aim was the detection of an interaction between the LBD of LRH-1 and a CoA, in 
case a compound was able to activate this NR. Before starting the assay, one 
equivalent of phospholipid was added and bound to the ligand-binding pocket of 
LRH-1. Compound 27 turned out to be an extremely promising agonist with an 
EC50 = 430 nM, capable of displacing the initially bound phospholipid. 
 
Compound 27 was synthesized using a “one-pot” sequence from 1,6-enyne 23 that 
was cyclized in the presence of Negishi’s reagent (Cp2ZrBu2) to form the 
zirconacyclopentene 24. Insertion of phenyl isonitrile led to intermediate 25. Insertion 
of 4-octyne into the carbon-zirconium bond followed by protonolysis gave bicycle 
26. Under slightly acidic conditions (silica gel), the latter underwent a rearrangement 
that gave amine 27 in 53% yield (Scheme 8). Compound 27 turned out to be very 
sensitive to acidic conditions leading to rapid decomposition. In order to tackle this 
issue and try to improve the yield of the reaction, the authors treated 26 with ten 
equivalents of aniline and a catalytic amount of camphor sulfonic acid to generate 27 
that was purified by chromatography on basic alumina. However, this method didn’t 
improve the yield of the reaction even though no major decomposition was observed. 
 
 
 
Scheme 8 – One-pot tandem reaction to cis-bicyclo[3.3.0]oct-2-ene 27 
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SAR studies were then investigated. Variation (phenyl ring) of the starting material 
1,6-enyne 23 allowed the formation of analogues with various substituents at 
position 2 of the bicycle. Trapping of the intermediate 25 with different alkynes and 
alkenes led to the formation of compounds with variations at position 3. Finally, the 
introduction of a wide range of amines at position 1 was done using an alternative 
synthesis (Scheme 9). Enyne 23 was first converted to bicyclic cyclopentenone 28 
using Pauson-Khand cyclization conditions. Then, 1,2-addition of a Grignard reagent 
in the presence of cerium chloride led to tertiary alcohol 29. The latter was finally 
engaged in an acid-catalysed displacement of the alcohol with aniline to generate 
amine 30. 
 
 
 
Scheme 9 – Synthesis of cis-bicyclo[3.3.0]oct-2-ene 30 via Pauson-Khand  
cyclization 
 
Analogues such as 27 and 30 showed good biological activity against LRH-1 and SF-
1. SAR studies allowed the identification of selective compounds for these two NRs. 
However, the main issue with this series of analogues was their instability under 
acidic conditions, leading to rapid decomposition and raising doubts about the 
compounds stability during biological evaluation. Considering this, there was a clear 
need for the design and synthesis of a new class of compounds, structurally related to 
27 but stable under acidic conditions.  
  
In 2011, Whitby et al. developed a new series of compounds with comparable or 
improved binding and efficacy compared to 27.59 A co-crystal structure of 27 bound 
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to the LBD of human LRH-1 was solved, allowing the authors to point out the key 
interactions between this compound and residues from the LBD (Figure 12). The 
LBD of LRH-1 being mainly hydrophobic, no polar interactions between 27 and the 
NR were observed. However, there was a key π-stacking interaction between His390 
and the aniline moiety of 27. Considering the fact that the polar nitrogen atom did not 
seem to improve the binding of 27, the plan was to replace the acid-labile bridgehead 
anilino group by a 1-ethenyl group, making these new compounds more stable and 
easier to handle.  
 
 
 
Figure 12 – Analogue 27 co-crystallized with human LRH-159 
 
The synthesis started from the co-cyclization of enyne 31 in the presence of Negishi’s 
reagent to generate zirconacyclopentene 32. Carbenoid nHexBr2CLi, generated in 
situ, was then inserted into the carbon-zirconium bond leading to a ring expansion 
and formation of intermediate 34.60 The latter was subjected to a ring-closing 
rearrangement, induced by addition of lithiated phenylacetylene to afford 36. Finally, 
a second equivalent of lithiated phenylacetylene could add to 36 and eliminate allyl 
anion 38 and bis(alkynyl) zirconocene 39. Readdition of this allyl anion to the β-
carbon of the zirconocene would generate 40 and finally the racemic analogue 41 
after aqueous work-up (Scheme 10). 
 
2268 dx.doi.org/10.1021/jm1014296 |J. Med. Chem. 2011, 54, 2266–2281
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further SAR studies, of which 9 was most act ve (IC50 =
200 nM).41,42 At high levels (10 μM), 9 modestly suppressed
doxycycline (DOX) induced proliferation of H295R cell line
with little eﬀect on the SF-1 negative SW-13 cell line. Closely
related isoquinolines aﬀected both cell lines in a similar way,
suggesting a non-SF-1 mechanism. The SAR for these series
seems complex; for example, replacing the methoxy group in 9
with ethoxy gave a compound highly active against a range of
other receptors and exhibiting strong cell toxicity, suggesting
transactivation assay artifacts (promiscuous inhibition of the
reporter system).
Although 5 and related compounds 6 have proven to be
excellent biological probes for LRH-1 and SF-1, they have a
number of limitations.Most important is that they are unstable to
acid, making handling diﬃcult and raising doubts about stability
during biological application. The series also shows little discri-
mination between LRH-1 and SF-1. The aim of this work was
thus ﬁrst to develop new series of compounds that were more
stable and easily handled than series 6, but with at least compar-
able binding and eﬃcacy, and second to ﬁnd compounds that
were selective for LRH-1 and/or SF-1.
’COCRYSTAL STRUCTURE OF 5 WITH hLRH-1
As a basis for the design of improved analogues of 5, we solved
the cocrystal structure of compound 5 bound to the human LRH-
1 LBD (Figures 3 and 4). Although racemic 5 was used, the
1S,5R-bicyclo[3.3.0]oct-2-ene enantiomer cocrystallized with
LRH-1 LDB. Compound 5 occupied the same binding pocket
volume as the terminal 12 carbon atoms in both acyl chains of a
phospholipid bound in LRH-1.35b This smaller size permitted
LRH-1 to contract, narrowing the gap between the N-terminal
half of helix 3 (residues 338-350, yellow in the PL-bound
structure) and the β-turn/helix 6 region (residues 408-427, orange
in the PL-bound structure) where the phospholipid headgroup is
situated in the PL þ LRH-1 structure, and completely enclose
th ligand within the binding pocket. Making no polar interac-
tions with the protein, 5 was a compact, hydrophobic mass
complementing the inner surface of the binding pocket. There
was pi stacking between the His390 and the aniline of 5 with a
centroid-centroid distance of 3.8 Å and a deviation from
coplanarity of around 10!.
Figure 3. CR trace from the phospholipid35b (magenta, orange, and
yellow) and 5 (white) bound conformations of LRH-1 were super-
imposed for comparison. The pocket contracts around the smaller 5,
with the biggest shifts occurring for residues 338-350 in helix 3 (yellow)
and residues 408-427 in the β-turn and helix 6 (orange), where the
phospholipid headgroup protrudes.
Figure 4. Compound 5 is shown in the LRH-1 ligand binding pocket.
Contacting residues are indicated, along with the His390-aniline
distance. The surfac of the po ket is shown, colored by the nearest
atom type. The region of the pocket adjacent to helix 5 and the β-turn
contain polar residues and several trapped water molecules.
Figure 5. Two-dimensional compound interaction diagram depicting
adjacent residues and thepi stacking interaction withHis390. The crystal
structure is available from the RCSB with access code 3PLZ and is
further described in the Experimental Section.
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Scheme 10 – Synthesis of analogue 41 in a single pot via three-component coupling 
 
41 was tested in a FRET-based peptide recruitment assay and displayed interesting 
biological properties. It gave good binding and activation of LRH-1 and showed good 
selectivity, as this compound was inactive against SF-1. This difference in activity 
between these two NRs might be explained by the presence of the 3-hydroxypropyl 
moiety. The latter could make a hydrogen bond in the N-terminal region of helix 3 
of LRH-1 whereas this region of SF-1 is mainly hydrophobic. In comparison to 
27, analogue 41 showed improved stability towards acidic conditions but lower 
activity.  
 
The co-crystal structure between LRH-1 and 27 suggested that a new series of 
compounds could be designed, the main idea being the introduction of polar moieties 
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within the His390, Arg393 and Gln432 region of the LBD. In fact, these three 
residues were within a 5 Å distance of the ligand. The X-ray showed that the 6-exo-
position of the saturated cyclopentane ring was pointing directly towards these three 
amino acids and the synthesis of compounds with a hydroxyl group attached to this 
position was investigated. The synthesis started from acrolein 42 that was converted 
to iodoacetal 43 in two steps using the powerful electrophile Me3SiI and 
ethanol (Scheme 11).61 Nucleophilic displacement of the iodide with lithiated 
phenylacetylene followed by acetal cleavage under acidic conditions led to 
aldehyde 44 in 81% yield over 2 steps. The latter was then converted to a secondary 
alcohol by addition of vinyl magnesium bromide. Protection of this alcohol as a TBS-
silyl ether gave the desired cyclization precursor 45. The single-pot, three component 
coupling (cocylization using Negishi’s reagent, carbenoid insertion and lithiated 
phenylacetylene addition) followed by silyl group deprotection led to a racemic 
mixture of bicyclic alcohols 46 and 47 in 67% yield over 4 steps. Both endo and exo 
isomers (1:1.6 ratio) were separated by column chromatography. 
 
 
 
Scheme 11 – Synthesis of 6-hydroxyl analogues 46 and 47 (exo-endo isomers) 
 
As expected, 46 (exo isomer) showed better activity compared to 47 (endo isomer) 
probably due to the fact that the exo-hydroxyl group is within the polar region of the 
LDB of LRH-1 and can potentially make a hydrogen bond that would improve its 
binding affinity. 46 exhibits excellent properties compared to 27: stable under acidic 
conditions, similar solubility in polar solvents, improved binding and efficacy against 
LRH-1. 
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In their two papers, Whitby et al. managed to design and synthesize different classes 
of agonists of the NR LRH-1.58,59 They first described the synthesis of substituted cis-
bicyclo[3.3.0]oct-2-enes that led to the development of 27, a potent agonist that was 
co-crystallized with human LRH-1 LBD. This crystal structure allowed the 
identification of key hydrophobic interactions between 27 and the protein. A second 
generation of compounds were then developed, the main idea being the synthesis of 
acid stable agonists with similar biological activity compared to 27. With that in 
mind, the acid-labile anilino group was replaced by a 1-ethenyl group and a key 
hydroxyl group (important for binding and solubility properties) was introduced on 
the 6-exo-position of the saturated cyclopentane ring leading to potent agonist 46 
(Scheme 12). 
 
 
 
Scheme 12 – Development of a second generation of agonists of LRH-1 
 
Whitby developed agonists of LRH-1 using a high-yielding single-pot sequence 
starting from easily accessible starting materials (either commercially available or 
prepared in few steps). However, by looking in the literature, no potent antagonists of 
LRH-1 have been reported making the design of such compounds very useful and 
exciting. 
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5. Objectives of the project 
 
The main functions and properties of LRH-1 have been described earlier in this thesis 
(see Introduction § 4.1.). Professors Simak Ali and Charles Coombes from 
Hammersmith Hospital London have been studying this NR for a long time, their 
goal being the identification of a possible link between LRH-1 and breast cancer 
treatment. In 2005, by using estrogen-responsive and ER-positive MCF-7 breast 
cancer cell lines, they showed that LRH-1 was a key estrogen-regulated gene in 
breast cancer cells.62 In addition, LRH-1 down-regulation by RNAi led to reduction 
in ER expression, whilst LRH-1 agonists stimulated ER expression.51 These findings 
highlighted LRH-1 as a key regulator of estrogen response in breast cancer cells 
through the regulation of ERα expression. This suggests that inhibition of LRH-1 
could provide a powerful new approach for the treatment of breast cancer. 
Considering this, the development of small molecule antagonists of LRH-1 became 
an attractive target. 
 
The emphasis of this project was the design and synthesis of small molecule 
antagonists of LRH-1. LRH-1 seemed to be a druggable target as it can bind small 
lipophilic ligands. The development of molecules with good binding affinity for the 
LRH-1 LBD should, in principle, be capable of displacing these bound lipids and 
either activating or antagonizing this NR. In addition, Whitby already described the 
synthesis of potent agonists of LRH-1. With a crystal structure of LRH-1 available, it 
was believed that computational ligand docking studies would allow the design of 
antagonists of this NR (Figure 13).63 In order to reach that goal, we have been 
working in collaboration with the CADD group headed by Professors Jim Snyder and 
Dennis Liotta at Emory University, Atlanta, GA, USA. 
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Figure 13 – Crystal structure of LRH-1 LBD with highlighted residue Leu532 
from H12 (orange sticks) 
 
Many NRs such as SF-1, ERα or farnesoid X receptor (FXR) have already been well-
studied in the literature. Considering that, it was decided to try and identify LRH-1 
antagonists via the docking of these NRs. We first examined the differences between 
these NRs and LRH-1 and then tried to tailor a ligand for LRH-1. The starting point 
was the superimposition of LRH-1 and SF-1 as these two NRs had related structures. 
Few differences between LRH-1 and SF-1 were pointed out especially when we 
investigated two channels located at both the northern and eastern parts of the 
proteins. When we looked at the northern region of the superimposed proteins, we 
observed that a channel, called tunnel A, was partially blocked in SF-1 due to the 
presence of amino acid residues. The same observation was made for the eastern part 
of the protein where another channel was discovered (called tunnel C). However, 
interestingly, for LRH-1, both tunnels A and C were “available” and no residues 
seemed to block the virtual binding of a small molecule into these two 
tunnels (Figure 14). 
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View (a) 
 
View (b) 
 
Figure 14 – View (a) - Superimposition of LRH-1 (green) and SF-1 (grey), view 
from the top of the proteins (Tunnel A) 
View (b) - Superimposition of LRH-1 (green) and SF-1 (grey), view from the right 
hand side of the proteins (Tunnel C) 
 
Further investigations allowed the identification of the LBD of LRH-1 as mainly 
hydrophobic and as one of the largest in the NR family. Following these docking 
studies, a schematic showing the idealized spatial relationships among the channels 
surrounding the LBD of LRH-1 was postulated (Figure 15).  
Tunnel  A , SF-1 (grey), LRH-1 (green) 
Tunnel  C ,   SF-1 (grey), LRH-1 (green) 
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Figure 15 – Schematic of the LBD of LRH-1 
 
A virtual agonist or antagonist analogue would bind at the same site within the core 
of the LBD but would demonstrate different binding modes (it could take the pose A, 
C or H). However, as explained earlier, binding of an antagonist would induce a 
conformational change within the LBD of LRH-1, involving a rotation of H12 and 
preventing CoA recruitment. With that in mind, the aim was the design of 
compounds, which upon binding would take the desired pose H and produce a steric 
clash with H12 (Leu532 residue) (Figure 16). 
 
 
 
Figure 16 – Example of a ligand (green) taking the desired pose H and leading to a 
steric clash with H12 
3 
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Tunnel C Helix 12 
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shows conflict with H12 residues (e.g. Leu532, grey). 
Ligand Binding Domain (LBD) approach - Docking studies 
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Polysubstituted steroid analogues such as 48, capable of virtually acting as LRH-1 
antagonists were initially designed using molecular modeling. It was then decided to 
work on the design and synthesis of compounds structurally related to the two well-
studied anti-estrogens, tamoxifen (12) and raloxifene (20). In fact, it was believed 
that modification of these two hydrophobic compounds would generate high MW 
molecules such as 49 and 50, capable of binding to the hydrophobic LBD of LRH-1 
and therefore act as potential antagonists in case of any disruption of 
H12 (Scheme 13). 
 
 
 
Scheme 13 – Virtual antagonists initially designed from our CADD approach 
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Results and discussion 	  
1. General aspects of the computer-aided drug design approach and 
biological evaluation of the newly designed analogues 
 
1.1. General introduction to the docking experiments 
 
Back in the early twentieth century, organic chemists did not have a wide range of 
tools and techniques available for doing their research. However, the drug discovery 
process started earlier than we might believe. For example, in 1909, chemists from 
the Ehrlich laboratory discovered arsphenamine (51),64 also referred to as salvarsan, 
an organoarsenic compound considered as the first chemotherapeutic 
agent (Scheme 14). This compound was developed using a novel approach based on 
investigations and chemical modifications of a lead compound to optimize its 
biological properties leading to the synthesis of a wide range of analogues. This 
approach is now widely used in the pharmaceutical research area and referred to as 
SAR. Ehrlich’s approach proved to be a great success and arsphenamine was used as 
an anti-syphilitic agent. However, this class of compounds displayed toxic properties 
leading to many side effects and was replaced a few years later by the well-known 
antibiotic penicillin (52), discovered in 1928 by Alexander Fleming.65 
 
 
 
Scheme 14 – Two drugs used for the treatment of syphilis 
 
The post-World War II period was then marked by advances in X-ray crystallography 
techniques and the structures of complex molecules such as penicillin or vitamin B12 
were solved. Then, in the late 1950s, crystal structures of proteins began to be solved, 
starting with the structure of myoglobin.66 In the 1970s, X-ray of protein-ligand 
complexes began to emerge and rational drug discovery received enormous benefits. 
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In addition, at the same time, the rapid development of computers was also observed. 
Researchers started to believe that drug design could be facilitated if the structures of 
proteins and small ligands could be displayed on a terminal computer. The potential 
of this new technology was quickly realized and in the early 1970s, X-ray diffraction 
studies were represented on computers.67 The development of protein crystal 
structures grew exponentially and went from about 200 in 1990 to more than 75500 
by September 2011.68 
 
Considering the large number of protein crystal structures available, medicinal 
chemists from academia and pharmaceutical companies are now using virtual design 
to develop new potential drugs. It has the great advantage of being relatively 
inexpensive compared to a classic hit identification by HTS. This approach, initially 
known as structure-based drug design (SBDD), consists of the identification and 
optimization of interactions between a desired protein/ligand complex using its three-
dimensional X-ray crystallography. The resolution of the crystal structure is critical 
for the identification of accurate key protein/ligand interactions.69 A good X-ray with 
a resolution between 1.5 Å and 2 Å might reveal empty pockets or spaces that could 
be filled by ligand modification in order to increase its affinity and sometimes 
selectivity. One example is the discovery and development of the neuraminidase 
inhibitor relenza (55), used against influenza A and B infections.70 A random 
screening did not provide any potent inhibitor of the desired enzyme but 53 was 
identified as a non-selective neuraminidase ligand (Scheme 15).  
 
 
 
Scheme 15 – From inhibitor 53 to relenza (55) by SBDD 
 
When the crystal structure of the influenza A neuraminidase bound with 53 was 
solved and computationally processed,71 it became clear that the replacement of the 
4-hydroxyl group of 53 by an amine that could be protonated would generate 54, 
capable of forming electrostatic interactions with the amino acid residue Glu119. 
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Further modifications led to relenza (55), bearing a guanidinium group at position C-
4 capable of interacting with both residues Glu119 and Glu227 (Figure 17). 
 
               
 
Figure 17 – Crystal structures of 53 (a) and relenza (55) (b) bound to neuraminidase 
active site70 
 
Another technique commonly used in virtual screening is known as ligand-based drug 
design (LBDD). In this case, a large number of small molecules are virtually screened 
to determine their affinity for the protein binding pocket. The virtual screen allows 
the identification of molecules that share structural similarities or chemical 
properties. This approach may lead to the generation of lead compounds in a short 
amount of time without having to perform many synthetic modifications. 
 
Over the last twenty years, much progress has been made in drug virtual design 
leading to a new concept referred to as CADD. With the declining costs of memory 
and storage associated with the development of new powerful software and hardware 
equipment, it became easy for pharmaceutical companies and even small academic 
research groups to be equipped and use molecular modeling for drug identification 
and development.72 The main goal of CADD studies is the prediction of how a small 
molecule will bind to the protein of interest and more importantly, if it does, how 
strongly. One key challenge when using CADD software is the prediction of the 
ligand “real” docking pose. If an inhibitor has been co-crystallized with the studied 
protein and the poses of docked compounds (structurally related to the inhibitor) 
arrange in the same orientation as the known inhibitor, one can be confident in the 
docking experiment and pose prediction. If no ligand has been reported and co-
© 1993 Nature Publishing Group© 1993 Nature Publishing Group
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crystallized, the pose prediction may be less reliable. However, this approach could 
provide an enormous benefit in cases where crystal structures of the protein-ligand 
complexes are not easily obtained. 
 
As a crystal structure of LRH-1 was available from the protein data bank (see 
Figure 13, pdb code 1YOK), docking studies were performed using the program 
Maestro v9.0 (Schrödinger). All compounds were initially processed using the 
program LigPrep v2.3 (Schrödinger) to determine their least energetic conformation. 
Before performing docking studies, H12 was virtually removed from the LRH-1 
LBD. It was believed that the removal of H12 before doing our docking experiments 
and finally placing H12 back in its original position would provide valuable insight 
regarding the antagonistic properties of the compounds and their ability to display 
steric clashes with this helix. Experimental docking poses in extra precision (XP) 
were then obtained using the program Glide v5.5 (Schrödinger). Finally, to gain a 
more realistic appraisal of the poses, it was decided to use the MM-GBSA protocol as 
a rescoring function.73 The MM-GBSA function is a powerful tool that takes into 
account not only the molecular mechanics (MM) but also uses an implicit solvent 
model (GBSA) of the protein/ligand complex.74,75 
 
After careful interpretations of our docking experiments, a selection of the best 
virtual LRH-1 antagonists were synthesized and then assayed to determine their 
biological properties towards LRH-1. The biology of this project was carried out by 
Fiona Kyle under the supervision of Professors Simak Ali and Charles Coombes, 
Department of Oncology, Hammersmith Hospital, Imperial College London, UK. 
 
1.2. General introduction to the assays used to test our analogues 	  
Freshly prepared analogues were tested in an in vitro assay using the AlphaScreen™ 
(Amplified Luminescent Proximity Homogenous Assay) technology. It consists of 
studying the biomolecular interactions between two beads called “donor bead” and 
“acceptor bead”. In order to minimize the non-specific binding and self-aggregation, 
both bead types are generally coated with a hydrogel. The donor beads contain a 
photosensitizer, which upon activation with light at 680 nM can convert ambient 
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oxygen to excited singlet-state oxygen molecules. Upon specific biological 
interactions, both bead types come in close proximity and the excited oxygen is 
transferred to the acceptor beads leading to a fluorescence cascade at 520-620 nM.76 
For example, this assay proved to be an extremely useful tool for the biological 
evaluation of peroxisome proliferator-activated receptor-α (PPARα) antagonists.77 
 
In our in vitro AlphaScreen™ assay, the donor beads were initially coated with 
streptavidin and attached to a biotinylated LRH-1 CoA peptide. The acceptor beads, 
bearing a nickel chelate coating, were attached to a polyhistidine-tagged LRH-1 LBD 
protein. LRH-1 is a constitutively active NR meaning that without the presence of 
ligand, this AlphaScreen™ assay will display constant fluorescence. Upon binding of 
a small molecule agonist, the binding between LRH-1 LBD (acceptor bead) and CoA 
(donor bead) should be emphasized  (Figure 18). 
 
 
 
Figure 18 – Activation of the assay by agonist binding 
 
Binding of an antagonist to the LRH-1 LBD would generate an inactive conformation 
that would prevent CoA recruitment and both beads to interact (Figure 19). 
 
 
 
Figure 19 – Deactivation of the assay by antagonist binding 
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Preliminary investigations have also been made regarding our compounds activity in 
vivo. A cell based dual reporter gene assay has been developed and a few compounds 
were tested. This approach consists of creating a gene fusion between LRH-1 binding 
sites and a reporter gene (luciferase gene used for our studies). Activation of the 
LRH-1 protein by a small molecule agonist would induce the protein to bind to the 
LRH-1 binding sites within the fused gene. Transcription to a single messenger RNA 
(mRNA) followed by translation to the desired luciferase protein (LUC) would then 
occur. In the presence of luciferin in the cellular media, the luciferase can catalyse the 
oxidation of luciferin to oxyluciferin and produce light during the 
process (Figure 20). If an antagonist binds within the LRH-1 LBD, the protein adopts 
an inactive conformation that fails to bind to the fused gene. Under these conditions, 
the luciferase protein is not produced and the oxidation step cannot be catalysed (the 
luciferin oxidation in extremely slow without the presence of catalyst). 
 
 
 
Figure 20 – Cell based dual reporter gene assay 
 
In this section, the general aspects of the CADD approach used to identify potential 
small molecule antagonists of LRH-1 have been reviewed. The techniques developed 
to biologically assay (both in vitro and in vivo) these molecules have also been 
introduced. In the next chapter of this thesis the design, synthesis and biological 
evaluation of new LRH-1 antagonists will be discussed in more detail. 
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2. Design and synthesis of steroids as potential LRH-1 antagonists 
 
In 2005, Hashimito and Miyachi developed a series of antagonists targeting NRs such 
as retinoic acid receptor (RAR), retinoid X receptor (RXR), androgen receptor (AR) 
and vitamin D receptor (VDR).78 These new compounds were designed using 
reported crystal structures of the NR LBD of interest. By studying the binding mode 
of estradiol (19) and making key modifications to its core structure, steroid-based 
antagonists such as 56, 57 and 58 were designed (Scheme 16).  
 
 
 
Scheme 16 – Steroid-based compounds designed as inhibitors of H12 folding 
 
Introduction of bulky side chains at the 7- or 11-position of the steroid core generated 
compounds capable of positioning H12 in an inactive antagonist conformation 
(Figure 21). 
 
 
 
Figure 21 – Mode of action of the steroid antagonists78 
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Figure 4. 
Classification of NR antagonists.
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The LRH-1 LBD being mainly hydrophobic, it was believed that steroid-based 
analogues (ABCD only carbon ring system) could eventually be designed as 
virtual antagonists of LRH-1. Docking studies were initiated with the FXR agonist 
MFA-1 (59).79 From a design point of view this steroid had the advantage of only 
being substituted at positions 3 and 17 (in addition to the two methyl groups referred 
to as C-18 and C-19), leaving the remainder of the core free for manipulation 
(Scheme 17). This gave the opportunity to develop new analogues bearing side chains 
at key positions. 
 
 
 
Scheme 17 – MFA-1 (59) as potential virtual LRH-1 antagonist 
 
2.1. Design of LRH-1 antagonists from MFA-1 
 
Docking of MFA-1 in the LRH-1 LBD showed a promising pose whereby the phenol 
and acid moieties made key hydrogen bonding with hydrophilic residues. From this 
energically favored docking pose, we then identified two positions (2 and 11) from 
the steroid core that were pointing directly towards H12. In order to induce antagonist 
activity, groups capable of interacting with H12 were virtually introduced on these   
C-2 and C-11 positions. It was found that a methyl group at C-11 would not directly 
interact with H12, probably due to the considerable distance between this group and 
H12 residues (Figure 22, view (a)). However, introduction of a methyl functionality 
at C-2 placed this group closer to H12 although no direct interaction with Leu532 was 
observed (Figure 22, view (b)).  
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View (a) 	  
 
View (b) 
 
Figure 22 – View (a) - Binding mode of MFA-1 (59) (grey) and analogue 60 with 
methyl group at the C-11 position (green) 
View (b) - Binding mode of analogue 61 with methyl group at the C-2 
position (green) 
 
With the discovery of this promising docking pose (Figure 22, view (b)), we then 
focused on introducing a wide range of functionalities at the C-2 position. 
Interestingly, some compounds displayed key steric interactions with H12, with 
aromatic and aliphatic ethers being the most exciting targets (Table 1, entries 4, 5 and 
6). As a result, the synthesis of the two most promising steroid-based LRH-1 
antagonists 48 and 63 was undertaken. 
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Entry Compound R1 R2 
Docking results and 
comments 
1 60  H 
No pose change but R1 too 
far from H12 
2 61 H  
No pose change but R2 
closer to H12 
3 62 H 
 
Not MM-GBSA preferred  
4 48 H 
 
MM-GBSA preferred and 
steric clash with H12 
5 63 H 
 
MM-GBSA preferred and 
steric clash with H12 
6 64 H 
 
MM-GBSA preferred  
 
Table 1 – Docking results following in silico modifications of MFA-1 
 
2.2. Synthesis of analogue 48, best virtual steroid-based antagonist of LRH-1 	  
2.2.1. Retrosynthetic analysis 
 
The synthesis of steroid-based analogues (such as 48 and 63) with an ether linkage at 
the C-2 position of the core presented a significant synthetic challenge. Consequently, 
a novel and efficient approach had to be developed to access these two compounds. 
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It was believed that the phenol functionality from synthetic target 65 could 
be introduced by addition of an aryl organometallic to the corresponding activated 
ester 66 (Scheme 18). The C-3 acid moiety could be obtained by 
hydrolysis of a methyl ester. The C-3 dienyl methyl ester 66 could be generated 
by palladium-catalysed carbonylation followed by methanolysis of the 
corresponding triflate 67.  
 
 
 
Scheme 18 – Retrosynthetic analysis to access analogue 65 from triflate 67 
 
Triflate 67 could come from enolate formation followed by treatment with triflic 
anhydride starting from enone 68 (Scheme 19). The C-2 linkage could be introduced 
by nucleophilic displacement of bromide 69. The latter could be obtained through 
formation of the kinetic enolate of enone 70 and subsequent trapping with an 
electrophilic bromine source. Enone 70 could be prepared in five steps from 
commercially available pregnenolone (71) by following literature procedures.80,81 
 
 
 
Scheme 19 – Retrosynthetic analysis of triflate 67 from commercially available 
pregnenolone (71) 
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2.2.2. Synthesis of key enone 70 from pregnenolone (71) 
 
By following the work published by Xia et al., enone 70 was synthesized in five steps 
from cheap commercially available pregnenolone (71).81 The synthesis began by 
treatment of 71 with pyridine and iodine to generate acylpyridinium iodide 72 
(Scheme 20). Methanolysis provided methyl ester 73 in 83% yield over two steps. 
Oppenauer oxidation of homoallylic alcohol 73, followed by olefin migration, led to 
enone 74 in good yield. Saponification of methyl ester 74 led to acid 75. This was 
then converted to the key tert-butyl ester intermediate 70 by treatment with 
isobutylene and sulfuric acid. Within the Barrett group, this five-step sequence led to 
synthesis and isolation of ester 70 on a multigram scale.82 
 
 
 
Scheme 20 – Synthesis of key intermediate 70 from pregnenolone (71) 
 
With multigram quantities of enone 70 in hand, we then investigated the synthesis of 
virtual LRH-1 antagonist 48. In our CADD studies, this analogue showed a 
promising energically favored docking pose, with the para-chlorophenyl ether side 
chain being responsible for a key steric clash with H12 (Figure 23). 
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Figure 23 – Binding mode of virtual antagonist 48 showing a steric clash with H12 in 
LRH-1 LBD 	  
2.2.3. Synthesis of C-2 aryl ether 78 by nucleophilic displacement 
 
According to our retrosynthetic analysis, we believed that compounds such as 68, the 
R substituent being an aryl ether, could be synthesized by nucleophilic displacement 
of the corresponding bromide 69 (Scheme 21). 
 
 
 
Scheme 21 – Retrosynthetic analysis of aryl ether intermediate 68 
 
The kinetic enolate derived from enone 70 was formed using lithium 
hexamethyldisilazide (LiHMDS) at low temperature. In order to improve the 
reactivity of this intermediate towards electrophilic addition, the enolate was first 
treated with hexamethylphosphoramide (HMPA) to solvate the lithium anion and 
then quenched with trimethylsilyl chloride (TMSCl) to yield silyl enol ether 76. The 
required bromide substituent was then introduced by trapping the kinetic silyl enol 
ether with N-bromosuccinimide as electrophilic source of bromine providing 69 as a 
2:3 mixture (α:β) of C-2 epimers, the axial bromide compound being the major 
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product. Attempts to improve the epimeric ratio by recrystallization and treatment 
with lithium bromide were unsuccessful. Pleasingly, addition of the bromide epimers 
69 to a solution of para-chlorophenol (77) led to isolation of ether 78 as a 10:1 
mixture (α:β) of C-2 epimers in 75% yield, the desired equatorial ether side chain 
intermediate being the major product. Interestingly, under these conditions, the 
desired α-C-2 stereoisomer was formed preferentially (Scheme 22). We can postulate 
that β-C-2 epimer generated in situ can rapidly react with another equivalent of para-
chlorophenolate leading to the α-epimer. In fact, considering the geometry of the 
molecule, oxygen nonbinding electron pairs (ether side chain) could overlap with the 
C-3 π* carbonyl orbital, making this intermediate highly reactive towards a second 
nucleophilic attack.   
 
 
 
Scheme 22 – Synthesis of C-2 para-chloroaryl ether 78 by nucleophilic displacement 
of bromide 69 
 
Even though bromide displacement with 77 led to an enhanced 10:1 mixture of 
epimers, our goal was the isolation of 78 as a single isomer for characterization 
purposes and to simplify the rest of the synthesis. The mixture of epimers was further 
purified by recrystallization from EtOAc leading to 78 as a single diastereomer. 
Stereochemistry at C-2 was determined by 1H NMR: a doublet of doublets at 
4.78 ppm corresponding to H-2 with coupling constants of 13.7 Hz (ax-ax) and 
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4.9 Hz (ax-eq) showed the presence of the aryl ether side chain in equatorial 
position (Figure 24). 
 
 
 
Figure 24 – Three-dimensional structure of single diastereoisomer 78 
 
2.2.4. Synthesis of C-3 dienyl methyl ester 81 via palladium-catalyzed carbonylation 
 
The dienyl methyl ester moiety was introduced in two steps via palladium-catalysed 
carbonylation of dienyl triflate 80.83,84 Enone 78 was initially treated with 2,6-di-tert-
butyl-4-methylpyridine (79) and triflic anhydride to generate 80. Use of hindered 
base 79 in association with temperatures between -20 ºC and 0 ºC led preferentially to 
thermodynamic dienyl triflate 80 that was isolated but not purified. The carbonylation 
reaction proceeded at ambient temperature in the presence of 
bis(triphenylphosphine)palladium (II) diacetate as catalyst and under a carbon 
monoxide atmosphere. The carbonylated intermediate was quenched with methanol, 
leading to isolation of dienyl methyl ester 81 in an excellent 73% yield over two 
steps (Scheme 23). 
 
 
 
Scheme 23 – Synthesis of C-3 dienyl methyl ester 81 from enone 78 
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2.2.5. Introduction of phenol moiety via aryl organometallic addition to activated 
ester 85 
 
It was first thought that tert-butyl ester 81 could be selectively deprotected under 
acidic conditions. However, use of triethylsilane as carbocation scavenger in the 
presence of trifluoroacetic acid in dichloromethane led only to decomposition of the 
starting material.85 These reaction conditions generated a mixture of byproducts 
where C-2 aryl ether had been cleaved. This observation clearly demonstrated the 
high sensitivity of the ether linkage under acidic conditions. An alternative milder 
procedure was then investigated. Treatment of tert-butyl ester 81 with a 1:1 mixture 
of trimethylsilyl trifluoromethane sulfonate and triethylamine also led to partial 
cleavage of the C-2 aryl ether side chain, probably due to the presence of 
trifluoromethanesulfonic acid.86 As a consequence, 81 was initially stirred with a 
large excess of triethylamine followed by dropwise addition of trimethylsilyl 
trifluoromethane sulfonate. Under these conditions, selective tert-butyl ester 
deprotection was observed and desired acid 82 was isolated in 92% 
yield (Scheme 24). 
 
 
 
Scheme 24 – Selective deprotection of tert-butyl ester 81 
 
According to our retrosynthetic analysis, it was then believed that phenol 48 could be 
obtained via aryl organometallic addition to activated ester 83 (Scheme 25). 
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Scheme 25 – Retrosynthetic analysis of phenol 48 from acid 82 
 
In 2004, Fürstner et al. reported the synthesis of aryl ketones by addition of Grignard 
reagents to acyl chlorides employing iron catalysts.87 Unfortunately, application of 
this method to substrate 82 proved to be unsuccessful. In his studies, Fürstner used 
relatively small substrates to validate his methodology. Steroid 82 on the other hand 
is a large molecule displaying steric hindrance that could have led to the low 
reactivity under these conditions. An alternative approach to introduce the phenolic 
moiety was therefore developed, whereby acid 82 was treated with 
triphenylphosphine and 2,2′-dithiodipyridine (84) to form activated thiopyridyl ester 
85 in 94% yield (Scheme 26).88 
 
 
 
Scheme 26 – Synthesis of thiopyridyl intermediate 85 from acid 82 
 
Following the work of Knochel describing halogen/metal exchanges, aryl iodide 87 
was treated with an excess of isopropylmagnesium chloride (88) generating in situ the 
Grignard {4-[(tert-butyldimethylsilyl)oxy]phenyl}magnesium chloride.89,90 This was 
then added to a solution of  ester 85 at -50 oC, affording protected phenol 
intermediate 89. Treatment of this silyl protected phenol with an excess of 
tetrabutylammonium fluoride (TBAF) led to 90, isolated as a single diastereoisomer 
in an excellent 59% over two steps (Scheme 27). 
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Scheme 27 – Synthesis of phenol 90 using halogen/metal exchange methodology 
 
2.2.6. Synthesis of acid 48 by saponification of methyl ester 90 
 
It was previously observed that the C-2 ether linkage was acid sensitive. With this in 
mind, methyl ester deprotection was attempted using basic conditions. Treatment of 
90 with aqueous potassium hydroxide led to unreacted starting material after stirring 
the reaction mixture at room temperature. Heating the reaction mixture at reflux did 
not afford the desired acid 48. Instead, the elimination byproduct 91 was isolated in 
81% yield. Surprisingly, a disfavored syn elimination of the equatorial ether linkage 
occurred under these reaction conditions. The assumption was made that under 
refluxing conditions, 90 can adopt a new conformation where ether linkage 
elimination is favored under strongly basic conditions. Alternative milder conditions 
were then investigated for the cleavage of ester 90. Treatment of 90 with an excess of 
lithium hydroxide monohydrate at room temperature for four days led to the desired 
acid 48.91 Purification of 48 by flash column chromatography was unsuccessful due 
to high affinity of this compound for silica gel. Use of acid traces in the eluent 
purification system mainly led to partial ether linkage cleavage. Pleasingly, 
purification by preparative TLC afforded acid 48 in 51% yield (Scheme 28). 
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Scheme 28 – Saponification with LiOH leading to analogue 48 
 
With a powerful strategy for the synthesis of analogue 48 from key intermediate 69 
established, formation of C-2 phenyl ether analogue 63 was undertaken. 
 
2.3. Synthesis of C-2 phenyl ether analogue 63 
 
In our CADD studies, phenyl ether analogue 63 showed a similar binding mode 
to 48. The ether side chain at position C-2 displayed key steric interactions with H12, 
characteristic of the desired antagonistic docking pose (Figure 25). 
 
 
 
Figure 25 – Binding mode of virtual antagonist 63 showing a steric clash with H12 in 
LRH-1 LBD 
O
H H
H
OH
O
MeO
O
Cl
90
O
H H
H
OH
O
HO
O
Cl
48
KOH
MeOH/H2O
rt
O
H H
H
OH
O
MeO
O
Cl
90
O
H H
H
OH
O
HO
O
Cl
48
LiOH monohydrate
MeOH/H2O
rt, 4 days
51%
O
H H
H
OH
O
HO
91
KOH
MeOH/H2O
reflux, 18 h
	   66	  
 
Following the strategy used for the synthesis of acid 48, addition of bromide epimers 
69 to a solution of phenol (92) and sodium hydride led to ether 93 in 79% yield. The 
latter was isolated as a single diastereoisomer after purification by column 
chromatography. Stereochemistry of the newly generated C-2 ether linkage was 
confirmed by 1H NMR analysis. Dienyl ester 95 was introduced via dienol triflate 
formation followed by palladium-catalyzed carbonylation reaction and 
methanolysis (Scheme 29). 
 
 
 
Scheme 29 – Synthesis of C-3 dienyl methyl ester 95 from bromide epimers 69 
 
tert-Butyl ester 95 was then selectively deprotected using trimethylsilyl 
trifluoromethane sulfonate in presence of an excess of triethylamine. Under these 
conditions, acid 96 was isolated in 64% yield. This was then treated with 
triphenylphosphine and 2,2′-dithiodipyridine (84) to generate activated ester 97 in 
86% yield (Scheme 30). 
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Scheme 30 – Synthesis of thiopyridyl activated ester 97 
 
Protected phenol intermediate 98 was synthesized via Grignard reagent addition to 
thiopyridyl ester 97. This was then treated with TBAF, generating phenol 99 in 62% 
yield over 2 steps. Finally, methyl ester 99 was deprotected with lithium hydroxide 
monohydrate and purified by preparative TLC leading to acid 63 in 64% 
yield (Scheme 31). 
 
 
 
Scheme 31 – Aryl addition and saponification leading to analogue 63 
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2.4. Biological evaluation of steroids 48 and 63 
 
Analogues 48 and 63, as well as few key intermediates were then tested in our in 
vitro assay at 10 µM (Figure 26). None of these compounds seemed to act as potent 
LRH-1 antagonists and only displayed 5% to 20% inhibition at this concentration. 
 
 
Figure 26 – In vitro biological evaluation of steroid analogues at 10 µM 
 
2.5. Design and synthesis of a new class of steroid analogues 
 
With steroids 48 and 63 showing little antagonistic activity towards LRH-1, 
investigations into the synthesis of a new class of analogues, structurally related to 
these two targets were begun. According to our docking studies, 48 and 63 made key 
hydrogen bonding with the LRH-1 LBD through their acid and phenol moieties. This 
allowed both molecules to virtually take the desired antagonistic docking pose, 
placing ether side chain in a position that generated a steric clash with H12. The 
initial idea was to synthesize analogues such as 100 and 101, where both acid and 
phenol moieties have been inverted (Scheme 32). 
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Scheme 32 – Design of a new class of steroid analogues 100 and 101 
 
To access these two challenging molecules, a new synthetic approach had to be 
developed. We believed that our initial strategy to introduce the phenol moiety via 
activated ester formation followed by aryl Grignard addition would not work on 
position C-3 of the steroid ring-system, due to the presence of two reactive C-4 and 
C-6 unsaturated positions. Recently, Chen et al. published the total syntheses of 
nakiterpiosin (102) and nakiterpiosinone (103) using an interesting carbonylative 
cross-coupling reaction to generate an aryl ketone (Scheme 33).92  
 
 
 
Scheme 33 – Synthesis of natural products 102 and 103 using a carbonylative cross-
coupling strategy 
 
Stannane 104 being readily available from commercial sources was used in a 
carbonylative Stille coupling for the synthesis of aryl ketone 105. Enone 93 was 
firstly converted to dienol triflate 94 using standard conditions. This was then treated 
with stannane 104 in presence of bis(triphenylphosphine)palladium (II) diacetate and 
copper (I) chloride as catalysts, under a carbon monoxide atmosphere. Using these 
cross-coupling conditions, aryl ketone 105 was isolated in 56% yield over two steps. 
Unfortunately, use of TMSOTf for the deprotection of the tert-butyl ester moiety led 
only to formation of unidentified byproducts (Scheme 34). Under these Lewis acidic 
conditions, the aryl ketone was activated leading to two highly reactive C-4 and C-6 
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positions and causing formation of byproducts. Using acidic conditions generated C-2 
ether linkage loss and the tert-butyl ester was unreactive towards mild lithium 
hydroxide deprotection conditions. Considering these facts, there was a real need for 
an alternative protecting group at C-17 position that could easily be cleaved under 
mild basic conditions. With this in mind, the tert-butyl ester was replaced by a methyl 
ester. 
 
 
 
Scheme 34 – Synthesis of aryl ketone 105 by carbonylative Stille coupling 
 
Synthesis of cross-coupling precursor 108 began with the conversion of acid 75 to 
methyl ester 74 in presence of iodomethane and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU).93 The C-2 position was then selectively brominated using our previously 
developed synthetic strategy and a 4:5 (α:β) mixture of epimers 107 was isolated in 
an excellent 71% yield. Nucleophilic displacement by phenol (92) led to enone 108 as 
a single diastereoisomer (α) after purification by column chromatography. This was 
converted to its dienol triflate derivative and then followed by carbonylative Stille 
coupling with stannane 104. After purification, aryl ketone 109 was isolated in 57% 
yield over two steps. Deprotection of methyl ester with lithium hydroxide 
monohydrate did not provide the desired product 106. If 109 was stirred for several 
hours in presence of lithium hydroxide, decomposition of the starting material to 
unidentified byproducts was observed. Slightly acidic conditions also led to 
decomposition of 109 (Scheme 35).  
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Scheme 35 – Synthesis of methyl ester cross-coupling precursor 108 and attempt for 
the isolation of 106 
 
In summary, both tert-butyl and methyl esters 105 and 109 displayed high sensitivity 
towards acidic (Brønsted and Lewis) and basic conditions. Ester deprotection 
attempts generally led to isolation of a mixture of byproducts making their 
characterization extremely difficult. When these new steroid targets were initially 
designed, it was believed that introduction of the dienyl aryl ketone moiety would be 
challenging due to possible byproducts formation during the carbonylative cross-
coupling reaction (hydrolysis to dienyl acid or enone, decomposition or hydrolysis of 
stannane 104 etc). However, the carbonylative Stille coupling worked well, giving 
reproducible results for both ester precursors 93 and 108. It was not anticipated that 
ester deprotection conditions would generate highly reactive intermediates leading to 
a mixture of byproducts. At this point, the decision was made to start working on the 
design and synthesis of new classes of compounds, structurally related to anti-
estrogens tamoxifen and raloxifene. 
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3. Design and synthesis of tamoxifen analogues as potential LRH-1 
antagonists 	  
In the introduction, it was shown how tamoxifen (12) became the first 
chemotherapeutic drug to target ER-positive breast cancer cells and prevent 
tumorigenesis in high-risk women. Tamoxifen is extensively metabolized in the 
gastrointestinal tract and the liver, generating the active species 4-hydroxytamoxifen 
(13). Estradiol (19) binds ER leading to CoA recruitment, DNA binding and 
gene expression. 4-Hydroxytamoxifen also exhibits high affinity for ER but displays 
a different binding mode compared to estradiol. Tamoxifen’s 2-(dimethylamino)ethyl 
side chain prevents H12 from adopting an active conformation and is responsible for 
the compound’s antagonistic properties towards ER. Based on this evidence, 
computational studies were conducted to modify 4-hydroxytamoxifen’s structure to 
allow the design of new small molecule antagonists of LRH-1. 
	  
3.1. In silico modifications of 4-hydroxytamoxifen’s structure 
 
The initial approach studied the main similarities and differences between 4-
hydroxytamoxifen (13) binding modes in ERα and LRH-1. Ligands capable of 
displacing H12 by steric contacts were then tailored. Superimposition of ERα and 
LRH-1 crystal structures with virtual binding modes of 13 is reported in Figure 27.  
 
 
 
Figure 27 – (a) - Binding mode of 4-hydroxytamoxifen (13) in ERα from co-crystal 
structure (pdb code 2JF9)94 - Orange ligand 
(b) - Binding mode of 4-hydroxytamoxifen (13) in LRH-1 - Green ligand 
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4-Hydroxytamoxifen bound to ERα shows the desired antagonistic pose H but LRH-
1 places the ligand core closer to tunnel C (unavailable in ERα due to blockage by 
amino acid residues). In addition, the dimethyl amino tail is located in the small 
hydrophobic pocket below H12 (absent in ERα). 
 
As the ethyl moiety from 13 was located inside tunnel C, this part of the molecule 
was initially modified to alter its docking mode. Due to the fact that LRH-1 LBD is 
mainly hydrophobic, it was believed that introducing an extra cyclohexyl side chain, 
attached to the ethyl moiety would eventually generate new docking poses where the 
cyclohexyl moiety would be ejected from tunnel C due to the size of the side chain. 
Pleasingly, docking studies on cyclohexyl analogue 110 displayed a new pose where 
the dimethyl amino tail resides in tunnel A, while the cyclohexyl moiety sits close to 
H5 and the small hydrophobic pocket. Interestingly, the unsubstituted phenyl group 
was directed towards H12 but not close enough to displace it (Figure 28). 
 
 
 
 
 
Figure 28 – Virtual docking pose of cyclohexyl analogue 110 
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With lead compound 110 showing a promising docking pose, the docking of 
compounds substituted on the free phenyl ring was investigated (Table 2). According 
to Figure 28, this group was pointing directly towards H12, suggesting that 
introduction of additional functionalities attached to the phenyl ring could generate 
compounds capable of displacing H12 by introducing a key steric clash with residue 
Leu532.  
 
 
 
Entry Compound R Docking results and comments 
1 112  
Slight rotation of docking pose but 
unlikely to displace H12 
2 113  
Reorganization of docking pose 
MM-GBSA preferred and steric 
clash with H12 
3 49 
 
Reorganization of docking pose 
MM-GBSA preferred and steric 
clash with H12 
4 114  
Reorganization of docking pose 
MM-GBSA preferred and steric 
clash with H12 
5 115  
Reorganization of docking pose 
MM-GBSA preferred and steric 
clash with H12 
 
Table 2 – Docking results following in silico modifications of lead compound 110 
 
Due to the hydrophobicity of LRH-1 LBD, we initially focused on small non-polar 
chemical groups. Variations at the para- position of the phenyl ring led to better 
results with energetically favored docking poses. Methyl functionality gave 
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comparable docking results to lead compound 110, with 112 being unlikely to 
displace H12. Introduction of bigger groups such as ethyl or isopropyl reorganized 
the docking poses with both functionalities relocated to the small hydrophobic pocket 
below H12, while the dimethyl amino tail docked near H12 and showed a steric clash 
with Leu532. 114 and 115 also took desired antagonistic poses with binding modes 
comparable to previous two analogues 113 and 49 (Figure 29). Therefore, the 
synthesis of these four virtual LRH-1 antagonists was undertaken to verify these 
computational results. 
 
 
 
Figure 29 – Superimposed docking poses of virtual LRH-1 antagonists (114, 115, 
113 and 49) 
 
3.2. Syntheses of analogues 114, 115, 113 and 49, best virtual LRH-1 antagonists 	  
3.2.1. Examples of syntheses of tamoxifen (12) and analogues 	  
Many academic groups and pharmaceutical companies have been interested in the 
synthesis of tamoxifen and structurally related analogues. Considering tamoxifen 
biological properties and role as breast cancer therapy, there was a real need for the 
development of atom friendly and simple synthetic approaches to access this drug in 
good yield and purity. In addition, development of a procedure that offers a chemical 
pathway suitable for large-scale industrial production would be beneficial. While 
many syntheses of tamoxifen and analogues have been reported in the literature, only 
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few of them are stereoselective. Synthesis of the hydroxytriphenylethylene motif was 
extremely challenging especially in a stereoselective manner. Another challenge in 
the preparation of compounds bearing this motif was to avoid isomerization of the 
olefin. Interestingly, (Z)-4-hydroxytamoxifen (13) has a good affinity for ER (about 
three times that of estradiol (19)) but its (E)-isomer has an affinity of only 5%. 
 
3.2.1.1. Non-selective syntheses of tamoxifen (12) and 4-hydroxytamoxifen (13) 
 
In 1982, Katzenellenbogen reported the synthesis of (E)- and (Z)-isomers of 
tamoxifen (12) and 4-hydroxytamoxifen (13).95 A seven-step sequence was 
developed starting with Friedel-Crafts acylation between anisole (116) and para-
bromophenylacetic acid (117). Ketone 118 was isolated in 78% yield and alkylated 
with ethyl iodide via formation of an enolate generated with sodium hydride. Under 
these conditions, ketone 119 was obtained in an excellent 94% yield. The latter was 
then deprotected and the 2-(dimethylamino)ethyl side chain introduced by alkylation 
of the newly formed phenol group in 32% yield over two steps. Ketone 121 was 
treated with phenylmagnesium bromide and the resulting mixture of alcohols was 
dehydrated under acidic conditions giving a cis/trans mixture (1:1.3) of 
bromotamoxifen (122) in 84% yield. Finally, bromo-hydrogen exchange under 
palladium catalysis led to the same cis/trans ratio of tamoxifen (12) isomers in 92% 
yield (Scheme 36). 
 
 
 
Scheme 36 – Synthetic route developed by Katzenellenbogen to access 
tamoxifen (12)95 
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The synthesis of 4-hydroxytamoxifen (13) was achieved using a similar synthetic 
route. The key step was a nucleophilic Grignard addition of [4-[(2-
tetrahydropyranyl)oxy]phenyl] magnesium bromide to ketone 121, that led to a 
tertiary alcohol which could then be dehydrated and deprotected under acidic 
conditions giving an equimolar cis/trans mixture of bromo-4-hydroxytamoxifen 
(123) in 63% yield over three steps. Bromo-hydrogen exchange under palladium 
catalysis proceeded smoothly and 4-hydroxytamoxifen (13) was isolated in excellent 
yield (Scheme 37). 
 
 
 
Scheme 37 – Synthesis of 4-hydroxytamoxifen (13) by Grignard addition95 
 
Development of this synthetic route where a bromine atom was introduced at the 
beginning of the synthesis and finally cleaved by hydrogenation may seem surprising. 
Back in 1982, there was still a lot to learn about tamoxifen and 4-hydroxytamoxifen. 
The choice of this strategy was based on the need to develop radiolabeled derivatives. 
Introduction of the bromine provided precursors for tritium radiolabeling that allowed 
the study of the mode of action, metabolism and pharmacokinetics of 4-
hydroxytamoxifen. 
 
Husson et al. also developed synthesis of tertiary alcohol intermediates that could be 
dehydrated under acidic conditions to generate tamoxifen (12) and 4-
hydroxytamoxifen (13).96 Inspired by Schlosser’s work,97 propylbenzene 126 was 
regioselectively metalated at the α-carbon center using n-BuLi-t-BuOK-TMEDA as 
triple super-base combination (Scheme 38). The corresponding carbanion was then 
added to ketones 124 and 125 generating respectively tertiary alcohols 127 and 128. 
Treatment of these alcohols with sulfuric acid led to tamoxifen (12) and 4-
hydroxytamoxifen (13) in good overall yields. Both compounds were isolated as a 1:1 
mixture of cis/trans isomers. 
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Scheme 38 – Synthetic route developed by Husson to access tamoxifen (12) and 4-
hydroxytamoxifen (13)96 
 
Soon after, alternative syntheses to form the triphenylethylene motif were developed. 
Intermolecular McMurry coupling between two ketones to generate the sterically 
hindered tetrasubstituted alkene appeared to be an excellent approach. However, 
under intermolecular McMurry conditions, the olefin is generally obtained with poor 
stereoselectivity although there is a slight preference for the formation of (E)-isomers. 
 
Forman investigated the intermolecular McMurry coupling between symmetrical 
4,4′-dihydroxybenzophenone (129) and propiophenone (130) in presence of zinc and 
titanium tetrachloride in dry THF under refluxing conditions.98 Pleasingly, 
tetrasubstituted alkene 131 was isolated in 87% yield on a multigram scale. The latter 
was then alkylated with 2-(dimethylamino)ethyl chloride hydrochloride (120), 
generating an equimolar cis/trans mixture of 4-hydroxytamoxifen (13). Screening of 
solvents allowed selective crystallization of (Z)-isomer from hexanol in 49% yield 
and (E)-isomer from methanol in 41% yield (Scheme 39). This two-step sequence 
allowed the high-yielding large-scale synthesis of both 4-hydroxytamoxifen isomers. 
However, the (E)-isomer being biologically inactive towards ER, there was a real 
need for development of stereoselective approaches for the synthesis of the (Z)-
isomer. 
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Scheme 39 – Synthesis of both 4-hydroxytamoxifen (13) isomers by intermolecular 
McMurry coupling98 
 
3.2.1.2. Stereoselective syntheses of tamoxifen (12) and 4-hydroxytamoxifen (13) 
via McMurry coupling 
 
Calogeropoulou et al. worked on the stereoselective McMurry coupling between 
monoprotected ketone 132 and propiophenone 130.99 Alkene 133 was isolated after 
column chromatography in a promising 4:1 mixture in favor of the desired (E)-
isomer. Unfortunately, this mixture was inseparable by crystallization or trituration. 
Introduction of perfluorotolyl protecting group on the free phenol moiety allowed 
separation of the minor undesirable geometrical isomer by crystallization. 134 was 
then treated with NaOMe in DMF to remove the perfluorotolyl protecting group and 
alkylation of the resulting phenol led to the corresponding tertiary amine. Finally, 
mild catalytic hydrogenolysis gave (Z)-4-hydroxytamoxifen (13) as a single isomer 
(Scheme 40).  
 
 
 
Scheme 40 – Stereoselective synthesis 4-hydroxytamoxifen (13) by intermolecular 
McMurry coupling99 
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Although Calogeropoulou’s stereoselective McMurry coupling provided alkene 133 
in an acceptable 4:1 ratio, this mixture of isomers proved to be inseparable by 
traditional purification methods. Two additional steps and one crystallization were 
required for isolation of pure (Z)-134 and considering this, this approach seemed 
inapplicable for multiple analogues and large-scale syntheses. 
 
Gauthier also based his synthesis of 4-hydroxytamoxifen (13) on a key 
stereoselective intermolecular McMurry coupling.100 Benzyl protected coupling 
partner 132 was replaced by monopivaloate 135. McMurry coupling between 135 and 
propiophenone 130 nicely afforded alkene 136 in a greatly improved 14:1 ratio (E/Z). 
Pleasingly, this mixture could be further purified by trituration from methanol giving 
pure (E)-isomer 136 (>100:1 (E/Z)) in 82% yield. Introduction of the                          
2-(dimethylamino)ethyl side chain under standard conditions followed by pivaloyl 
deprotection with methyl lithium led to 4-hydroxytamoxifen (13) after trituration 
from ethanol. This efficient synthesis allowed the stereoselective formation of 13 in 
only four steps from cheap starting materials in 10% overall yield (Scheme 41). 
 
 
 
Scheme 41 – Synthesis of 4-hydroxytamoxifen (13) by highly stereoselective 
McMurry coupling100 
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Calogeropoulou and Gauthier’s syntheses showed that desymmetrization of           
4,4′-dihydroxybenzophenone (129) by introduction of protecting groups led 
preferentially to formation of (E)-isomers in the McMurry coupling. This interesting 
stereoselectivity is discussed in the next section. 
 
3.2.1.3. Stereoselectivity in the McMurry coupling 
 
It is now well established that McMurry coupling consists of treating carbonyl 
compounds (ketones and aldehydes) with low-valent titanium to form alkene 
products.101 If two equivalents of the same carbonyl are used, homocoupling products 
are synthesized. However, mixed products could also be generated by intermolecular 
coupling. One great advantage of this reaction is that sterically hindered olefins such 
as tetrasubstitued alkenes can be prepared in good yields whereas other methods have 
failed to provide the desired olefinic compound. Considering that, McMurry coupling 
seemed to be the method of choice for the synthesis of 4-hydroxytamoxifen (13) and 
triphenylethylene analogues.  
 
Even though the mechanism of the reaction has not been fully elucidated, it clearly 
involves two distinct steps. The first step consists of a reductive coupling (single 
electron transfer) of both carbonyl compounds to generate a pinacol type intermediate 
140. Then, deoxygenation of the 1,2-diol is observed, leading to formation of a 
mixture of isomeric alkenes 143 and 144 (Figure 30). 
 
 
 
Figure 30 – Accepted mechanism for McMurry homocoupling of ketone 138 
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In Gauthier’s synthesis of 4-hydroxytamoxifen (13), McMurry coupling between 
ketones 130 and 135 led selectively to formation of a 14:1 mixture of E/Z geometrical 
isomers 136. One explanation for the observed stereoselectivity of the reaction is use 
of bulky pivaloyl protecting group. In the transition state, the pivaloyl group will lie 
on the same side as the ethyl substituent in order to minimize steric hindrance with 
the phenol ring (Figure 31). In addition, the electron rich free phenol ring could make 
a π-stacking type interaction with phenyl group of propiophenone accentuating the 
stereoselectivity of the reaction. 
 
 
 
Figure 31 – Transition state leading preferentially to (E)-isomer 136 
 
Considering the stereoselectivity, a McMurry coupling approach seems to be an 
excellent method for the stereoselective synthesis of hindered tetrasubstituted 
alkenes, as present in tamoxifen. Carbonyl olefination or cross-metathesis reactions 
only showed limited application for the synthesis of such compounds. Recently, a 
novel approach to synthesize tamoxifen has been developed. It consists in a 
palladium-catalysed cross-coupling synthetic approach, generating the hindered 
triphenylethylene motif in one-pot. 
 
3.2.1.4. Stereoselective synthesis of tamoxifen (12) via a cross-coupling reaction 
 
Hiyama showed that tamoxifen (12) could be synthesized in one-pot by palladium-
catalysed cross-coupling reaction from 1,1-diboryl-1-alkene 146.102 Addition of one 
equivalent of phenyl iodide (147) to 146 at room temperature led selectively to 
intermediate 148. It is interesting to point out that replacing the ethyl side chain from 
146 by bulkier functionalities such as tert-butyl or isopropyl also led selectivity to 
cross-coupled intermediates trans to the phenyl group. The observed selectivity 
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implicates that electronic activation of this carbon-boron bond probably plays a 
prominent role in the coupling compared to steric hindrance. Intermediate 148 was 
then treated with aryl iodide 149 at elevated temperature to generate tamoxifen (12) 
in 47% yield (Scheme 42). Despite using toxic metallic reagents in the last step of the 
synthesis, this highly stereoselective approach proved to be extremely useful for the 
synthesis of sterically hindered olefins. 
 
 
 
Scheme 42 – Synthesis of tamoxifen (12) by one-pot stereoselective cross-coupling102 
 
With this non-exhaustive list of useful protocols to synthesize tamoxifen and 
analogues, a robust synthetic route to access our best virtual LRH-1 antagonists was 
developed. 
 
3.2.2. Synthetic route to access best virtual LRH-1 antagonists  
 
3.2.2.1. Retrosynthetic analysis to 4-hydroxytamoxifen analogues 
 
Gauthier’s protocol to access stereoselectively 4-hydroxytamoxifen (13) looked like 
the method of choice to synthesize our computer generated analogues.100 It was 
believed that the synthetic targets 111 could be obtained by pivaloyl protecting group 
deprotection and nucleophilic addition on free phenol 150. The desired (E)-olefin 150 
would be stereoselectively synthesized by McMurry intermolecular coupling between 
ketones 135 and 151. Finally, depending on the nature of the R- group, ketone 151 
could either be obtained by copper-catalysed cross-coupling from α-chloroketone 152 
(R = Cl, OMe) or by Grignard addition to aldedyde 153 (R = Et, iPr) followed by 
subsequent oxidation of the newly formed tertiary alcohol (Scheme 43).  
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Scheme 43 – Retrosynthetic analysis of 4-hydroxytamoxifen analogues from 
commercially available ketones 152 and aldehydes 153 
 
3.2.2.2. Syntheses of virtual LRH-1 antagonists 114 and 115 	  
With analogues 114 and 115 showing extremely promising docking poses from our 
computational studies, rapid and efficient syntheses of these compounds had to be 
developed (Figure 32). 
 
	  	  	  	  	  	  	  	   	  	  
Figure 32 – Promising docking poses of analogues 114 (left) and 115 (right) 
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enabled introduction of cyclohexyl moiety, generating ketones 158 and 159 in high 
yields (Scheme 44). Mechanistically, direct nucleophilic substitution of alkyl chloride 
154 and 155 with an organometallic intermediate seems to be favored (in comparison 
to either 1) addition to the ketone followed by 1,2-migration of the alkyl group or 2) 
alkylcopper enolate formation followed by reductive elimination). The facile 
nucleophilic attack could be explained by overlap of the π* orbital from the adjacent 
carbonyl group with the carbon-chlorine σ* orbital generating a low-energy LUMO 
orbital. Nucleophilic attack at the carbon-chlorine bond being irreversible, the desired 
ketones 158 and 159 were obtained selectively. 
 
 
 
Scheme 44 – Cross-coupling approach for syntheses of ketones 158 and 159 
 
With ketones 158 and 159 in hand, the stereoselective McMurry coupling was 
explored. As explained earlier, steric hindrance due to the presence of bulky pivaloyl 
protecting group leads preferentially to (E)-isomer where the ester is cis to the small 
ethyl functionality. In our design, the ethyl side chain was replaced by a bulkier 
cyclohexylmethyl moiety that could potentially increase the formation of the 
undesired (Z)-isomer. Pleasingly, treatment of ketones 158 and 159 with pivaloyl 
protected intermediate 135 under McMurry conditions led stereoselectively to 
formation of (E)-isomers 160 and 161 (ratio >10:1 (E/Z) in the crude mixture). This 
conserved degree of selectivity can also be explained by intramolecular π-stacking 
between both phenyl and phenol rings in the transition state. Several triturations and 
recrystallization from ethanol allowed isolation of pure (E)-alkene 160 in moderate 
yield. The desired (E)-selectivity was confirmed by NOE experiment: selective 
irradiation of H-1 showed spacial relationship with H-2. Compound 161 was isolated 
as a mixture of geometric isomers (>10:1), even after several recrystallizations. Both 
alkenes were then carefully alkylated with 2-(dimethylamino)ethyl chloride 
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hydrochloride (120) to avoid transesterification and pivaloyl protecting group was 
removed using methyl lithium at -78 ºC. Analogues 114 and 115 were finally isolated 
as white solids after trituration from ethanol (Scheme 45). 
 
 
 
Scheme 45 – Synthesis of analogues 114 and 115 by McMurry coupling 
 
3.2.2.3. Syntheses of virtual LRH-1 antagonists 113 and 49 
 
These two compounds, generated by in silico modifications of 4-
hydroxytamoxifen (13) displayed similar binding modes compared to previously 
synthesized analogues 114 and 115 (Figure 33). 
 
       
 
Figure 33 – Promising docking poses of analogues 113 (left) and 49 (right) 
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(cyclohexylmethyl)magnesium bromide (166) to generate the corresponding racemic 
tertiary alcohols 167 and 168 in good yields. The latter was then oxidized using the 
convenient Parikh-Doering reaction conditions, leading to ketones 169 and 170 in 
64% and 70% yield respectively (Scheme 46).104 
 
 
 
Scheme 46 – Two-step procedures for syntheses of ketones 169 and 170 
 
With ketones 169 and 170 in hand, a similar three-step sequence (stereoselective 
McMurry coupling, alkylation, pivaloyl deprotection) allowed us to synthesize virtual 
LRH-1 antagonists 113 and 49 (Scheme 47). However, with the introduction of these 
two non-polar functionalities (Et and iPr), both analogues were isolated in low overall 
yields (especially for 49). One explanation could be the difficulties faced to purify 
intermediates 171 and 172 as well as final compounds 113 and 49 by standard 
methods. 
 
 
 
Scheme 47 – Synthesis of analogues 113 and 49 by McMurry coupling 
 
In conclusion, our CADD studies allowed virtual design of four 4-hydroxytamoxifen 
analogues that could potentially act as LRH-1 antagonists. Functionalization of the 
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unsubstituted phenyl ring and replacement of the ethyl side chain by a 
cyclohexylmethyl moiety generated compounds with low energy docking poses that 
displayed clashes with H12. Synthesis of these analogues proceeded via a highly 
stereoselective McMurry coupling in favor of the desired (E)-intermediate. With 
these four analogues in hand, compounds were submitted to our collaborators for 
biological evaluation. 
 
3.3. Biological evaluation of 4-hydroxytamoxifen analogues 
 
All 4-hydroxytamoxifen analogues were initially tested in our in vitro assay at a fixed 
10 µM concentration. They all displayed good antagonist activity towards LRH-1 
with more than 50% inhibition in all cases (Figure 34).  
 
 
Figure 34 – In vitro biological evaluation at 10 µM 
 
Biological evaluation at lower concentration was then investigated. At 1 µM, 
compounds 114 and 115 showed good LRH-1 inhibition even though the significant 
error did not allow us to confirm an inhibitory activity above 50%. In all cases, our 
initial design work seemed to be validated as compounds 114, 115, 113 and 49 
displayed interesting antagonistic properties (Figure 35). As expected, these 
compounds must adopt a specific binding mode when bound to LRH-1 LBD and be 
able to displace H12 to prevent CoA recruitment and activation. 
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Figure 35 – In vitro biological evaluation at 1 µM 
 
Titration curves for most active compounds 114 and 115 were then made (Figure 36). 
Analogue 114 showed excellent antagonist activity with an IC50 value of 170 nM. 
115 was less active (IC50 = 6.8 µM) but could also be considered as a lead compound 
for our computer assisted lead modification/generation approach. 
 
      
 
Figure 36 – Titration curves and IC50 values of analogues 114 and 115 
 
In view of these promising biological results, the design and synthesis of a new 
structurally related series of compounds was then investigated. 
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3.4. Design and syntheses of a second generation of 4-hydroxytamoxifen 
analogues 
 
3.4.1. Dimethylamine replacement by piperidine 
 
The most favorable energetically docking poses were obtained for compounds 
displaying a steric clash with H12 via their 2-(dimethylamino)ethyl side chain. With 
this in mind, it was believed that replacement of the dimethyl amino tail by a bulkier 
functionality could eventually generate compounds with improved antagonistic 
properties and so docking studies were initiated with compounds bearing a piperidine 
side chain. It was assumed that the piperidine moiety would increase the length of the 
side chain and sit closer to H12, generating new steric hindrance around this helix. In 
silico introduction of a piperidine side chain to the four lead compounds (114, 115, 
113 and 49) led to analogue 175 showing a promising docking pose (Figure 37). As 
expected, the piperidine moiety seemed to be able to displace H12 by taking the 
desired antagonistic docking pose. 
 
 
 
       
 
Figure 37 – Piperidine 175 virtually bound to LRH-1 LBD (left) and superimposed 
docking pose with 114 (pink) (right) 
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The synthesis started by alkylation of key intermediate 171 with                                 
1-(2-chloroethyl)piperidine hydrochloride (176) under basic conditions. 177 was 
isolated as a single geometric isomer in 62% yield (Scheme 48). The pivaloyl 
ester protecting group was then cleaved with methyl lithium and the crude 
mixture was triturated with ethanol. Recrystallization from a mixture of 
dichloromethane/methanol gave solely the (Z)-isomer 175 in 41% yield. 
 
 
 
Scheme 48 – Synthesis of piperidine analogue 175 
 
In our in vitro assay, 175 displayed antagonist properties towards LRH-1 
(10 µM screen) but at a concentration of 1 µM, this compound seemed slightly less 
active than our best lead compounds 114 and 115 (Figure 38).  
 
 
Figure 38 – In vitro biological evaluation of 175 at 10 µM and 1 µM 
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objective would be the synthesis of medium-sized side chain analogues such as 
diethylamine 178 and pyrrolidine 179 as potential LRH-1 antagonists (Scheme 49). 
 
 
 
Scheme 49 – New synthetic targets as LRH-1 antagonists 
 
3.4.2. Alkene replacement by cyclopropane 
 
Although our four lead compounds showed very good biological properties as LRH-1 
antagonists, the major issue of this series of analogues was their instability under 
slightly acidic conditions. If chloroform was used as an NMR solvent for analogues 
114, 115, 113 and 49, the samples underwent a facile isomerization to a mixture of 
(Z/E)-isomers. The isomerization was probably caused by acid catalysis leading to 
bond rotation. In the solid state, final analogues proved to be stable for months when 
stored at -20 ºC, but doubts were raised about their stability in solution during 
biological application. In order to tackle this isomerization problem, we decided to 
investigate the replacement of the acid-sensitive alkene by a cyclopropane that would 
generate more stable compounds. Docking studies led to design of analogue 180 that 
docked closer to tunnel C on the right hand side of the LRH-1 LBD (Figure 39), but 
introduction of the cyclopropane ring did not seem to alter the antagonistic binding 
pose of this analogue. 
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Figure 39 – Cyclopropane 180 virtually bond to LRH-1 LBD (left) and superimposed 
docking pose with 114 (yellow) (right) 
 
Many methods of efficient asymmetric cyclopropanations have been reported in the 
literature including introduction of chiral auxiliaries, use of stoichiometric chiral 
ligands and chiral catalytic systems.105 We initially investigated the direct 
cyclopropanation of alkene 114 using non-stereoselective conditions to generate 
racemic 180. With a robust synthetic approach towards 180, we could then screen 
different method to access this analogue enantioselectively. 
 
Treatment of olefins 114 and 162 under Simmons-Smith cyclopropanation conditions 
did not provide the desired products and both starting material alkenes proved to be 
unreactive towards these reaction conditions (Scheme 50).106 This could be explained 
by the steric hindrance of the alkenes, making them unreactive under these relatively 
mild conditions. 
 
 
 
Scheme 50 – Cyclopropanation using Simmons-Smith reaction conditions 
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The less hindered alkene (E)-stilbene (182) was then chosen as a model study for the 
cyclopropanation reaction. This compound proved to be unreactive under Simmons-
Smith conditions and only starting material was recovered. Addition of trifluoroacetic 
acid to catalyze the reaction led to the same conclusion.107 Reaction of 182 with the 
difluorocarbene generated by thermal decomposition of the sodium salt of 
chlorodifluoro acetic acid also failed to give the desired compound 185 (Table 3).108  
 
 
 
Entry Compound R Conditions Results 
1 184 H 
Et2Zn (2 eq), CH2I2 (4 eq), CH2Cl2, 
rt 
No reaction 
2 184 H 
Et2Zn (8 eq), CH2I2 (16 eq), 
CH2Cl2, rt 
No reaction 
3 184 H 
Et2Zn (8 eq), CH2I2 (16 eq), 
CH2Cl2, CF3COOH (few drops), rt 
No reaction 
4 185 F CClF2COONa, diglyme, 175 ºC No reaction 
 
Table 3 – Attempts towards the synthesis of cyclopropanes 184 and 185 
 
Considering these results, a new synthetic route to obtain cyclopropane analogue 180 
was chosen. Cyclopropanation of olefins using transition metal catalysis in the 
presence of diazoalkane intermediates appeared to be a possible alternative for the 
synthesis of 180. Many metals such as Cu, Rh and Pd have been reported as excellent 
catalysts for carbenoid formation followed by cyclopropanation with a desired 
olefin.109 With this in mind, it was believed that 180 could be obtained from diazo 
intermediate 186 and alkene 187 (Scheme 51).  
182
(rac)-183
R R
Conditions
	   95	  
 
 
 
Scheme 51 – Retrosynthetic analysis for cyclopropane analogue 180 
 
The reaction would proceed either via metal carbenoid 188 formation followed by 
cyclopropanation (Scheme 52, path A) or, without addition of catalyst, via 
(3+2) cycloaddition to form pyrazoline intermediate 190, which under thermal 
conditions could rearrange to the desired cyclopropane 191 (Scheme 52, path B). 
 
 
 
Scheme 52 – Metal carbenoid and pyrazoline pathways to synthesize 191 
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mixture of isomeric hydrazones 194 using hydrazine hydrate in ethanol at reflux. 
Finally, by following Miller’s work on the preparation of crystalline 
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diphenyldiazomethane,110 hydrazone 194 was oxidized in presence of yellow mercury 
(I) oxide and ethanolic potassium hydroxide as catalyst. Strictly anhydrous conditions 
were essential to prevent hydrolysis of sensitive diazo 186, which was isolated as a 
crude purple solid after filtration and solvent evaporation (Scheme 53). 
 
 
 
Scheme 53 – Synthesis of diazo intermediate 186 via hydrazone oxidation 
 
A Wittig reaction between ketone 158 and methyltriphenylphosphonium 
bromide (195) led quantitatively to alkene 187 (Scheme 54).111 
 
 
 
Scheme 54 – Synthesis of alkene 187 by Wittig reaction 
 
With diazo compound 186 and external alkene 187 in hand, the cyclopropanation 
reaction between these two reagents via metal carbenoid formation was then 
investigated. Acceptor groups generally stabilize the diazo compound by resonance 
meaning that active catalysts are required to generate the metal carbenoid 
intermediate. 186 being substituted with two electron rich substituents, it was 
believed that the metal insertion would proceed smoothly, generating the carbenoid 
that would then react with alkene 187 to form the desired cyclopropane 191. 
Unfortunately, treatment of 186 with rhodium (II) octanoate (dimer), palladium (II) 
diacetate or copper (II) triflate in presence of alkene 187 did not lead to the desired 
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product 191. Under Rh and Pd catalysis, the solution kept a purple color for several 
hours indicating that diazo 186 failed to react or reacted very slowly with the catalyst. 
Upon addition of copper (II) triflate, instant discoloration of the reaction mixture and 
gas evolution was observed. However, in all cases, no traces of product were isolated 
but formation of unidentified byproducts was observed (Table 4). In addition, a small 
amount of hydrazone 194 was recovered after purification of the mixture by column 
chromatography indicating that hydrazone oxidation to the corresponding diazo did 
not go to completion. 
 
 
 
Entry Conditions Results 
1 
Rh2(octanoate)4 (0.2 eq to 1.5 
eq), THF, rt 
Long discoloration and 
byproducts formation 
2 
Pd(OAc)2 (0.2 eq to 1.5 eq), 
THF, rt 
Long discoloration and 
byproducts formation 
3 Cu(OTf)2 (0.2 eq), THF, rt 
Rapid discoloration/gas 
evolution and byproducts 
formation 
 
Table 4 – Attempts towards the synthesis of cyclopropane 191 via metal carbenoid 
intermediate 
 
Use of metal free conditions were then investigated. Diazo 186 being relatively 
electron rich, it was believed that this intermediate would react in a 1,3-dipolar 
cycloaddition with alkene 187 under thermal conditions (see scheme 52, path B). 
Heating 186 and 187 in THF at reflux only led to formation of unidentified 
byproducts. Brewer reported that THF might react with diazo intermediate generating 
byproducts.112 With this in mind, diazo 186 was heated in 5 equivalents of neat alkene 
187. Pleasingly, under these conditions, cyclopropane 191 was isolated in 27% yield 
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over two steps (Scheme 55). No enantio- or diastereoselectivity was observed for this 
transformation and cyclopropane 191 was obtained as a 1:1 mixture of 
diastereoisomers (confirmed by NMR and LCMS). Variation of the number of alkene 
equivalents and/or temperature did not improve the yield of the reaction.  
 
 
 
Scheme 55 – Synthesis of cyclopropane 191 via 1,3-dipolar cycloaddition 
 
Compound 191 was then tested in our in vitro assay and displayed around 50% LRH-
1 inhibition at 10 µM. At 1 µM, this compound had almost no effect on LRH-1 
activity (Figure 40). Replacing the olefin by a cyclopropane did not seem to increase 
the inhibitory activity of the compound. However, 191 was tested as a racemic 
mixture of diastereoisomers. As a future plan, it would be interesting to develop an 
enantio- or diastereoselective synthesis of cyclopropane 191 to test each isomer 
independently.  
 
 
Figure 40 – In vitro biological evaluation of 191 at 10 µM and 1 µM 
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3.5. In vivo biological evaluation of the tamoxifen series 
 
In order to obtain preliminary data on how these compounds would behave in vivo, 
all the tamoxifen analogues were tested in a cell-based reporter gene assay that was 
developed by our collaborators from Hammersmith hospital (see Results and 
discussion § 1.2.). Except 191, none of these compounds displayed the desired 
antagonistic profile for concentrations ranging from 0.1 µM to 10 µM (Figure 41). 
Most of these analogues showed high cell toxicity for concentrations above 1 µM. 
This was probably due to the insolubility issues observed at high concentrations 
leading to the possible formation of aggregates. Under these conditions, cells can die 
instantly. In addition, considering the hydrophobicity of these tamoxifen analogues, 
they might display difficulties to penetrate the cell membrane, which would explain 
the “flat biological profile” observed at low concentrations. 
 
	  
Figure 41 – In vivo biological evaluation of tamoxifen analogues 	  
This in vivo reporter gene assay proved to be a biologically relevant model. However, 
few limitations were also pointed out; it was difficult to see small changes in activity 
meaning that this assay had a poor overall sensitivity. In addition, many variations 
between runs were also observed. 
 
At this point, the decision was made to start working on the design, synthesis and 
biological evaluation of raloxifene analogues. 
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4. Design and synthesis of raloxifene analogues as potential LRH-1 
antagonists 
 
Raloxifene (20) is considered to be a selective estrogen receptor modulator (SERM) 
because of its estrogen agonist action in some target tissues while acting as estrogen 
antagonist in others. Like tamoxifen, raloxifene acts as ERα antagonist in breast 
cancer cells but one key advantage of this compound is that it does not promote 
endometrial cancer. It also displays bone-protective and lipid-lowering activities. 
Raloxifene is used in breast cancer therapy and prevention for women presenting high 
risk of developing breast cancer. 
 
The idea to develop potential LRH-1 antagonists by modifying raloxifene’s structure 
was driven by the excellent work published in Nature by Brzozowski.46 In this paper, 
crystal structures of 17β-estradiol (19) and raloxifene bound to ERα were reported 
(Figure 42). Interestingly, both molecules bound within the same region of the ERα 
LBD but displayed different properties.  Upon binding of 17β-estradiol, ERα takes an 
active conformation leading to DNA binding and gene expression. That is not the 
case for raloxifene which involves ERα to take an inactive conformation by 
displacing H12. Two key hydrogen bonds placed the benzothiophene core in a similar 
conformation as 17β-estradiol but raloxifene’s hydrophobic side chain was then too 
long to be contained within the ligand binding pocket and displaced H12 (Figure 42, 
right structure). 
 
Figure 42 – Crystal structures of 17β-estradiol (19) (left) and raloxifene (20) (right) 
bound to ERα46 
	   101	  
 
Considering the fact that raloxifene’s side chain is responsible for ERα inactivation, 
it was then believed that modifications of raloxifene’s structure could generate virtual 
LRH-1 antagonists.  
 
4.1. First generation of analogues 	  
4.1.1. In silico modifications of raloxifene’s structure 
 
A similar approach used for both steroid and tamoxifen series was initially 
investigated. Docking studies were performed with raloxifene (20) virtually bound to 
LRH-1 LBD. Raloxifene displayed different binding modes in ERα and LRH-1, 
primarily due to the presence of an extra cavity (tunnel C) in LRH-1, responsible for 
the relocation of the piperidine side chain (Figure 43). Under these circumstances, 
H12 was not displaced and remained in an active conformation.  
 
 
 
Figure 43 – (a) - Binding mode of raloxifene (20) in ERα from co-crystal structure 
(pdb code 2JFA)94 - Orange ligand 
(b) - Binding mode of raloxifene (20) in LRH-1 - Grey ligand 
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In view of raloxifene’s docking pose in LRH-1, two key modifications were 
considered in order to alter its binding mode and generate compounds capable of 
displacing H12 (Scheme 56). In silico modifications of the piperidine ring were 
performed, the main idea being the ejection of this side chain from tunnel C and 
relocation close to H12.  
 
 
 
Scheme 56 – In silico modifications of raloxifene (20) 
 
Introduction of small non-polar groups such as methyl or ethyl moieties at position R1 
altered the docking poses but did not generate energetically favored poses (Table 4, 
entries 1 and 2). In addition, these analogues seemed unable to make steric clashes 
with H12.  
 
A second approach consisted of substituting the C-7 position of the benzothiophene 
ring (R2). In fact, this position was pointing directly towards H12 allowing these new 
C-7 substituted compounds to adopt the desired antagonist pose. LRH-1 LBD being 
mainly hydrophobic, various analogues with C-7 phenyl ring systems (Table 4, 
entries 3, 4 and 5) were designed leading to compound 50 with an extremely 
promising docking pose (entry 5, R2 = para-chlorophenyl). Phenyl 199 and phenol 
200 analogues displayed new altered and energetically disfavored docking poses, 
unable to displace H12. 
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Entry Compound R1 R2 
Docking results and 
comments 
1 197  H 
Pose change but R1 too far 
from H12 
2 198  H 
Pose change but R1 too far 
from H12 
3 199 H 
 
Not MM-GBSA preferred  
4 200 H 
 
Not MM-GBSA preferred 
5 50 H 
 
MM-GBSA preferred and 
steric clash with H12 
 
Table 4 – Docking results following in silico modifications of raloxifene (20) 
 
4.1.2. Synthesis of raloxifene analogue 50, best virtual LRH-1 antagonist 	  
In our computational studies, raloxifene analogue 50 took the desired antagonistic 
pose with the piperidine side chain located inside tunnel C and the para-chlorophenyl 
ring close to H12, showing a steric clash with the amino acid residue 
Leu532 (Figure 44). In order to validate our docking studies, synthesis of 50 was 
undertaken. 
 
H3C
H3C
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Cl
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Figure 44 – Promising docking pose of C-7 para-chlorophenyl analogue 50 	  
4.1.2.1. Retrosynthetic analysis 	  
The piperidine side chain from synthetic target 50 could be introduced by 
nucleophilic aromatic substitution on activated para-fluorobenzoyl 
intermediate 201 (Scheme 57). C-7 para-chlorophenyl compound 201 could be 
obtained by palladium-catalysed cross-coupling with iodide 202. C-3 aroyl moiety 
would be generated from benzothiophene 203 by Friedel-Crafts acylation. Finally, 
203 could be prepared in two steps from commercially available thiophenol 204 and 
α-bromo ketone 205 by following a literature procedure.113 	  
	  	  
Scheme 57 – Retrosynthetic analysis of raloxifene analogue 50 
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4.1.2.2. Synthesis of key intermediate 209 	  
The synthesis of benzothiophene intermediate 209 was performed in four steps from 
small building blocks available from commercial sources. Jones et al. showed that 
under basic conditions, nucleophilic substitution between thiophenol 204 and α-
bromo ketone 205 led to ketone 206 (Scheme 58).113 The latter was then cyclized in 
neat polyphosphoric acid at 85 ºC generating a mixture of isomers. In fact, the 
cyclization could take place either at the ortho- or para- positions of the methoxy- 
substituent. Both isomers were separated by selective crystallization from refluxing 
acetone, the major product 203 being isolated by filtration in 63% yield. The structure 
of the cyclized product was confirmed by NMR experiments and analysis of the 
aromatic protons coupling constants. The substituent at the C-3 position was 
introduced by Friedel-Crafts acylation in the presence of para-fluorobenzoyl 
chloride (207) and aluminium chloride leading to 208 in 69% yield.114 Finally, both 
methoxy- groups were deprotected using boron tribromide at low temperature.115 
Under these conditions, key bisphenol 209 was isolated in an excellent 95% yield. 
 
 
 
Scheme 58 – Synthesis of intermediate 209 
 
Interestingly, the acid-catalyzed benzothiophene cyclization led exclusively to C-2 
substituted intermediate 203 where a 3,2-shift of the methoxyphenol ring took place 
(Scheme 59). Under acidic conditions, an initial hydroalkylation by the protonated 
ketone 206 followed by aromatization generated intermediate 210 substituted at C-3 
position. The latter could then be protonated followed by a 3,2-shift and 
aromatization leading to the desired product 203.116 Protonation of 203 can still 
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happen, but in that case, the newly formed cation 213 is stabilized by resonance and 
unreactive. 
 
 
 
Scheme 59 – Formation of benzothiophene derivative 203 by 3,2-shift 
 
4.1.2.3. Synthesis of aryl chloride 201 by palladium-catalyzed cross-coupling  	  
With key intermediate 209 in hand, the selective introduction of the para-
chlorophenyl functionality at C-7 position of the benzothiophene ring was then 
investigated. Due to the electronic participation of the C-6 hydroxyl and sulfur atom, 
positions C-5 and C-7 appeared to be the most reactive towards electrophilic 
iodination. In 1991, Katzenellenbogen showed that iodination took place exclusively 
at the C-7 position of various benzothiophene intermediates.117 Even though the C-5 
position appears to be less sterically hindered towards an electrophilic attack of 
iodine, it seems like the presence of the sulfur atom plays a prominent role in the 
observed C-7 selectivity. In fact, it is possible that iodine could attach first to the 
sulfur atom followed by an intramolecular transfer to the C-7 position (Scheme 60). 
In presence of the iodine-morpholine complex, phenol 209 was converted to iodide 
202 in 63% yield. The latter was then converted to key aryl chloride 201 by Suzuki 
coupling using boronic acid 216. Stirring the solution at room temperature only led to 
the recovery of starting material 202.118 The same result was observed when the 
solution was heated at reflux for several hours. Pleasingly, the use of microwave 
irradiations at elevated temperature afforded the desired compound 201 in 87% yield. 
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Scheme 60 – Synthesis of aryl chloride 201 by Suzuki coupling 
 
4.1.2.4. Nucleophilic aromatic substitution approach to access analogue 50 
 
Schmid et al. reported the direct nucleophilic aromatic substitution of para- 
substituted aroyl compounds with various alcohols and applied this methodology to 
the synthesis of raloxifene (20).119 Using an excess of sodium hydride, fluoride 201 
was converted to final analogue 50 bearing the desired piperidine side chain. Under 
these reaction conditions, 50 was isolated in 30% yield (Scheme 61). This moderate 
yield could be explained by the presence of two unprotected phenolic functionalities. 
Under basic conditions, both phenols are deprotonated, generating an electron-rich 
intermediate less reactive towards nucleophilic aromatic substitution. 
 
 
 
Scheme 61 – Synthesis of final analogue 50 by nucleophilic aromatic substitution 
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4.1.3. High-throughput virtual screening of chemical database 
 
While working on the synthesis of analogue 50, we then decided to investigate into 
the docking of other classes of compounds in order to identify additional potential 
LRH-1 antagonists. By using our docking software and virtual chemical databases 
available at Emory University, Atlanta, USA, a high-throughput virtual screening was 
attempted on more than eight million compounds. Interestingly, the top hit selected 
was raloxifene-based analogue 218 bearing identical side chains at positions C-3 and 
C-7. This finding also comforted us on our initial idea to develop LRH-1 antagonists 
by modifying raloxifene’s structure. Analogue 218 took the desired antagonistic 
docking pose and displayed a similar binding mode compared to 50 (Figure 45). One 
piperidine side chain was located inside tunnel C and the C-7 substituent was 
pointing directly towards H12. 
 
 
 
Figure 45 – Docking pose of analogue 218 
 
Using a similar strategy developed for analogue 50, both piperidine side chains from 
synthetic target 218 could be introduced by nucleophilic aromatic substitution 
(Scheme 62). C-3 and C-7 aroyl functionalities could be generated from key 
intermediate 203 by Friedel-Crafts acylation. 
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Scheme 62 – Retrosynthetic analysis of raloxifene analogue 218 
 
Starting from benzothiophene intermediate 203, a double Friedel-Crafts acylation was 
attempted using an excess of para-fluorobenzoyl chloride (207) and 220 was isolated 
in 70% yield (Scheme 63). The acylation proceeded at positions C-3 and C-7 using a 
large excess of aluminium chloride. Under these conditions, the C-6 methoxy- 
functionality was also deprotected, generating free phenol 220. This could be 
explained by the presence of the carbonyl group ortho- to the methoxy- functionality. 
The deprotection presumably proceeds via the same mechanism as a boron trichloride 
methoxy- deprotection.120 In fact, the reaction is accelerated by formation of a 6-
membered ring chelate between the aluminium, the carbonyl and phenolic oxygen 
atom leading to free phenol 220. The remaining methoxy- group was removed using a 
solution of boron tribromide in dichloromethane affording bisphenol 219 in 79% 
yield. Finally, the latter was engaged in nucleophilic aromatic substitutions 
generating analogue 218 in a moderate 52% yield. 
 
 
 
Scheme 63 – Synthesis of analogue 218 via double Friedel-Crafts acylation 
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4.1.4. Biological evaluation of both raloxifene analogues 	  
Titration curves for both raloxifene analogues 50 and 218 were then made to evaluate 
their activity towards LRH-1 at different concentrations (Figure 46). Pleasingly, 
analogue 50 showed excellent antagonistic properties with an IC50 value of 30 nM. 
However, we rapidly observed that this compound proved to have insolubility issues 
in many organic solvents leading to the possible formation of aggregates capable of 
producing false positions during the biological evaluation of this compound. DMSO 
and ethanol are generally used to run the assay. Compound 50 proved to be mainly 
insoluble in ethanol and crashed out from solution after a few hours if dissolved in 
DMSO. Compound 218 displayed better solubility in DMSO and no insoluble 
particles were observed, at least by eye. This compound proved to be more polar due 
to its extra piperidine side chain and carbonyl moiety. Despite being less active than 
50, 218 showed promising antagonistic properties towards LRH-1 with an IC50 value 
of 1.91 µM. 
 
     
 
Figure 46 – Titration curves and IC50 values of analogues 50 and 218 
 
Both compounds displayed interesting properties but there was a real need for the 
development of alternative analogues. On one hand, 50 had to be modified to 
generate more polar compounds with increased solubility properties in DMSO. On 
the other hand, 218 showed activity in the µM range giving us the opportunity to 
slightly modify its structure to design compounds with better potency. 
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4.2. Second generation of analogues 	  
4.2.1. In silico modifications of raloxifene analogue 218 
 
Analogue 218 displayed the desired antagonistic docking pose with the C-7 aroyl 
functionality being responsible for steric interactions with H12 (see Figure 45). 
However, it seemed that the key steric contact between this side chain and the amino 
acid residue Leu532 from H12 was made through the meta- hydrogen attached to the 
aromatic ring (Figure 47). 
 
 
 
Figure 47 – Docking pose of analogue 218 
 
In view of this docking pose, analogue 218 could be modified to potentially increase 
its potency against LRH-1. It was believed that meta- hydrogens from the C-7 aroyl 
moiety could be replaced by methyl groups to emphasize the steric clash with H12. In 
addition, the ethoxypiperidine side chain did not seem to play a major role and was 
replaced by a hydrogen atom to simplify the analogue’s structure. 
 
Friedel-Crafts acylation between benzothiophene 208 and 3-methylbenzoyl 
chloride (221) afforded intermediate 222 that was directly deprotected using boron 
tribromide to yield phenol 223 (Scheme 64). Nucleophilic aromatic substitution 
between aryl fluoride 223 and alcohol 217 led to the desired analogue 224 in 
moderate yield. 
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Scheme 64 – Synthesis of analogue 224 via Friedel-Crafts acylation 
 
CADD studies performed on analogue 228 led to two reorganized docking poses 
where the 3,5-dimethylbenzoyl C-7 moiety proved to be flexible due to its smaller 
size compared to 218 C-7 side chain (Figure 48). View (a) did not display steric 
interactions with Leu532 but was the energetically favored docking pose. View (b) 
was slightly higher in energy and showed virtual antagonistic properties. The 
synthesis and biological evaluation of this analogue was then investigated to validate 
one of these two docking poses: view (a) implicates that 228 would act as an agonist 
whereas view (b) presents 228 as a virtual LRH-1 antagonist. 
 
     
    View (a)         View (b) 
 
Figure 48 – Best two docking poses of analogue 228 
 
Using a similar approach developed for 224, analogue 228 was synthesized in three 
steps from key intermediate 208 (Scheme 65). 
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Scheme 65 – Synthesis of analogue 228 via Friedel-Crafts acylation 	  
4.2.2. In silico modifications of raloxifene analogue 50 	  
As explained earlier, analogue 50 was too hydrophobic to be easily dissolved in 
DMSO and accurately biologically assayed. In a drug discovery context, the 
compound’s structure had to be modified by introduction of more polar 
functionalities to improve its solubility properties. It was initially decided to work on 
the piperidine replacement as this side chain was introduced at the very last step of 
the synthesis. This strategy would allow the design and synthesis of a wide range of 
analogues in a short amount of time.  
 
SAR studies started with the piperidine moiety replacement by a morpholine and 
piperazine rings. It was thought that introduction of extra oxygen or nitrogen atoms 
would increase the solubility of these new compounds. The docking software 
QikProp, widely used in drug discovery to predict several absorption, distribution, 
metabolism, excretion and toxicity (ADMET) properties of small molecules, was 
used to predict the solubility of analogues 229 and 230.121 Compound 50 had a 
predicted solubility of -9.0 whereas morpholine 229 (-8.1) and piperazine 230 (-6.8) 
displayed better solubility properties (Scheme 66). 
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Scheme 66 – Predicted solubility of new generation of analogues 229 and 230 
 
Docking studies performed on these two compounds 229 and 230 revealed promising 
binding poses (Figure 49). In fact, both compounds displayed energetically favored 
docking poses with virtual antagonistic properties. However, introduction of extra 
oxygen and nitrogen atoms reorganized the poses in comparison to analogue 50. 
Morpholine and piperazine side chains were ejected from tunnel C and relocated 
closer to H12 where steric interactions could occur. 
 
 
 
Figure 49 – Superimposed docking poses of analogues 229 (pink) and 230 (blue) 
 
Starting from key intermediate 201, morpholine analogue 229 was synthesized in one 
step by direct nucleophilic aromatic substitution with alcohol 231 in 34% yield 
(Scheme 67). 
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Scheme 67 – Synthesis of morpholine analogue 229 by nucleophilic aromatic 
substitution 
 
A similar approach was attempted for the synthesis of piperazine analogue 230.            
1-(2-Hydroxyethyl)piperazine (232) was initially protected as a carbamate in 90% 
yield to prevent any N-alkylation during the nucleophilic aromatic substitution 
(Scheme 68).122 Compound 233 was then reacted under basic conditions with key 
intermediate 201 generating 234 in 49% yield. Finally, acidic deprotection afforded 
quantitatively piperazine analogue 230.123   
 
 
 
Scheme 68 – Synthesis of piperazine analogue 230 by nucleophilic aromatic 
substitution 
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4.2.3. Rapid SAR studies on piperazine analogue 230 
 
With piperazine analogue 230 bearing a secondary amine functionality, it was 
believed that the design and synthesis of analogues substituted on this nitrogen atom 
would tell us if groups at this basic position were tolerated to maintain reasonable 
activity. Any significant differences in activity between 230 and substituted 
piperazine analogues would resolve the importance of the free secondary amine. 
 
1-(2-Hydroxyethyl)piperazine (232) was initially converted to methylpiperazine 235 
by reductive amination using an aqueous solution of formaldehyde and sodium 
cyanoborohydride as reducing agent (Scheme 69).124 The resulting primary alcohol 
was then engaged in a nucleophilic aromatic substitution with 201 leading to final 
analogue 236. When heated between 50 ºC and 100 ºC, no conversion was observed 
and both starting materials were recovered. Pleasingly, the use of microwave 
irradiation allowed the isolation of analogue 236 in 69% yield. 
 
 
 
Scheme 69 – Synthesis of methylpiperazine analogue 236 
 
It was then believed that introduction of an ethyl group would decrease the 
compound’s polarity and that again a solubility issue might be observed. Considering 
that, the synthesis of a more polar amide 238 was attempted. 230 was treated with 
diisopropylamine (Hünig’s base) and acetyl chloride (237).125 Under these conditions, 
amide 238 was isolated in 66% yield (Scheme 70). 
 
SHO
O
ONN
OH
236
Cl
SHO
O
OH
201Cl
F
NaH, DMF, 80 oC
µwave
69%
HO N
N R
232, R = H
235, R = CH3, 100%
CH2O, NaBH3CN
THF, 50 oC
H3C
	   117	  
 
 
Scheme 70 – Synthesis of amide analogue 238 
 
4.2.4. Introduction of BS-194 polar side chain 	  
4.2.4.1. BS-194 as cyclin-dependent protein kinase inhibitor 
 
Within the Barrett group, a potent and selective cyclin-dependent protein kinase 
(CDK) inhibitor 239 (BS-194) was recently identified and developed.126 This 
compound proved to reduce activity of CDK2, CDK1, CDK5 and CDK9 at IC50 
values of 3 nM, 33 nM, 30 nM and 90 nM respectively. These excellent properties are 
believed to be mainly due to the presence of the triol side chain that makes key water 
mediated interactions within the adenosine triphosphate (ATP) binding pocket. This 
was confirmed by a crystal structure of 239 bound to the inactive form of 
CDK2 (Figure 50). 
 
                             
 
Figure 50 – CDK inhibitor 239 (BS-194) co-crystallized with inactive form of CDK2 
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In addition, this compound displayed good ADMET properties and pharmacokinetic 
data including high oral bioavailability. In order to increase the polarity of lead 
analogue 50, it was believed that the piperidine moiety could be replaced by the BS-
194 triol side chain. Introduction of such a side chain would not necessarily generate 
new hydrogen bonding interactions analogous to CDK2 but rather increase the 
analogue’s polarity, which would improve solubility properties. By using the 
QikProp software, the solubility of analogue 240 was then calculated.121 With a 
predicted solubility of -6.1, triol analogue 240 potentially displayed excellent 
solubility properties compared to piperidine analogue 50 (-9.0) (Scheme 71). 
 
 
 
Scheme 71 – Predicted solubility of triol analogue 240 compared to piperidine 50 and 
piperazine 230 analogues 
 
Docking studies on analogue 240 also displayed a promising antagonistic binding 
pose where the triol side chain was located close to H12 (Figure 51). Considering 
that, the synthesis of this LRH-1 virtual antagonist was attempted. 
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Figure 51 – Docking pose of analogue 240 bearing the BS-194 side chain 
 
4.2.4.2. Retrosynthetic analysis of analogue 240 	  
It was thought that the synthetic target 240 could be obtained using a similar 
approach compared to piperidine 50, morpholine 229 and piperazine 230 analogues. 
The triol side chain could be introduced by nucleophilic aromatic substitution 
between primary alcohol 241 and fluoride intermediate 201. 241 could be synthesized 
by reductive amination from primary amine 242. The amine would then be obtained 
in seven steps from commercially available (–)-diethyl tartrate (243) (Scheme 72).126 
 
	  	  
Scheme 72 – Retrosynthetic analysis of analogue 240 	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4.2.4.3. Synthesis of protected BS-194 side chain 242 	  
The synthesis started by formation of the cyclic sulfite 244 by treatment of (–)-diethyl 
tartrate (243) with an excess of thionyl chloride in presence of 
triethylamine (Scheme 73). The resulting sulfite 244 was then opened with sodium 
azide leading to azido-alcohol 245 in 64% yield over two steps.127 Diethyl ester 245 
was reduced using lithum borohydride generated in situ from lithium chloride and 
sodium borohydride.128 Due to the exothermic nature of the reaction, the temperature 
had to be carefully monitored to prevent epimerization of the substrate. The crude 
boronic esters were then cleaved using acidic conditions and the pH of the reaction 
mixture was adjusted to 4. Triol 246 proved to be extremely sensitive to acidic 
pH (< 4) and elevated temperatures leading to partial epimerization. Filtration 
through silica gel afforded the desired triol intermediate 246 that was used without 
further purification. Vicinal diol was then protected as an acetonide with 2,2-
dimethoxypropane. Heating the reaction mixture at 50 ºC afforded the 
thermodynamic 1,3-acetal. Under these conditions, protection of the remaining 
primary alcohol as a hemiketal was also observed. Treatment of the reaction mixture 
with a saturated aqueous solution of ammonium chloride led to alcohol 247 in 
69% yield over three steps. Finally, MOM- protection of the primary alcohol 
followed by azide reduction to the primary amine led to the desired protected BS-194 
side chain 242 in two high-yielding steps. 
 
	  	  
Scheme 73 – Synthesis of protected BS-194 side chain 242 	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4.2.4.4. Synthesis of alcohol 241 and SNAr attempts 	  
With protected BS-194 side chain 242 in hand, the synthesis of primary alcohol 241 
was then investigated. Shah et al. reported very convenient reaction conditions for the 
reductive amination of aldehydes with primary amines.129 Acetal 242 being relatively 
unstable towards acidic conditions, mild conditions had to be used. In the reductive 
amination of aldehydes with primary amines, dialkylation is a common side reaction. 
In order to tackle this issue and prevent any aldehyde reduction, 250130,104 was 
initially treated with an excess of amine 242 in dichloroethane. After fifteen minutes 
at room temperature, sodium triacetoxyborohydride was added to convert the in situ 
generated imine to the corresponding secondary amine 251. Under these conditions, 
251 was isolated in 68% yield over three steps (Scheme 74). Amine 251 was then 
protected as a carbamate and silyl ether deprotection using TBAF afforded primary 
alcohol 241. 
 
 
 
Scheme 74 – Synthesis of primary alcohol 241 from amine 242 
 
Alcohol 241 was then engaged in a nucleophilic aromatic substitution with key 
intermediate 201. However, the use of standard conditions only led to the recovery of 
unreacted fluoride 201 (Table 5, entry 1). Heating the solution at 80 ºC did not 
provide the desired product but decomposition of alcohol 241 was observed. The 
same observation was made when the reaction mixture was stirred at 50 ºC under 
microwave irradiations. As explained earlier, under basic conditions both free phenol 
functionalities from 201 are deprotonated, generating an electron rich intermediate 
globally unreactive towards a nucleophilic aromatic substitution at the carbon-
fluorine position. 
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Entry Conditions Results 
1 
241 (4 eq), NaH (6.4 eq), 
DMF, 50 ºC 
Unreacted starting material 201 
2 
241 (4 eq), NaH (6.4 eq), 
DMF, 80 ºC 
Decomposition of alcohol 241 
3 
241 (4 eq), NaH (6.4 eq), 
DMF, microwave, 50 ºC 
Decomposition of alcohol 241 
 
Table 5 – Attempts towards the nucleophilic aromatic substitution between 
alcohol 241 and fluoride 201 
 
Considering these results, there was a real need for the development of a new 
synthetic approach to access compound 240. It was believed that protection of both 
phenol functionalities from 201 would provide a new intermediate, more reactive 
towards nucleophilic aromatic substitution conditions.  
 
4.2.4.5. New synthetic approach to access analogue 240 	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194 side chain 242 and the aldehyde derived from acetal 253. 253 could be 
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approach as for intermediate 201, the C-7 para-chlorophenyl functionality could be 
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introduced in two steps via palladium-catalysed cross-coupling and iodination from 
intermediate 208 (Scheme 75).	  	  
	  	  
Scheme 75 – Retrosynthetic analysis of analogue 240 	  
The iodination of protected compound 208 was initially investigated. Attempts to 
introduce the C-7 iodine group using the mild morpholine-iodine complex proved to 
be unsuccessful probably due to the steric hindrance of the C-6 methoxy- 
functionality (Table 6, entry 1). More harsh reaction conditions were then used. 
Treating 208 with N-iodosuccinimide (NIS) in neat acetic acid afforded the desired 
compound 255 in excellent yield (98%).131 Reacting 208 with NIS in presence of 
catalytic trifluoroacetic acid also led to 255 in good yield.132 
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Entry Conditions Yields 
1 
Iodine (3 eq), morpholine (9 eq), 
benzene, dark 
Recovered starting material 
2 NIS (1.3 eq), AcOH, dark 98% 
3 
NIS (1.1 eq), CF3COOH (0.3 eq), 
CH3CN, dark 
80% 
 
Table 6 – Attempts towards the C-7 iodination of benzothiophene 208 
 
Compound 255 was then engaged in a Suzuki coupling with boronic acid 216 
generating aryl chloride 254 in 80% yield (Scheme 76). With both phenol 
functionalities protected, it was then expected that 254 would be more reactive 
towards nucleophilic aromatic substitution conditions. Treatment of 254 with primary 
alcohol 256 under basic conditions nicely afforded acetal 253 in 79% yield, 
validating our previous assumption.  
 
 
Scheme 76 – Synthesis of acetal 253 via nucleophilic aromatic substitution 
208 255
Conditions
6
7
S
OCH3
O
F
H3CO
S
OCH3
O
F
H3CO
I
Pd/C, Na2CO3
H2O/EtOH, µwave, 150 oC
80%S
OCH3
O
F
H3CO
255I
SH3CO
O
OCH3
254Cl
F
Cl
B OH
OH
216
NaH
DMF, 50 oC
79%
OHEtO
OEt
S
O
OCH3
O
H3CO
Cl
EtO
OEt
256
253
	   125	  
Acetal deprotection is generally carried out using aqueous acidic conditions. 
However, 253 proved to be unreactive towards treatment with a 1 M aqueous solution 
of hydrogen chloride in tetrahydrofuran.133 Heating the solution at reflux slightly 
increased the rate of the reaction but a conversion of only 10% was observed after 
twelve hours. The use of a stronger acid was then investigated.  
 
Li et al. reported the deprotection of diethyl acetals with trifluoroacetic acid without 
addition of water.134 Treatment of 253 with ten equivalents of trifluoroacetic acid in 
chloroform led to aldehyde 257 which was directly engaged in a reductive amination 
reaction with protected BS-194 side chain 242, generating secondary amine 258 in 
84% yield over three steps (Scheme 77).  
 
Kroll showed that the BS-194 side chain could be deprotected using a 5 M methanolic 
solution of hydrogen chloride.126 In order to minimize the number of steps to access 
analogue 240, it was believed that both methoxy- functionalities, the acetal and the 
MOM- ether could be cleaved in a single step using boron tribromide. The acidity of 
the reagent followed by an aqueous work-up should provide triol 240. Treatment of 
258 with three and four equivalents of boron tribromide only led to partial 
deprotection generating the free triol with only one methoxy- group being cleaved. 
Pleasingly, the use of five equivalents of boron tribromide led to the desired analogue 
240 in 82% yield (Scheme 77). The number of equivalents as well as the temperature 
of the reaction had to be carefully monitored to prevent cleavage of the substituted 
aminoethoxy side chain. 
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Scheme 77 – Synthesis of final analogue 240 bearing the BS-194 side chain 
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in energy compared to the agonist docking pose (view (a)). However, this compound 
showed a solubility issue in DMSO compared to analogue 218, probably due to the 
replacement of the polar ethoxypiperidine side chain and introduction of the 
hydrophobic 3,5-dimethylbenzyl functionality. 
 
	  
Figure 52 – In vitro biological evaluation of second generation of analogues 
at 10 µM 	  
In addition to these interesting biological properties, morpholine 229, piperazine 230 
and triol 240 analogues displayed better solubility properties compared to piperidine 
analogue 50. All compounds were easily dissolved in methanol for characterization 
and analysis purposes whereas 50 proved to be insoluble in such polar solvent. Once 
dissolved in DMSO, no precipitate or cloudiness of the solution was observed which 
was a great improvement compared to our first generation of analogues. 
 
It was then believed that structural modifications of the most active compounds, 
piperazine analogues 230 and 236 could be undertaken in order to further improve 
both their potency towards LRH-1 and solubility properties. In view of Figure 49, the 
virtual docking pose of 230 displayed a steric clash between the piperazine ring and 
the amino acid residue Leu532 from H12. Introduction of a polar methanol side chain 
on the C-2 and C-3 positions was then considered, leading to the generation of 
analogues 259 and 260 (Scheme 78). 
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Scheme 78 – New synthetic targets 259 and 260 bearing a methanol side chain on 
positions C-2 and C-3 of the piperazine ring 
 
4.3. Syntheses of piperazine analogues 259 and 260 	  
With a robust and reproducible approach to access aldehyde 257 (see Schemes 76 
and 77), it was believed that both piperazine analogues 259 and 260 could be 
synthesized by reductive amination between aldehyde 257 and the desired piperazine 
intermediates bearing the methanol side chain either at C-2 or C-3 positions. 
 
4.3.1. Synthesis of analogue 259 with C-3 substituted piperazine side chain 	  
The piperazine scaffold was introduced by condensation between diethyl 
bromomalonate (262) and N,N’-dibenzylethylenediamine (261).135 Heating both 
compounds in acetonitrile at reflux afforded 263 in good yield (Scheme 79). The 
more basic amine was then deprotected by hydrogenolysis and the resulting 
intermediate 264 was reduced with lithium aluminium hydride (LAH), generating 
racemic amino alcohol 265. 
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Scheme 79 – Synthesis of piperazine intermediate 265 
 
Even though the unprotected primary alcohol might react with the in situ generated 
imine, reductive amination between aldehyde 257 and amino alcohol 265 was 
attempted on a small scale (Scheme 80). Under these conditions, the reaction did not 
afford the desired compound 266 but an unidentified byproduct was isolated. 
 
 
 
Scheme 80 – Attempt towards the synthesis of alcohol 266 by reductive amination 
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silyl ether group had also been cleaved. It was then expected that the debenzylation 
by catalytic hydrogenation would be slow due to the in situ generation of a free 
secondary amine capable of poisoning the catalyst. It was thought that the addition of 
acid would catalyze the reaction by amine protonation. Treating benzyl amine 269 
under standard hydrogenation conditions in presence of hydrogen chloride generated 
by addition of acetyl chloride to methanol mainly led to the recovery of unreacted 
starting material.136 Pleasingly, debenzylation in presence of trifluoroacetic acid 
followed by purification under basic conditions afforded 3-methanolpiperazine 
analogue 259. 
 
 
 
Scheme 81 – Synthesis of 3-methanol piperazine analogue 259 
 
4.3.2. Synthesis of analogue 260 with C-2 substituted piperazine side chain 
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alcohol using a short sequence to avoid any side reaction during the reductive 
amination step. The protecting group also had to be acid stable to prevent any 
deprotection during the debenzylation step. With this in mind, amino alcohol 265 was 
converted to oxazolidinone 270 using diethylcarbonate.137 Debenzylation under 
acidic conditions afforded secondary amine 271 (Scheme 82). 
 
 
 
Scheme 82 – Synthesis of oxazolidinone intermediate 271 
 
Imine formation between aldehyde 257 and amine 271 followed by reduction using 
sodium triacetoxyborohydride led to tertiary amine 272 (Scheme 83). Methoxy- 
functionalities were then deprotected using an excess of boron tribromide and 
oxazolidinone 273 was converted to amino alcohol 260 using an aqueous solution of 
sodium hydroxide in methanol at reflux.138  
 
 
 
 
Scheme 83 – Synthesis of 2-methanol piperazine analogue 260 
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4.3.3. Biological evaluation of piperazine analogues 259 and 260 	  
Both analogues 259 and 260, bearing a methanol piperazine side chain, were then 
tested in our in vitro assay at 10 µM (Figure 53). Pleasingly, these compounds 
displayed excellent LRH-1 inhibition with a percentage of inhibition similar to initial 
piperazine lead compound 230 (40% at 10 µM). Introduction of a methanol side 
chain at positions C-2 and C-3 of the piperazine ring did not seem to improve the 
analogues activities but compounds 259 and 260 proved to be polar compounds that 
could be easily dissolved in DMSO for biological evaluation. 	  
	  
Figure 53 – In vitro biological evaluation of C-2 and C-3 substituted piperazine 
analogues 259 and 260 at 10 µM 	  
Piperazine analogue 230 was the most active compound from our second generation 
of analogues. With this in mind, a titration experiment was conducted to evaluate its 
activity towards LRH-1 at different concentrations (Figure 54). 230 displayed 
activity in the µM range with an IC50 value of 5.97 µM.  
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Figure 54 – Titration curve and IC50 value of piperazine analogue 230  
 
In this section, we managed to design and synthesize new LRH-1 antagonists by 
logical structural modifications of the anti-estrogen raloxifene (20). Piperazine 
analogue 230 displayed good in vitro activity (5.97 µM) and solubility properties that 
proved to be extremely important to perform accurate and reproducible biological 
evaluations. 
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Conclusion 
 
Our collaborators from Hammersmith Hospital showed that LRH-1 acts as a key 
regulator of the estrogen response in breast cancer cells through the regulation of 
ERα expression. Considering this, the development of small molecules capable of 
inhibiting LRH-1 activity appeared to be an excellent approach for the treatment of 
breast cancer. As a result computational studies were performed to discover LRH-1 
antagonists.  
 
Steroid-based analogues 
 
Steroid-based analogues bearing an unusual and challenging C-2 ether side chain 
were initially designed. Docking studies performed on analogues 48 and 63 displayed 
promising virtual binding poses where the C-2 linkage was responsible for key steric 
interactions with H12. It was believed that H12 displacement would generate an 
inactive conformation of LRH-1 and prevent CoA recruitment followed by gene 
expression. A novel and efficient approach was then developed to isolate 48 and 63. 
These two analogues were synthesized in fifteen steps starting from steroid-based 
starting material pregnenolone (71) (Scheme 84). 
 
 
 
Scheme 84 – Synthetic approach for the syntheses of analogues 48 and 63 
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4-Hydroxytamoxifen analogues 
 
Analogues of the anti-estrogen 4-hydroxytamoxifen (13) were also designed and 
synthesized. Computational studies displayed energetically favored docking poses for 
the four analogues 114, 115, 113 and 49. A stereoselective approach allowed the 
formation of the internal alkene with the desired (Z)-conformation (Scheme 85). A 
second generation of analogues was then designed to either improve biological 
potency (piperidine introduction) or prevent isomerization of the acid sensitive alkene 
(cyclopropane introduction). 
 
 
 
Scheme 85 – Synthetic approach for the syntheses of 4-hydroxytamoxifen analogues 
 
Raloxifene analogues 
 
Finally, the design of analogues structurally related to the selective estrogen receptor 
modulator (SERM) raloxifene (20) was investigated. Docking studies performed on 
20 showed that the C-7 position of the benzothiophene ring was pointing directly 
towards H12. A first generation of analogues 50 and 218 was designed and 
synthesized but proved to be too hydrophobic and insoluble in many organic 
solvents (Scheme 86). It was then believed that the replacement of the piperidine 
moiety by more polar functionalities such as morpholine, piperazine and a triol side 
chain would overall improve the solubility profile of these compounds. Finally, with 
230 as a lead compound for our design, the synthesis of a third generation of 
analogues was investigated. The piperazine ring, responsible for steric clashes with 
H12, was replaced by bulkier and more polar 2-methanol and 3-methanol piperazine 
side chains (analogues 259 and 260). 
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Scheme 86 – Design and syntheses of raloxifene analogues 
 
These three series of compounds were tested in an in vitro assay to evaluate their 
biological activity towards LRH-1. All of these analogues displayed antagonistic 
properties but the steroid series only showed little activity. Tamoxifen analogue 114 
had an IC50 in the high nM range but this series of compounds proved to have 
insolubility issues in many organic solvents including DMSO, raising doubts about 
their biological application. Structural modifications of these compounds with 
introduction of polar functionalities might generate more active compounds with 
good solubility properties. Finally, the raloxifene series showed the most encouraging 
results. SAR studies performed on initial lead 50 led to analogue 230 that displayed 
good antagonist activity towards LRH-1 and improved solubility properties. In 
conclusion, the CADD approach proved to be very useful to rapidly generate LRH-1 
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antagonists. This demonstrates that with a crystal structure of the protein of interest 
available, rational drug design could be envisaged to synthesize hit compounds with 
good activity. However, many structural changes are required to generate compounds 
with optimized physicochemical properties that could progress into a drug candidate. 
Our best raloxifene analogues will now be tested in vivo to evaluate their activities at 
the cellular level and structural modifications will be attempted to design and 
synthesize “drug-like” molecules.  
 
	   138	  
Experimental part 	  	  	  
All chemicals were used as received, or purified using standard procedures. Solvents 
were dried by standard techniques and distilled under nitrogen before use. 
Tetrahydrofuran and diethyl ether were distilled from sodium with benzophenone 
indicator. Toluene was distilled from sodium. Dichloromethane and methanol were 
distilled from calcium hydride. N,N-Dimethylformamide, dimethylsulfoxide, ethanol 
and benzene were purchased anhydrous and used as received. All experiments were 
carried out in oven-dried glassware under an inert atmosphere of nitrogen or argon. 
 
Analytical thin layer chromatography (TLC) was performed using pre-coated Merck 
aluminium or glass backed plates (Silicagel 60 F254). Visualization was by ultraviolet 
light and/or treatment with potassium permanganate (KMnO4), vanillin or ninhydrin 
stains followed by heating as deemed appropriate. 
 
Flash column chromatography was carried out using Merck 9385 Kieselgel 60 (230-
400 mesh) under a positive pressure of nitrogen. 
 
NMR spectra were recorded on a Bruker DRX-400 spectrometer using an internal 
deuterium lock at ambient probe temperatures. Chemical shifts (δ) are quoted in parts 
per million (ppm) and are referenced to a residual solvent peak.139 Alternatively, 
spectra were recorded at 500 MHz (1H NMR) and 125 MHz (13C NMR) by the NMR 
Service, Imperial College London, Department of Chemistry. Assignments were 
determined on the basis of unambiguous chemical shift and coupling pattern. 
Additional experiments (COSY, DEPT 135, HSQC, HMBC and NOE) were used to 
aid assignments but are not included. 
 
Mass spectra were recorded by the Mass Spectrometry Service, Imperial College 
London, Department of Chemistry using a Micromass Platform II and Micromass 
AutoSpec-Q spectrometer. 
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Infra-red (IR) spectra were recorded on a Perkin-Elmer Spectrum BX II FT-IR 
System with ATR technique, monitoring from 4000-700 cm-1. All samples were run 
neat or as thin films deposited via the evaporation of solvent. 
 
Melting points were determined using a Reichert-Thermovar melting point apparatus 
and are uncorrected. 
 
Specific rotations were measured at 25 °C on a Perkin-Elmer 241 polarimeter with a 
path length of 1 dm, using a sodium lamp (λ = 589 nm, D-line); concentrations (c) are 
quoted in g/100 mL. 
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(8S,9S,10R,13S,14S,17S)-tert-Butyl-2-bromo-10,13-dimethyl-3-oxo-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] 
phenanthrene-17-carboxylate (69) 
 
 
 
A solution of ketone 7082 (1.50 g, 4.03 mmol, 1.0 eq) in THF (40 mL) was added 
dropwise to a solution of LiHMDS (4.83 mL, 4.83 mmol, 1.2 eq, 1.0 M in THF) in 
THF (4.8 mL) at -78 °C. The reaction mixture was stirred for 30 min and HMPA 
(840 µL, 4.83 mmol, 1.2 eq) was added. The solution was stirred for an additional 
30 min at -78 °C. Trimethylsilyl chloride (3.07 mL, 24.2 mmol, 6.0 eq) was added 
and the reaction mixture was stirred at -78 °C for 1 h, warmed to 0 °C and stirred for 
a further 30 min. The mixture was then concentrated in vacuo and the crude silyl enol 
ether 76 was dissolved in THF (40 mL) and cooled to 0 °C. A solution of N-
bromosuccinimide (789 mg, 4.43 mmol, 1.1 eq) in THF (9.0 mL) was then added 
dropwise and the reaction mixture was stirred for 30 min. The mixture was diluted 
with Et2O and quenched by addition of an aqueous solution of HCl (1.0 M). The 
aqueous layer was extracted with Et2O (× 3) and the combined organic extracts were 
dried over MgSO4, filtered and concentrated. The yellow crude solid was purified by 
flash column chromatography (gradient PE/Et2O 80:20 to 70:30) to yield C-2 
bromide 69 as a white amorphous solid (1.22 g, 67%, 2:3 mixture of C-2 epimers 
α:β (Breq:Brax)). 
 
1H-NMR (400MHz, CDCl3): Selected peaks only as mixture of isomers 
(Breq): δH = 5.82 (s, 1H, H4, CH=C), 4.81 (dd, 1H, Jax-ax = 14.5 Hz, Jax-eq = 5.1 Hz, H2, 
CH-Br), 1.45 (s, 9 H, CO2C(CH3)3), 1.28 (s, 3H, H19, C-CH3), 0.72 (s, 3H, H18, C-
CH3) 
(Brax): δH = 5.84 (s, 1H, H4, CH=C), 4.54 (dd, 1H, Jeq-ax = 6.2 Hz, Jeq-eq = 5.4 Hz, H2, 
CH-Br), 1.45 (s, 9 H, CO2C(CH3)3), 1.37 (s, 3H, H19, C-CH3), 0.72 (s, 3H, H18, C-
CH3) 
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13C-NMR (100MHz, CDCl3): δC = 191.4, 190.9, 173.0, 172.5, 171.4, 121.5, 120.6, 
79.9, 55.8, 55.3, 54.0, 53.9, 51.1, 48.0, 46.4, 43.9, 43.6, 42.0, 40.1, 38.2, 38.0, 35.4, 
35.3, 33.2, 32.5, 31.7, 28.3, 24.3, 23.3 
 
IR: υmax/cm−1 (neat): 2940, 1717, 1681, 1623, 1453, 1367, 1222, 1149, 847  
 
MS (ESI): m/z = 451 [M(79Br)+H]+, 453 [M(81Br)+H]+ 
HRMS (ESI): calculated for C24H3679BrO3 [M+H]+ 451.1848, found: 451.1851 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-tert-Butyl-2-(4-chlorophenoxy)-10,13-dimethyl-3-
oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]-
phenanthrene-17-carboxylate (78) 
 
 
 
Sodium hydride (68.8 mg, 1.72 mmol, 3.1 eq, 60% dispersion in mineral oil) was 
added to a solution of para-chlorophenol 77 (214 mg, 1.66 mmol, 3.0 eq) in THF 
(3.4 mL) at 0 °C and the reaction mixture was stirred for 30 min. A solution of 
bromide epimers 69 (250 mg, 0.553 mmol, 1.0 eq, 2:3 (α:β)) in THF (1.1 mL) was 
then added and the mixture stirred at 0 °C for 30 min and then warmed to room 
temperature over a 3-hour period. The mixture was diluted with EtOAc and quenched 
by addition of a saturated aqueous solution of NH4Cl. The aqueous layer was 
extracted with EtOAc (× 2). The combined organic extracts were washed with a 10% 
aqueous KOH solution (× 2) and brine, then dried over MgSO4, filtered and 
concentrated. The crude solid was purified by flash column chromatography (gradient 
PE/Et2O 80:20 to 50:50) to yield ether 78 as a white solid (208 mg, 75%, 10:1 
mixture of C-2 epimers α:β). The mixture was further purified by recrystallization 
2
4
19
O OtBu
H H
H
O
O
Cl
18
	   143	  
from EtOAc to provide 78 as a single diastereoisomer (aryl ether in equatorial 
position (α)). 
 
1H-NMR (400MHz, CDCl3): δH = 7.21 (d, 2H, J = 8.9 Hz, ArH), 6.84 (d, 2H, 
J = 8.9 Hz, ArH), 5.78 (s, 1H, H4, CH=C), 4.78 (dd, 1H, Jax-ax = 13.7 Hz, Jax-eq 
= 4.9 Hz, H2, CH-OAr), 2.41-2.32 (m, 3H), 2.26 (t, 1H, J = 9.2 Hz), 2.12-2.02 (m, 
2H), 1.94-1.85 (m, 2H), 1.80-1.65 (m, 2H), 1.61-1.54 (m, 3H), 1.45 (s, 9H, 
CO2C(CH3)3), 1.33 (s, 3H, H19, C-CH3), 1.30-1.22 (m, 2H), 1.14-1.00 (m, 3H), 0.72 
(s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 195.7, 173.1, 170.7, 156.9, 129.3, 126.3, 122.0, 
117.1, 79.9, 75.8, 55.8, 55.3, 54.3, 43.6, 42.2, 40.7, 38.0, 35.2, 32.3, 31.9, 28.3, 24.3, 
23.2, 20.8, 18.2, 13.2 
 
IR: υmax/cm−1 (CHCl3): 2938, 1721, 1687, 1490, 1367, 1245, 1215, 1151, 823, 733 
 
MS (ESI): m/z = 499 [M(35Cl)+H]+, 501 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C30H4035ClO4 [M+H]+ 499.2615, found: 499.2612 
 
Melting point: 204-207 °C (EtOAc) 
 
Specific rotation: [α]D25 = +40.8 (c 4.2, CHCl3) 
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(2R,8S,9S,10R,13S,14S,17S)-17-tert-Butyl-3-methyl 2-(4-chlorophenoxy)-10,13-
dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a] 
phenanthrene-3,17-dicarboxylate (81) 
 
 
 
Triflic anhydride (222 µL, 1.32 mmol, 2.0 eq) was added to a solution of enone 78 
(330 mg, 0.660 mmol, 1.0 eq) and 2,6-di-tert-butyl-4-methylpyridine (79) (448 mg, 
2.18 mmol, 3.3 eq) in CH2Cl2 (6.8 mL) at -20 °C. The reaction mixture was stirred 
for 2.5 h (without addition of dry ice to the acetone/dry ice bath) and then poured into 
a saturated aqueous solution of NH4Cl. The aqueous layer was extracted with 
CH2Cl2 (× 2). The combined organic extracts were washed with a saturated solution 
of NaHCO3, dried over MgSO4, filtered and concentrated. The crude enol triflate 80 
was dissolved in a 1:1 mixture of DMF and MeOH (1.4 mL). Triethylamine (184 µL, 
1.32 mmol, 2.0 eq) was added and the mixture was sparged with N2 for 5 min. 
Bis(triphenylphosphine)palladium (II) diacetate (50.4 mg, 0.0660 mmol, 0.10 eq) 
suspended in dry DMF (0.50 mL) was then added and the reaction mixture sparged 
with carbon monoxide for 5 min and stirred under an atmosphere of carbon monoxide 
for 18 h. The mixture was then diluted with EtOAc and washed successively with an 
aqueous solution of HCl (1.0 M) and brine. The organic phase was dried over MgSO4, 
filtered and concentrated. The crude black oil was dry loaded on silica gel and 
purified by flash column chromatography (gradient PE/Et2O 85:15 to 80:20) to yield 
dienyl ester 81 as a white solid (262 mg, 73% over 2 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.22 (d, 2H, J = 8.8 Hz, ArH), 7.03 (s, 1H, 
H4, CH=C), 6.92 (d, 2H, J = 8.8 Hz, ArH), 5.95 (m, 1H, H6, CH=C), 5.17 (dd, 1H, 
Jax-ax = 9.2 Hz, Jax-eq = 6.8 Hz, H2, CH-OAr), 3.69 (s, 3H, CO2-CH3), 2.44 (dd, 1H, 
J = 12.7 Hz, J = 6.4 Hz), 2.33-2.24 (m, 2H), 2.15-2.03 (m, 2H), 1.82-1.60 (m, 5H), 
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1.44 (s, 9H, CO2C(CH3)3), 1.41-1.27 (m, 4H), 1.17-1.10 (m, 2H), 0.99 (s, 3H, H19, C-
CH3), 0.70 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 173.1, 167.0, 157.3, 139.9, 139.8, 133.4, 129.3, 
126.4, 125.9, 117.9, 79.8, 72.7, 56.0, 55.7, 51.5, 47.9, 43.7, 40.1, 38.0, 36.5, 32.1, 
30.6, 28.2, 24.3, 23.2, 20.9, 19.8, 13.1 
 
IR: υmax/cm−1 (CHCl3): 2970, 2850, 1709, 1638, 1590, 1487 
 
MS (ESI): m/z = 413 [M-OPhCl]+ 
HRMS (ESI): calculated for C26H37O4 [M-OPhCl]+ 413.2692, found: 413.2701 
 
Melting point: 161-163 °C (EtOAc) 
 
Specific rotation: [α]D25 = -138.0 (c 4.2, CHCl3) 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-2-(4-Chlorophenoxy)-3-(methoxycarbonyl)-10,13-
dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a] 
phenanthrene-17-carboxylic acid (82) 
 
 
 
Triethylamine (930 µL, 6.66 mmol, 18 eq) was added to a solution of ester 81 
(200 mg, 0.370 mmol, 1.0 eq) in CH2Cl2 (5.0 mL) at 0 °C. Trimethylsilyl 
trifluoromethane sulfonate (600 µL, 3.33 mmol, 9.0 eq) was then added and the 
reaction mixture stirred at 0 °C for 2 h, warmed to room temperature and stirred for 
an additional 1 h. The solution was then diluted with EtOAc and quenched by 
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addition of a saturated aqueous solution of NaHCO3. The aqueous layer was extracted 
with EtOAc (× 3) and the combined organic extracts were dried over MgSO4, filtered 
and concentrated. The crude oil was purified by flash column chromatography 
(gradient PE/EtOAc 85:15 to 80:20) to yield acid 82 as white foam (165 mg, 92%). 
Repurified by flash column chromatography (gradient CH2Cl2/Et2O 100:0 to 96:4) 
for analytically pure sample. 
 
1H-NMR (400MHz, CDCl3): δH = 7.23 (d, 2H, J = 8.8 Hz, ArH), 7.04 (s, 1H, 
H4, CH=C), 6.93 (d, 2H, J = 8.8 Hz, ArH), 5.95 (m, 1H, H6, CH=C), 5.18 (dd, 1H, 
Jax-ax = 8.8 Hz, Jax-eq = 6.8 Hz, H2, CH-OAr), 3.69 (s, 3H, CO2-CH3), 2.46-2.38 (m, 
2H), 2.34-2.28 (dt, 1H, J = 20.1 Hz, J = 4.9 Hz), 2.16-2.09 (m, 2H), 1.90-1.71 (m, 
3H), 1.64-1.61 (m, 2H), 1.48-1.27 (m, 4H), 1.21-1.10 (m, 2H), 1.00 (s, 3H, H19, C-
CH3), 0.76 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 179.7, 167.0, 157.3, 139.9, 139.8, 133.2, 129.3, 
126.5, 126.0, 117.9, 72.7, 56.0, 54.9, 51.6, 47.8, 44.1, 40.1, 37.7, 36.5, 32.1, 30.7, 
24.4, 23.3, 20.9, 19.8, 13.2 
 
IR: υmax/cm−1 (CHCl3): 2949, 1699, 1638, 1489, 1240, 1005 
 
MS (ESI): m/z = 357 [M-OPhCl]+ 
HRMS (ESI): calculated for C22H29O4 [M-OPhCl]+ 357.2066, found: 357.2076 
LCMS for purity – decomposition on the HPLC column 
 
Specific rotation: [α]D25 = -98.8 (c 4.2, CHCl3) 
 
 
 
 
 
 
 
 
 
	   147	  
(2R,8S,9S,10R,13S,14S,17S)-Methyl-2-(4-chlorophenoxy)-10,13-dimethyl-17-
((pyridin-2-ylthio)carbonyl)-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-
cyclopenta[a]phenanthrene-3-carboxylate (85) 
 
 
 
Triphenylphosphine (65 mg, 0.25 mmol, 1.7 eq) and 2,2ʹ-dithiodipyridine (84) 
(55 mg, 0.25 mmol, 1.7 eq) were added to a solution of acid 82 (71 mg, 0.15 mmol, 
1.0 eq) in toluene (0.70 mL). The reaction mixture was stirred at room temperature 
for 24 h and then purified by flash column chromatography (gradient CH2Cl2/Et2O 
100:0 to 98:2) to yield thiopyridyl ester 85 as a colorless oil (79 mg, 94%). 
 
1H-NMR (400MHz, CDCl3): δH = 8.61 (dd, 1H, J = 4.9 Hz, J = 1.5 Hz, PyrH), 7.76-
7.71 (dt, 1H, J = 7.8 Hz, J = 2.0 Hz, PyrH), 7.61 (d, 1H, J = 7.8 Hz, PyrH), 7.29-7.22 
(m, 3H, PyrH, ArH), 7.04 (s, 1H, H4, CH=C), 6.94 (d, 2H, J = 8.8 Hz, ArH), 5.96 (m, 
1H, H6, CH=C), 5.18 (dd, 1H, Jax-ax = 9.3 Hz, Jax-eq = 6.4 Hz, H2, CH-OAr), 3.70 (s, 
3H, CO2-CH3), 2.74 (t, 1H, J = 9.3 Hz), 2.44 (dd, 1H, J = 12.7 Hz, J = 6.4 Hz), 2.34-
2.26 (m, 3H), 1.97-1.90 (m, 1H), 1.85-1.61 (m, 4H), 1.48-1.27 (m, 4H), 1.25-1.14 (m, 
2H), 1.00 (s, 3H, H19, C-CH3), 0.78 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 196.8, 167.0, 157.4, 151.8, 150.2, 139.8, 137.1, 
133.1, 130.2, 129.3, 126.5, 126.0, 123.4, 118.0, 72.7, 64.5, 56.2, 51.6, 47.8, 45.0, 
40.1, 38.0, 36.5, 32.1, 30.7, 24.5, 24.1, 20.9, 19.8, 13.3 
One quaternary carbon signal missing 
 
IR: υmax/cm−1 (CHCl3): 2947, 1713, 1640, 1576, 1489, 1264, 1240, 1038, 1005 
 
MS (ESI): m/z = 578 [M(35Cl)+H]+, 580 [M(37Cl)+H]+ 
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HRMS (ESI): calculated for C33H37NO4S35Cl [M+H]+ 578.2132, found: 578.2134 
 
Specific rotation: [α]D25 = -17.7 (c 3.5, CHCl3) 
 
 
 
tert-Butyl-(4-iodophenoxy)dimethylsilane (87)140 
 
 
 
To a solution of 4-iodophenol (86) (4.00 g, 18.2 mmol, 1.0 eq) in CH2Cl2 (7.3 mL) 
was successively added TBSCl (3.01 g, 20.0 mmol, 1.1 eq) and triethylamine 
(2.80 mL, 20.0 mmol, 1.1 eq). The reaction mixture was then stirred at room 
temperature for 16 h, diluted with CH2Cl2 and quenched by addition of a 1 M aqueous 
solution of HCl. The aqueous phase was extracted with CH2Cl2 (× 1) and the 
combined organic extracts were washed with brine, dried over MgSO4, filtered and 
concentrated. The resulting crude oil was purified by flash column chromatography 
(PE 100%) to yield 87 as a colorless oil (4.35 g, 72%). The spectroscopic data were 
identical to that in the literature.140 
 
1H-NMR (400MHz, CDCl3): δH = 7.52 (d, 2H, J = 8.8 Hz, ArH), 6.63 (d, 2H, 
J = 8.8 Hz, ArH), 0.99 (s, 9H, C-(CH3)3), 0.20 (s, 6H, Si-(CH3)2) 
 
13C-NMR (100MHz, CDCl3): δC = 155.6, 138.3, 122.5, 83.7, 25.6, 18.2, -4.5 
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(2R,8S,9S,10R,13S,14S,17S)-Methyl-17-(4-(tert-butyldimethylsilyloxy)benzoyl)-2-
(4-chlorophenoxy)-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-
1H-cyclopenta[a]phenanthrene-3-carboxylate (89) 
 
 
 
Isopropylmagnesium chloride (88) (316 µL, 0.424 mmol, 3.5 eq, 1.4 M in THF) was 
added dropwise to a solution of aryl iodide 87 (106 mg, 0.315 mmol, 2.6 eq) in dry 
THF (2.3 mL) under N2 at 0 °C. The mixture was stirred for 2.5 h and then added to a 
solution of thiopyridyl ester 85 (70.5 mg, 0.121 mmol, 1.0 eq) in THF (0.60 mL) at           
-50 °C. The reaction mixture was then stirred for 30 min and quenched by addition of 
a saturated aqueous solution of NH4Cl and warmed to room temperature. The 
solution was diluted with Et2O and both phases were separated. The aqueous layer 
was extracted with Et2O (× 4) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. The yellow crude oil was dry loaded on silica gel 
and purified by flash column chromatography (PE/Et2O 80:20) to yield 78.5 mg of 
impure protected phenol 89 as a colorless oil (ArOTBS as byproduct – ratio 
89/ArOTBS 6.7:1). This was used directly in the next step without further 
purification. 
 
1H-NMR (400MHz, CDCl3): δH = 7.82 (d, 2H, J = 8.8 Hz, TBSOArH), 7.21 (d, 2H, 
J = 8.8 Hz, ArH), 7.04 (s, 1H, H4, CH=C), 6.91 (d, 2H, J = 8.8 Hz, ArH), 6.84 (d, 
2H, J = 8.8 Hz, TBSOArH), 5.97 (m, 1H, H6, CH=C), 5.17 (m, 1H, H2, CH-OAr), 
3.70 (s, 3H, CO2-CH3), 3.45 (t, 1H, J = 8.8 Hz), 2.47-2.32 (m, 3H), 1.80-1.76 (m, 
3H), 1.66-1.64 (m, 1H), 1.56-1.49 (m, 2H), 1.43-1.30 (m, 5H), 1.16-1.13 (m, 1H), 
0.98 (app-s, 12H, H19, C-CH3, OSiC(CH3)3), 0.64 (s, 3H, H18, C-CH3), 0.22 (s, 6H, 
OSi(CH3)2) 
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13C-NMR (100MHz, CDCl3): δC = 200.2, 167.1, 160.0, 157.4, 140.0, 139.8, 133.5, 
132.6, 130.5, 129.3, 126.5, 126.0, 119.7, 118.0, 72.8, 57.3, 56.6, 51.6, 48.0, 44.9, 
40.2, 39.0, 36.5, 32.3, 30.8, 25.6, 24.8, 24.1, 21.1, 19.8, 18.3, 13.6, -4.3 
 
IR: υmax/cm−1 (CHCl3): 2954, 2860, 1718, 1596, 1508, 1488, 1240, 1166, 911, 839, 
781 
 
MS (ESI): m/z = 547 [M-OPhCl]+, 675 [M+H]+ 
HRMS (ESI): calculated for C40H52O5Si35Cl [M+H]+ 675.3273, found: 675.3297 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-Methyl-2-(4-chlorophenoxy)-17-(4-
hydroxybenzoyl)-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-
1H-cyclopenta[a]phenanthrene-3-carboxylate (90) 
 
 
 
Tetrabutylammonium fluoride (0.15 mL, 0.15 mmol, 2 eq, 1 M in THF) was added 
dropwise to a solution of the impure silyl protected phenol 89 (51 mg, 0.076 mmol, 
1 eq) in dry THF (0.80 mL) under N2 at 0 °C. The reaction mixture was stirred at 
room temperature for 30 min, diluted with EtOAc and then washed with a saturated 
aqueous solution of NaHCO3. The aqueous layer was extracted with EtOAc (× 3) and 
the combined organic extracts were dried over MgSO4, filtered and concentrated. The 
crude oil was purified by flash column chromatography (gradient CH2Cl2/Et2O 100:0 
to 98:2) to yield phenol 90 as a white amorphous solid (35 mg, 59% over 2 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.83 (d, 2H, J = 8.8 Hz, HOArH), 7.20 (d, 2H, 
J = 8.8 Hz, ArH), 7.05 (s, 1H, H4, CH=C), 6.90 (d, 2H, J = 8.8 Hz, ArH), 6.85 (d, 
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2H, J = 8.8 Hz, HOArH), 6.75 (s, 1H, ArOH), 5.98 (m, 1H, H6, CH=C), 5.16 (m, 1H, 
H2, CH-OAr), 3.71 (s, 3H, CO2-CH3), 3.46 (t, 1H, J = 8.8 Hz), 2.49-2.32 (m, 3H), 
1.85-1.77 (m, 3H), 1.65-1.62 (m, 1H), 1.55-1.49 (m, 2H), 1.42-1.29 (m, 5H), 1.16-
1.10 (m, 1H), 0.95 (s, 3H, H19, C-CH3), 0.63 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 200.6, 167.3, 160.3, 157.2, 140.2, 139.7, 133.6, 
131.7, 130.9, 129.3, 126.3, 126.0, 117.9, 115.2, 72.6, 57.2, 56.6, 51.7, 47.9, 45.0, 
40.1, 39.0, 36.5, 32.2, 30.8, 24.7, 24.0, 21.1, 19.7, 13.5 
 
IR: υmax/cm−1 (CHCl3): 3349, 2949, 1715, 1639, 1602, 1488, 1238, 1167, 1007, 827, 
739 
 
MS (ESI): m/z = 433 [M-OPhCl]+, 561 [M+H]+ 
HRMS (ESI): calculated for C34H38O535Cl [M+H]+ 561.2408, found: 561.2418 
 
Specific rotation: [α]D25 = -120.5 (c 0.83, CHCl3) 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-2-(4-Chlorophenoxy)-17-(4-hydroxybenzoyl)-10,13-
dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a] 
phenanthrene-3-carboxylic acid (48) 
 
 
 
Ester 90 (76 mg, 0.14 mmol, 1.0 eq) was dissolved in a mixture of MeOH (4.8 mL) 
and H2O (0.30 mL). Lithium hydroxide monohydrate (0.11 g, 2.7 mmol, 20 eq) was 
then added in one portion and the reaction mixture stirred at room temperature for 
4 days. The solution was diluted with EtOAc and quenched by addition of an aqueous 
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solution of HCl (1.0 M). The aqueous layer was extracted with EtOAc (× 4) and the 
combined organic extracts were dried over MgSO4, filtered and concentrated. The 
crude solid was purified by preparative TLC (CH2Cl2/Et2O 90:10) to yield acid 48 as 
an amorphous white solid (38 mg, 51%). 
 
1H-NMR (500MHz, CD3OD): δH = 7.81 (d, 2H, J = 8.8 Hz, HOArH), 7.20 (d, 2H, 
J = 8.8 Hz, ArH), 7.00 (s, 1H, H4, CH=C), 6.94 (d, 2H, J = 8.8 Hz, ArH), 6.80 (d, 
2H, J = 8.8 Hz, HOArH), 5.97 (m, 1H, H6, CH=C), 5.16 (m, 1H, H2, CH-OAr), 3.55 
(t, 1H, J = 8.8 Hz), 2.45-2.31 (m, 3H), 1.85-1.73 (m, 3H), 1.68-1.61 (m, 1H), 1.49-
1.43 (m, 7H), 1.15-1.10 (m, 1H), 0.98 (s, 3H, H19, C-CH3), 0.59 (s, 3H, H18, C-CH3) 
 
13C-NMR (125MHz, CD3OD): δC = 202.5, 170.3, 163.5, 158.9, 141.3, 140.3, 134.2, 
132.2, 132.1, 130.3, 128.9, 126.7, 118.9, 116.1, 73.6, 58.2, 57.5, 49.4, 46.1, 41.3, 
40.0, 37.7, 33.3, 32.2, 25.8, 24.9, 22.2, 20.1, 14.1 
 
IR: υmax/cm−1 (CHCl3): 3248, 2939, 1684, 1637, 1601, 1582, 1488, 1423, 1379, 1236, 
1166, 1092, 1000, 824 
 
MS (ESI): m/z = 419 [M-OPhCl]+, 547 [M+H]+ 
HRMS (ESI): calculated for C33H36O535Cl [M+H]+ 547.2251, found: 547.2249 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-tert-Butyl-10,13-dimethyl-3-oxo-2-phenoxy-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] 
phenanthrene-17-carboxylate (93) 
 
 
 
Sodium hydride (316 mg, 7.91 mmol, 3.1 eq, 60% dispersion in mineral oil) was 
added to a solution of phenol (92) (719 mg, 7.64 mmol, 3.0 eq) in THF (15 mL) at 
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0 °C and the reaction mixture stirred for 30 min. A solution of bromide epimers 69 
(1.15 g, 2.55 mmol, 1.0 eq, 2:3 (α:β)) in THF (5.0 mL) was then added and the 
mixture stirred at 0 °C for 30 min, and then warmed to room temperature over a 3-
hour period. The mixture was diluted with EtOAc and quenched by addition of a 
saturated aqueous solution of NH4Cl. The aqueous layer was extracted with 
EtOAc (× 2). The combined organic extracts were washed with a 10% aqueous KOH 
solution (× 2) and brine, then dried over MgSO4, filtered and concentrated. The crude 
solid was dry loaded on silica gel and purified by flash column chromatography 
(gradient PE/Et2O 80:20 to 65:35) to yield ether 93 as a sticky, white paste (930 mg, 
79%) (no recrystallization needed, isolated as a single diastereoisomer, aryl ether in 
equatorial position (α)). 
 
1H-NMR (400MHz, CDCl3): δH = 7.28 (t, 2H, J = 7.4 Hz, ArH), 6.98 (t, 1H, J = 7.4 
Hz, ArH), 6.93 (d, 2H, J = 7.4 Hz, ArH), 5.81 (s, 1H, H4, CH=C), 4.87 (dd, 1H, Jax-ax 
= 13.7 Hz, Jax-eq = 4.9 Hz, H2, CH-OAr), 2.44-2.37 (m, 3H), 2.28 (t, 1H, J = 8.8 Hz), 
2.15-2.05 (m, 2H), 1.95-1.85 (m, 2H), 1.83-1.68 (m, 2H), 1.62-1.54 (m, 2H), 1.46 (s, 
9H, CO2C(CH3)3), 1.35 (s, 3H, H19, C-CH3), 1.34 (m, 1H), 1.32-1.24 (m, 2H), 1.15-
1.00 (m, 3H), 0.74 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 195.9, 173.0, 170.3, 158.1, 129.3, 122.0, 121.3, 
115.6, 79.8, 75.3, 55.6, 55.2, 54.2, 43.6, 42.2, 40.7, 37.9, 35.1, 32.2, 31.8, 28.2, 24.2, 
23.1, 20.7, 18.1, 13.1 
 
IR: υmax/cm−1 (CHCl3): 2970, 2934, 2853, 1722, 1688, 1598, 1495, 1366, 1243, 1216, 
1149, 751 
 
MS (ESI): m/z = 465 [M+H]+, 528 [M+Na+MeCN]+ 
HRMS (ESI): calculated for C30H41O4 [M+H]+ 465.3005, found: 465.3008 
 
Specific rotation: [α]D25 = +101.2 (c 1.0, CHCl3) 
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(2R,8S,9S,10R,13S,14S,17S)-17-tert-Butyl-3-methyl 10,13-dimethyl-2-phenoxy-
2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-
3,17-dicarboxylate (95) 
 
 
 
Triflic anhydride (384 µL, 2.28 mmol, 2.0 eq) was added to a solution of enone 93 
(530 mg, 1.14 mmol, 1.0 eq) and 2,6-di-tert-butyl-4-methylpyridine (79) (773 mg, 
3.76 mmol, 3.3 eq) in CH2Cl2 (12 mL) at -20 °C. The reaction mixture was stirred for 
2.5 h (without addition of dry ice to the acetone/dry ice bath) and then poured into a 
saturated aqueous solution of NH4Cl. The aqueous layer was extracted with 
CH2Cl2 (× 2). The combined organic extracts were washed with a saturated solution 
of NaHCO3, dried over MgSO4, filtered and concentrated. The crude enol triflate 94 
was dissolved in a 1:1 mixture of DMF and MeOH (2.4 mL). Triethylamine (318 µL, 
2.28 mmol, 2.0 eq) was added and the mixture was sparged with N2 for 5 min. 
Bis(triphenylphosphine)palladium (II) diacetate (86.5 mg, 0.114 mmol, 0.10 eq) 
suspended in dry DMF (0.50 mL) was then added and the reaction mixture sparged 
with carbon monoxide for 5 min and stirred under an atmosphere of carbon monoxide 
for 18 h. The mixture was then diluted with EtOAc and washed successively with an 
aqueous solution of HCl (1.0 M) and brine. The organic phase was dried over MgSO4, 
filtered and concentrated. The crude black oil was dry loaded on silica gel and 
purified by flash column chromatography (gradient PE/Et2O 85:15 to 80:20) to yield 
dienyl ester 95 as a white solid (374 mg, 65% over 2 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.28 (t, 2H, J = 7.4 Hz, ArH), 7.04-6.94 (m, 4H, 
H4, CH=C, ArH), 5.95 (m, 1H, H6, CH=C), 5.25 (m, 1H, H2, CH-OAr), 3.70 (s, 3H, 
CO2-CH3), 2.50 (dd, 1H, J = 12.7 Hz, J = 6.4 Hz), 2.35-2.25 (m, 2H), 2.15-2.03 (m, 
2H), 1.81-1.57 (m, 5H), 1.45 (s, 9H, CO2C(CH3)3), 1.44-1.36 (m, 2H), 1.31-1.21 (m, 
2H), 1.16-1.09 (m, 2H), 1.01 (s, 3H, H19, C-CH3), 0.71 (s, 3H, H18, C-CH3) 
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13C-NMR (100MHz, CDCl3): δC = 173.2, 167.2, 158.7, 139.9, 139.7, 133.0, 129.4, 
126.9, 121.1, 116.6, 79.8, 72.1, 56.1, 55.8, 51.5, 47.9, 43.8, 40.2, 38.0, 36.5, 32.1, 
30.7, 28.2, 24.3, 23.3, 21.0, 19.8, 13.2 
 
IR: υmax/cm−1 (CHCl3): 2966, 2935, 1721, 1641, 1597, 1492, 1367, 1263, 1153 
 
MS (ESI): m/z = 413 [M-OPh]+, 570 [M+Na+MeCN]+ 
HRMS (ESI): calculated for C34H45O5NNa [M+Na+MeCN]+ 570.3195, found: 
570.3194 
 
Specific rotation: [α]D25 = -146.6 (c 1.0, CHCl3) 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-3-(Methoxycarbonyl)-10,13-dimethyl-2-phenoxy-
2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-17-
carboxylic acid (96) 
 
 
 
Triethylamine (1.49 mL, 10.7 mmol, 18 eq) was added to a solution of ester 95 
(300 mg, 0.594 mmol, 1.0 eq) in CH2Cl2 (8.0 mL) at 0 °C. Trimethylsilyl 
trifluoromethane sulfonate (970 µL, 5.33 mmol, 9.0 eq) was then added and the 
reaction mixture stirred at 0 °C for 2 h, warmed to room temperature and stirred for 
an additional 1 h. The solution was then diluted with EtOAc and quenched by 
addition of a saturated aqueous solution of NaHCO3. The aqueous layer was extracted 
with EtOAc (× 3) and the combined organic extracts were dried over MgSO4, filtered 
and concentrated. The crude oil was purified by flash column chromatography 
(gradient PE/EtOAc 100:0 to 90:10) to yield acid 96 as white foam (170 mg, 64%). 
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1H-NMR (400MHz, CDCl3): δH = 7.29 (t, 2H, J = 7.4 Hz, ArH), 7.04-6.96 (m, 4H, 
H4, CH=C and ArH), 5.95 (m, 1H, H6, CH=C), 5.26 (m, 1H, H2, CH-OAr), 3.70 (s, 
3H, CO2-CH3), 2.49 (dd, 1H, J = 12.7 Hz, J = 6.4 Hz), 2.41 (t, 1H, J = 9.3 Hz), 2.36-
2.28 (dt, 1H, J = 19.6 Hz, J = 5.4 Hz), 2.16-2.09 (m, 2H), 1.90-1.71 (m, 3H), 1.65-
1.57 (m, 2H), 1.48-1.26 (m, 4H), 1.22-1.11 (m, 2H), 1.02 (s, 3H, H19, C-CH3), 0.77 
(s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 179.9, 167.2, 158.6, 139.9, 139.6, 132.8, 129.4, 
126.9, 121.1, 116.5, 72.0, 56.0, 54.9, 51.5, 47.8, 44.1, 40.2, 37.7, 36.5, 32.1, 30.7, 
24.4, 23.3, 20.9, 19.8, 13.2 
 
IR: υmax/cm−1 (CHCl3): 2948, 1699, 1638, 1596, 1491, 1435, 1265, 1239, 1038, 754 
 
MS (ESI): m/z = 357 [M-OPh]+, 514 [M+Na+MeCN]+ 
HRMS (ESI): calculated for C30H37O5NNa [M+Na+MeCN]+ 514.2569, 
found: 514.2560 
 
Specific rotation: [α]D25 = -130.6 (c 1.0, CHCl3) 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-Methyl-10,13-dimethyl-2-phenoxy-17-((pyridin-2-
ylthio)carbonyl)-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a] 
phenanthrene-3-carboxylate (97) 
 
 
 
Triphenylphosphine (153 mg, 0.585 mmol, 1.7 eq) and 2,2ʹ-dithiodipyridine (84) 
(129 mg, 0.585 mmol, 1.7 eq) were added to a solution of acid 96 (155 mg, 
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0.344 mmol, 1.0 eq) in toluene (1.5 mL). The reaction mixture was stirred at room 
temperature for 20 h and then purified by flash column chromatography (gradient 
CH2Cl2/Et2O 100:0 to 98:2) to yield thiopyridyl ester 97 as a colorless oil (160 mg, 
86%). 
 
1H-NMR (400MHz, CDCl3): δH = 8.62 (m, 1H, PyrH), 7.74-7.70 (dt, 1H, 
J = 7.8 Hz, J = 2.0 Hz, PyrH), 7.60 (d, 1H, J = 7.8 Hz, PyrH), 7.31-7.25 (m, 3H, 
PyrH, ArH), 7.04-6.96 (m, 4H, H4, CH=C and ArH), 5.95 (m, 1H, H6, CH=C), 5.26 
(m, 1H, H2, CH-OAr), 3.69 (s, 3H, CO2-CH3), 2.73 (t, 1H, J = 9.3 Hz), 2.49 (dd, 1H, 
J = 12.7 Hz, J = 5.9 Hz), 2.34-2.23 (m, 3H), 1.96-1.86 (m, 1H), 1.83-1.73 (m, 2H), 
1.69-1.59 (m, 2H), 1.51-1.30 (m, 4H), 1.25-1.12 (m, 2H), 1.01 (s, 3H, H19, C-CH3), 
0.78 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 196.8, 167.1, 158.6, 151.9, 150.3, 139.9, 139.5, 
136.9, 132.7, 130.1, 129.4, 127.0, 123.3, 121.1, 116.5, 72.0, 64.5, 56.2, 51.5, 47.8, 
44.9, 40.2, 38.0, 36.5, 32.0, 30.6, 24.5, 24.0, 20.9, 19.8, 13.2 
 
IR: υmax/cm−1 (CHCl3): 2949, 1710, 1641, 1596, 1490, 1421, 1262, 1239, 1037, 913, 
766, 729 
 
MS (ESI): m/z = 544 [M+H]+ 
HRMS (ESI): calculated for C33H38NO4S [M+H]+ 544.2522, found: 544.2507 
 
Specific rotation: [α]D25 = -21.0 (c 1.7, CHCl3) 
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(2R,8S,9S,10R,13S,14S,17S)-Methyl-17-(4-(tert-butyldimethylsilyloxy)benzoyl)-
10,13-dimethyl-2-phenoxy-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-
cyclopenta[a]phenanthrene-3-carboxylate (98) 
 
 
 
Isopropylmagnesium chloride (88) (740 µL, 0.928 mmol, 3.5 eq, 1.26 M in THF) was 
added dropwise to a solution of aryl iodide 87 (230 mg, 0.689 mmol, 2.6 eq) in dry 
THF (5.3 mL) under N2 at 0 °C. The mixture was stirred for 2.5 h and then added to a 
solution of thiopyridyl ester 97 (144 mg, 0.265 mmol, 1.0 eq) in THF (1.4 mL) at           
-50 °C. The reaction mixture was then stirred for 30 min and quenched by addition of 
a saturated aqueous solution of NH4Cl and warmed to room temperature. The 
solution was diluted with Et2O and both phases were separated. The aqueous layer 
was extracted with Et2O (× 4) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. The yellow crude oil was dry loaded on silica gel 
and purified by flash column chromatography (PE/Et2O 80:20) to yield 223 mg of 
impure protected phenol 98 as a colorless oil. The material was used directly in the 
next step without further purification. 
 
IR: υmax/cm−1 (CHCl3): 2956, 2932, 2860, 1719, 1596, 1491, 1254, 1239, 1165, 913, 
838, 781 
 
MS (ESI): m/z = 547 [M-OPh]+, 641 [M+H]+ 
HRMS (ESI): calculated for C40H53O5Si [M+H]+ 641.3662, found: 641.3677 
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(2R,8S,9S,10R,13S,14S,17S)-methyl-17-(4-hydroxybenzoyl)-10,13-dimethyl-2-
phenoxy-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a] 
phenanthrene-3-carboxylate (99) 
 
 
 
Tetrabutylammonium fluoride (0.530 mL, 0.530 mmol, 2 eq, 1 M in THF) was added 
dropwise to a solution of the impure silyl protected phenol 98 (0.265 mmol, 1 eq) in 
dry THF (2.7 mL) under N2 at 0 °C. The reaction mixture was stirred at room 
temperature for 30 min, diluted with EtOAc and then washed with a saturated 
aqueous solution of NaHCO3. The aqueous layer was extracted with EtOAc (× 3) and 
the combined organic extracts were dried over MgSO4, filtered and concentrated. The 
crude oil was purified by flash column chromatography (gradient CH2Cl2/Et2O 100:0 
to 98:2) to yield phenol 99 as an amorphous white solid (86.5 mg, 62% over 2 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.82 (d, 2H, J = 8.8 Hz, HOArH), 7.27-7.23 (m, 
2H, ArH), 7.16 (s, 1H, ArOH), 7.05 (s, 1H, H4, CH=C), 6.98-6.92 (m, 3H, ArH), 
6.86 (d, 2H, J = 8.8 Hz, HOArH), 5.97 (m, 1H, H6, CH=C), 5.23 (m, 1H, H2, CH-
OAr), 3.71 (s, 3H, CO2-CH3), 3.46 (t, 1H, J = 8.8 Hz), 2.45 (dd, 1H, J = 12.7 Hz, J = 
6.4 Hz), 2.37-2.32 (dt, 1H, J = 20.0 Hz, J = 4.9 Hz), 1.89-1.75 (m, 3H), 1.69-1.62 (m, 
1H), 1.55-1.49 (m, 2H), 1.38-1.28 (m, 5H), 1.16-1.11 (m, 1H), 0.96 (s, 3H, H19, C-
CH3), 0.64 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 200.8, 167.6, 160.6, 158.5, 140.0, 139.8, 133.3, 
131.5, 130.9, 129.4, 126.7, 121.2, 116.6, 115.2, 72.0, 57.2, 56.5, 51.7, 47.9, 45.0, 
40.2, 39.0, 36.5, 32.2, 30.8, 24.7, 24.0, 21.0, 19.7, 13.5 
 
IR: υmax/cm−1 (CHCl3): 3333, 2950, 1714, 1641, 1598, 1585, 1491, 1438, 1267, 1236, 
1168, 910, 730 
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MS (ESI): m/z = 433 [M-OPh]+, 549 [M+Na]+ 
HRMS (ESI): calculated for C34H38O5Na [M+Na]+ 549.2617, found: 549.2642 
 
Specific rotation: [α]D25 = -126.0 (c 0.83, CHCl3) 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-17-(4-hydroxybenzoyl)-10,13-dimethyl-2-phenoxy-
2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-
carboxylic acid (63) 
 
 
 
Ester 99 (75 mg, 0.14 mmol, 1.0 eq) was dissolved in a mixture of MeOH (5.0 mL) 
and H2O (0.30 mL). Lithium hydroxide monohydrate (0.12 g, 2.9 mmol, 20 eq) was 
then added in one portion and the reaction mixture stirred at room temperature for 
2 days. The solution was diluted with EtOAc and quenched by addition of an aqueous 
solution of HCl (1.0 M). The aqueous layer was extracted with EtOAc (× 4) and the 
combined organic extracts were dried over MgSO4, filtered and concentrated. The 
crude solid was purified by preparative TLC (CH2Cl2/Et2O 82:18) to yield acid 63 as 
an amorphous white solid (46 mg, 64%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.81 (d, 2H, J = 8.8 Hz, HOArH), 7.22 (m, 2H, 
ArH), 7.00 (s, 1H, H4, CH=C), 6.96 (m, 2H, ArH), 6.89 (m, 1H, ArH), 6.80 (d, 2H, 
J = 8.8 Hz, HOArH), 5.98 (m, 1H, H6, CH=C), 5.25 (m, 1H, H2, CH-OAr), 3.57 (t, 
1H, J = 9.0 Hz), 2.47 (dd, 1H, J = 12.7 Hz, J = 6.3 Hz), 2.39-2.32 (m, 2H), 1.88-1.73 
(m, 3H), 1.68-1.61 (m, 1H), 1.51-1.25 (m, 7H), 1.20-1.12 (m, 1H), 0.99 (s, 3H, H19, 
C-CH3), 0.60 (s, 3H, H18, C-CH3) 
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13C-NMR (125MHz, CD3OD): δC = 202.6, 170.5, 163.5, 160.1, 141.4, 140.2, 134.0, 
132.2, 132.1, 130.4, 129.2, 122.1, 117.5, 116.1, 73.1, 58.2, 57.5, 49.4, 46.1, 41.4, 
40.0, 37.8, 33.3, 32.2, 25.8, 24.9, 22.2, 20.1, 14.0 
 
IR: υmax/cm−1 (neat): 3249, 2941, 1680, 1638, 1597, 1490, 1440, 1379, 1233, 1166, 
1037, 842 
 
MS (ESI): m/z = 419 [M-OPh]+, 513 [M+H]+ 
HRMS (ESI): calculated for C33H37O5 [M+H]+ 513.2641, found: 513.2632 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-tert-Butyl-3-benzoyl-10,13-dimethyl-2-phenoxy-
2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-17-
carboxylate (105) 
 
 
 
Triflic anhydride (33 µL, 0.19 mmol, 2.0 eq) was added to a solution of 
enone 93 (45 mg, 0.097 mmol, 1.0 eq) and 2,6-di-tert-butyl-4-methylpyridine (79) 
(66 mg, 0.32 mmol, 3.3 eq) in CH2Cl2 (1.1 mL) at -20 °C. The reaction mixture was 
stirred for 2.5 h (without addition of dry ice to the acetone/dry ice bath) and then 
poured into a saturated aqueous solution of NH4Cl. The aqueous layer was extracted 
with CH2Cl2 (× 2) and the combined organic extracts were washed with a saturated 
solution of NaHCO3, dried over MgSO4, filtered and concentrated. The crude enol 
triflate 94 was dissolved in DMF (0.40 mL) and the solution sparged with carbon 
monoxide for 5 min. Stannane 104 (21 µL, 0.12 mmol, 1.2 eq) followed by 
bis(triphenylphosphine)palladium (II) diacetate (36 mg, 0.048 mmol, 0.50 eq) and 
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copper (I) chloride (4.9 mg, 0.048 mmol, 0.50 eq) both suspended in DMF (0.10 mL) 
were then added and the reaction mixture stirred under an atmosphere of carbon 
monoxide at 50 °C for 18 h. The mixture was then diluted with EtOAc and washed 
successively with a 1.0 M aqueous solution of HCl and brine. The aqueous phase was 
extracted with EtOAc (× 3) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. The crude black oil was dry loaded on silica gel 
and purified by flash column chromatography (gradient PE/Et2O 95:5 to 90:10) to 
yield 105 as a colorless oil (30 mg, 56% over 2 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.89 (d, 2H, J = 7.3 Hz, ArH), 7.57 (t, 1H, 
J = 7.3 Hz, ArH), 7.57 (dd, 2H, J = 7.3 Hz, J = 7.3 Hz, ArH), 7.27 (dd, 2H, 
J = 7.8 Hz, J = 7.3 Hz, ArH), 7.01 (d, 2H, J = 7.8 Hz, ArH), 6.96 (t, 1H, J = 7.3 Hz, 
ArH), 6.61 (s, 1H, H4, CH=C), 5.95 (m, 1H, H6, CH=C), 5.55 (dd, 1H, J = 9.8 Hz, 
J = 6.4 Hz, H2, CH-OAr), 2.58 (dd, 1H, J = 12.7 Hz, J = 6.4 Hz), 2.36-2.29 (m, 2H), 
2.18-2.08 (m, 2H), 1.87-1.64 (m, 5H), 1.57-1.49 (m, 2H), 1.46 (s, 9H, CO2C(CH3)3), 
1.37-1.29 (m, 2H), 1.25-1.15 (m, 2H), 1.08 (s, 3H, H19, C-CH3), 0.74 (s, 3H, H18, C-
CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 196.0, 173.2, 158.7, 140.2, 139.4, 137.8, 135.6, 
132.8, 132.2, 129.5, 129.3, 128.2, 121.3, 116.9, 79.8, 72.8, 56.1, 55.8, 48.1, 43.8, 
39.7, 38.1, 36.6, 32.2, 30.7, 28.2, 24.3, 23.3, 21.0, 19.9, 13.2 
 
IR: υmax/cm−1 (CHCl3): 2970, 2935, 1723, 1653, 1635, 1597, 1491, 1367, 1267, 1233, 
1152 
 
MS (ESI): m/z = 459 [M-OPh]+, 575 [M+Na]+ 
HRMS (ESI): calculated for C37H44O4Na [M+Na]+ 575.3137, found: 575.3138 
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(8S,9S,10R,13S,14S,17S)-Methyl-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14, 
15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-carboxylate (74)82 
 
 
 
DBU (1.89 mL, 12.6 mmol, 2 eq) and iodomethane (393 µL, 6.32 mmol, 1 eq) were 
added dropwise to a solution of acid 7582 (2.00 g, 6.32 mmol, 1 eq) in dry 
THF (60 mL). The reaction mixture was then stirred at room temperature for 3 h, 
diluted with CH2Cl2 and washed with a saturated aqueous solution of NaHCO3. The 
aqueous layer was extracted with CH2Cl2 (× 3). The combined organic extracts were 
washed with brine, dried over MgSO4, filtered and concentrated. The crude was 
firstly crystallized from EtOAc and the resulting solid was repurified by flash column 
chromatography (gradient PE/EtOAc 80:20 to 75:25) to yield methyl ester 74 as a 
white solid (1.18 g, 57%). 
 
1H-NMR (400MHz, CDCl3): δH = 5.71 (s, 1H, H4, CH=C), 3.66 (s, 3H, CO2-CH3), 
2.45-2.23 (m, 5H), 2.18-2.09 (m, 1H), 2.04-1.99 (m, 2H), 1.87-1.65 (m, 4H), 1.61-
1.49 (m, 2H), 1.45-1.22 (m, 3H), 1.16 (s, 3H, H19, C-CH3), 1.13-0.91 (m, 3H), 0.69 
(s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 199.6, 174.5, 171.2, 124.1, 55.4, 55.2, 53.9, 51.4, 
44.0, 38.7, 38.2, 35.8, 35.7, 34.1, 32.9, 32.1, 24.6, 23.7, 21.0, 17.5, 13.6 
 
IR: υmax/cm−1 (CHCl3): 2975, 2930, 2872, 2849, 1718, 1674, 1620 
 
MS (ESI): m/z = 331 [M+H]+, 372 [M+H+MeCN]+ 
HRMS (ESI): calculated for C21H31O3 [M+H]+ 331.2273, found: 331.2269 
 
Melting point = 129-132 °C (EtOAc) 
 
Specific rotation: [α]D25 = +150.0 (c 1.0, CHCl3) 
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(8S,9S,10R,13S,14S,17S)-Methyl-2-bromo-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10, 
11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-
carboxylate (107) 
 
 
 
A solution of ketone 74 (1.10 g, 3.33 mmol, 1.0 eq) in THF (33 mL) was added 
dropwise to a solution of LiHMDS (4.00 mL, 4.00 mmol, 1.2 eq, 1.0 M in THF) in 
THF (4.0 mL) at -78 °C. The reaction mixture was stirred for 30 min and HMPA 
(0.705 mL, 4.00 mmol, 1.2 eq) was added. The solution was stirred for an additional 
30 min at -78 °C. Trimethylsilyl chloride (2.54 mL, 20.0 mmol, 6.0 eq) was added 
and the reaction mixture was stirred at -78 °C for 1 h, warmed to 0 °C and stirred for 
a further 30 min. The mixture was concentrated in vacuo and crude silyl enol ether 
was dissolved in THF (33 mL) and cooled to 0 °C. A solution of N-
bromosuccinimide (652 mg, 3.66 mmol, 1.1 eq) in THF (7.5 mL) was then added 
dropwise and the reaction mixture was stirred for 30 min. The mixture was diluted 
with Et2O and quenched by addition of an aqueous solution of HCl (1.0 M). The 
aqueous layer was extracted with Et2O (× 3) and the combined organic extracts were 
dried over MgSO4, filtered and concentrated. The yellow crude solid was purified by 
flash column chromatography (gradient PE/Et2O 70:30 to 65:35) to yield C-2 
bromide 107 as a slightly yellow amorphous solid (970 mg, 71%, 4:5 mixture of C-2 
epimers α:β (Breq:Brax)). 
 
Mixture of isomers – intermediate not fully characterized 
 
IR: υmax/cm−1 (CHCl3): 2940, 1717, 1681, 1623, 1453, 1367, 1222, 1149, 847  
 
MS (ESI): m/z = 409 [M(79Br)+H]+, 411 [M(81Br)+H]+ 
HRMS (ESI): calculated for C21H3079BrO3 [M+H]+ 409.1378, found: 409.1377 
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(2R,8S,9S,10R,13S,14S,17S)-Methyl-10,13-dimethyl-3-oxo-2-phenoxy-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] 
phenanthrene-17-carboxylate (108) 
 
 
 
Sodium hydride (151 mg, 3.78 mmol, 3.1 eq, 60% dispersion in mineral oil) was 
added to a solution of phenol 92 (345 mg, 3.66 mmol, 3.0 eq) in THF (7.3 mL) at 
0 °C and the reaction mixture was stirred for 30 min. A solution of bromide 
epimers 107 (500 mg, 1.22 mmol, 1.0 eq, 4:5 (α:β)) in THF (2.4 mL) was then added 
and the mixture stirred at 0 °C for 30 min, then warmed to room temperature over a 
3-hour period. The mixture was diluted with EtOAc and quenched by addition of a 
saturated aqueous solution of NH4Cl. The aqueous layer was extracted with 
EtOAc (× 2). The combined organic extracts were washed with a 10% aqueous KOH 
solution (× 2) and brine, then dried over MgSO4, filtered and concentrated. The crude 
solid was dry loaded on silica gel and purified by flash column chromatography 
(gradient PE/Et2O 80:20 to 65:35) to yield ether 108 as a sticky, white paste (302 mg, 
59%) (no recrystallization needed, isolated as a single diastereoisomer, aryl ether in 
equatorial position (α)). 
 
1H-NMR (400MHz, CDCl3): δH = 7.26 (dd, 2H, J = 7.4 Hz, J = 7.4 Hz, ArH), 
6.96 (t, 1H, J = 7.4 Hz, ArH), 6.91 (d, 2H, J = 7.4 Hz, ArH), 5.79 (s, 1H, H4, CH=C), 
4.85 (dd, 1H, Jax-ax = 13.7 Hz, Jax-eq = 5.4 Hz, H2, CH-OAr), 3.67 (s, 3H, CO2-CH3), 
2.42-2.33 (m, 4H), 2.20-2.10 (m, 1H), 2.05-2.01 (m, 1H), 1.94-1.68 (m, 4H), 1.60-
1.52 (m, 2H), 1.46-1.39 (m, 1H) 1.33 (s, 3H, H19, C-CH3), 1.30-1.20 (m, 2H), 1.15-
0.99 (m, 3H), 0.70 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 195.9, 174.2, 170.2, 158.2, 129.4, 122.0, 121.3, 
115.6, 75.4, 55.0, 54.9, 54.2, 51.3, 43.8, 42.2, 40.7, 37.8, 35.1, 32.3, 31.8, 24.3, 23.5, 
20.7, 18.1, 13.4 
2
4
19
O OMe
H H
H
O
O
18
	   166	  
 
IR: υmax/cm−1 (CHCl3): 2939, 1730, 1686, 1598, 1495, 1211, 1165, 1057, 911, 753, 
732 
 
MS (ESI): m/z = 423 [M+H]+ 
HRMS (ESI): calculated for C27H35O4 [M+H]+ 423.2535, found: 423.2528 
 
 
 
(2R,8S,9S,10R,13S,14S,17S)-Methyl-3-benzoyl-10,13-dimethyl-2-phenoxy-
2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-17-
carboxylate (109)  
 
 
 
Triflic anhydride (82 µL, 0.52 mmol, 2.0 eq) was added to a solution of 
enone 108 (0.11 g, 0.26 mmol, 1.0 eq) and 2,6-di-tert-butyl-4-methylpyridine (79) 
(0.18 g, 0.86 mmol, 3.3 eq) in CH2Cl2 (2.9 mL) at -20 °C. The reaction mixture was 
stirred for 2.5 h (without addition of dry ice to the acetone/dry ice bath) and then 
poured into a saturated aqueous solution of NH4Cl. The aqueous layer was extracted 
with CH2Cl2 (× 2) and the combined organic extracts were washed with a saturated 
solution of NaHCO3, dried over MgSO4, filtered and concentrated. The crude enol 
triflate was dissolved in DMF (1.0 mL) and the solution sparged with carbon 
monoxide for 5 min. Stannane 104 (57 µL, 0.31 mmol, 1.2 eq) followed by 
bis(triphenylphosphine)palladium (II) diacetate (97 mg, 0.13 mmol, 0.50 eq) and 
copper (I) chloride (13 mg, 0.13 mmol, 0.50 eq) both suspended in DMF (0.20 mL) 
were then added and the reaction mixture stirred under an atmosphere of carbon 
monoxide at 50 °C for 18 h. The mixture was then diluted with EtOAc and washed 
successively with a 1.0 M aqueous solution of HCl and brine. The aqueous phase was 
2
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extracted with EtOAc (× 3) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. The crude black oil was dry loaded on silica gel 
and purified by flash column chromatography (gradient PE/Et2O 90:10 to 80:20) to 
yield 109 as a colorless oil (75 mg, 57% over 2 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.85 (d, 2H, J = 7.3 Hz, ArH), 7.54 (t, 1H, 
J = 7.3 Hz, ArH), 7.46 (dd, 2H, J = 7.3 Hz, J = 7.3 Hz, ArH), 7.24 (dd, 2H, 
J = 7.8 Hz, J = 7.8 Hz, ArH), 6.99 (d, 2H, J = 7.8 Hz, ArH), 6.93 (t, 1H, J = 7.8 Hz, 
ArH), 6.58 (s, 1H, H4, CH=C), 5.87 (m, 1H, H6, CH=C), 5.54 (dd, 1H, J = 9.8 Hz, 
J = 5.9 Hz, H2, CH-OAr), 3.68 (s, 3H, CO2CH3), 2.54 (dd, 1H, J = 12.7 Hz, 
J = 5.9 Hz), 2.40-2.27 (m, 2H), 2.21-2.12 (m, 1H), 2.05-2.02 (m, 1H), 1.89-1.61 (m, 
5H), 1.54-1.46 (m, 1H), 1.43-1.34 (m, 1H), 1.30-1.28 (m, 2H), 1.22-1.14 (m, 2H), 
1.04 (s, 3H, H19, C-CH3), 0.70 (s, 3H, H18, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 196.0, 174.4, 158.7, 140.2, 139.4, 137.8, 135.6, 
132.7, 132.2, 129.5, 129.4, 128.2, 121.3, 116.9, 72.8, 56.0, 55.0, 51.3, 48.0, 44.0, 
39.8, 37.9, 36.6, 32.2, 30.7, 24.4, 23.6, 20.9, 19.9, 13.4 
 
IR: υmax/cm−1 (CHCl3): 2950, 1731, 1653, 1638, 1596, 1490, 1267, 1231, 1199, 1159, 
1011, 913 
 
MS (ESI): m/z = 417 [M-OPh]+, 533 [M+Na]+, 574 [M+Na+MeCN]+ 
HRMS (ESI): calculated for C34H38O4Na [M+Na]+ 533.2668, found: 533.2681 
 
Specific rotation: [α]D25 = -162.5 (c 2.3, CHCl3) 
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General procedure 1: Formation of olefin via McMurry coupling 
 
To a suspension of zinc (8 eq) in THF (8.7 mL/mmol) was added TiCl4 (4 eq) 
dropwise under an atmosphere of N2. The mixture was then stirred at reflux for 2 h. A 
solution of 135 (1 eq) and ketone (3 eq) in dry THF (14 mL/mmol) was added and the 
reflux was continued for 5 h. The reaction mixture was cooled to room temperature 
and poured onto a 10% aqueous solution of K2CO3 and EtOAc. The resulting black 
suspension was filtered through Celite, the layers separated and the aqueous phase 
extracted with EtOAc (× 2). The combined organic extracts were dried over MgSO4, 
filtered and concentrated. The resulting solid was purified by trituration and 
recrystallization.  
 
General procedure 2: Introduction of 2-(dimethylamino)ethyl side chain 
 
To a solution of phenol (1.0 eq) and hydrochloride salt of 2-(dimethylamino)ethyl 
chloride (120) (2.0 eq) in a mixture of acetone (13 mL/mmol) and H2O (0.80 
mL/mmol) was added K2CO3 (3.3 eq). The reaction mixture was then refluxed in the 
dark for 5 h. The solution was cooled to room temperature, dried over MgSO4, 
filtered and concentrated. The crude product was purified by flash column 
chromatography to yield the corresponding amine. 
 
General procedure 3: Pivaloyl protecting group removal 
 
To a solution of pivaloyl ester (1 eq) in THF (21 mL/mmol) was added MeLi (3 eq, 
1.6 M in Et2O) at -78 ºC under an atmosphere of N2. The reaction mixture was stirred 
at this temperature for 2 h and quenched by addition of a saturated aqueous solution 
of NH4Cl (10 mL/mmol). The mixture was allowed to warm to room temperature and 
then extracted with EtOAc (× 4). The combined organic extracts were dried over 
MgSO4, filtered and concentrated. The crude solid was triturated to yield the 
corresponding phenol. 
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1-(4-Chlorophenyl)-2-cyclohexylethanone (158) 
 
 
 
Cyclohexylmagnesium chloride (156) (4.00 mL, 7.95 mmol, 1.5 eq, 2 M in Et2O) was 
added to a solution of ZnCl2 (1.08 g, 7.95 mmol, 1.5 eq) in Et2O (40.0 mL). The 
mixture was stirred vigorously at 0 ºC for 30 min. The resulting white suspension was 
then added to a solution of 154 (1.00 g, 5.30 mmol, 1.0 eq) and Cu(OAc)2 (48.5 mg, 
0.265 mmol, 0.05 eq) in THF (10.6 mL) at room temperature. The reaction mixture 
was stirred at room temperature for 17 h then diluted with Et2O and quenched by 
addition of a saturated solution of NH4Cl. The aqueous phase was extracted with 
Et2O (× 1) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude was dry loaded on silica gel and purified by flash column 
chromatography (PE/Et2O 97:3) to yield ketone 158 as a white solid (960 mg, 77%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.88 (d, J = 8.8 Hz, 2H, CH=C), 7.42 (d, 
J = 8.8 Hz, 2H, CH=C), 2.78 (d, J = 6.9 Hz, 2H, H1, CH2-C=O), 1.95 (m, 1H, H2, 
CH-CH2), 1.76-1.64 (m, 5H, CH2-CH2), 1.33-0.96 (m, 5H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 199.0, 139.3, 135.7, 129.6, 128.8, 46.2, 34.5, 
33.4, 26.2, 26.1 
 
IR: υmax/cm−1 (neat): 2924, 2851, 1686, 1583, 1398, 1284, 1217, 1088, 818 
 
MS (EI): m/z = 236 [M(35Cl)]+•, 238 [M(37Cl)]+• 
HRMS (EI): calculated for C14H17O35Cl [M]+• 236.0968, found: 236.0961 
 
Melting point: 55-60°C (PE) 
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2-Cyclohexyl-1-(4-methoxyphenyl)ethanone (159)141 
 
 
 
Cyclohexylmagnesium chloride (156) (4.07 mL, 8.13 mmol, 1.5 eq, 2 M in Et2O) was 
added to a solution of ZnCl2 (1.11 g, 8.13 mmol, 1.5 eq) in Et2O (41.0 mL). The 
mixture was stirred vigorously at 0 ºC for 30 min. The resulting white suspension was 
then added to a solution of 155 (1.00 g, 5.42 mmol, 1.0 eq) and Cu(OAc)2 (49.6 mg, 
0.271 mmol, 0.050 eq) in THF (10.9 mL) at room temperature. The reaction mixture 
was stirred at room temperature for 17 h then diluted with Et2O and quenched by 
addition of a saturated solution of NH4Cl. The aqueous phase was extracted with 
Et2O (× 1) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude was dry loaded on silica gel and purified by flash column 
chromatography (gradient PE/Et2O 95:5 to 90:10) to yield ketone 159 as a colorless 
oil (905 mg, 71%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.93 (d, J = 8.8 Hz, 2H, H3,7, CH=C), 6.93 (d, 
J = 8.8 Hz, 2H, H4,6, CH=C), 3.86 (s, 3H, H15, CH3-O), 2.76 (d, J = 6.9 Hz, 2H, H8, 
CH2-C=O), 1.95 (m, 1H, H9, CH-CH2), 1.76-1.66 (m, 5H, CH2-CH2), 1.33-1.13 (m, 
3H, CH2-CH2), 1.02-0.90 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 198.9, 163.3, 130.6, 130.4, 113.6, 55.4, 45.9, 
34.8, 33.5, 26.3, 26.2 
 
IR: υmax/cm−1 (neat): 2921, 2850, 1672, 1598, 1578, 1509, 1448, 1249, 1164, 1031, 
827 
 
MS (ESI): m/z = 233 [M+H]+ 
HRMS (ESI): calculated for C15H21O2 [M+H]+ 233.1542, found: 233.1535 
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4-(4-Hydroxyphenylcarbonyl)phenyl-2,2-dimethylpropanoate (135)100 
 
 
 
To a solution of 129 (5.00 g, 23.3 mmol, 1.0 eq) in THF (54 mL) was added 
NaH (1.03 g, 25.7 mmol, 1.1 eq, 60% in mineral oil). The mixture was stirred for 
30 min, cooled to 0 ºC and treated with pivaloyl chloride (3.20 mL, 25.7 mmol, 
1.1 eq). The reaction mixture was stirred at room temperature for 2 h and then 
quenched by addition of H2O (40 mL). The aqueous phase was extracted with EtOAc 
(× 4) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude mixture was dry loaded on silica gel and purified by flash 
column chromatography (CH2Cl2/EtOAc 95:5) to yield ketone 135 as a white 
solid (2.17 g, 31%). The spectroscopic data were identical to that in the literature.100 
 
1H-NMR (400MHz, CDCl3): δH = 7.80 (d, J = 8.8 Hz, 2H, H9,13, CH=C), 7.76 (d, 
J = 8.8 Hz, 2H, H3,7, CH=C), 7.18 (d, J = 8.8 Hz, 2H, H10,12, CH=C), 6.90 (d, 
J = 8.8 Hz, 2H, H4,6, CH=C), 6.13 (br s, 1H, H17, OH), 1.40 (s, 9H, H16, C-(CH3)3) 
 
13C-NMR (100MHz, CDCl3): δC = 194.8, 176.9, 160.0, 154.1, 135.5, 132.8, 131.3, 
130.0, 121.4, 115.2, 39.2, 27.1 
 
IR: υmax/cm−1 (neat): 3452, 2973, 1733, 1639, 1603, 1510, 1139, 758 
 
MS (ESI): m/z = 299 [M+H]+ 
HRMS (ESI): calculated for C18H19O4 [M+H]+ 299.1283, found: 299.1279 
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(E)-4-(2-(4-Chlorophenyl)-3-cyclohexyl-1-(4-hydroxyphenyl)prop-1-enyl) 
phenyl-2,2-dimethylpropanoate (160) 
 
 
 
Ketones 135 (1.05 g, 3.50 mmol, 1 eq) and 158 (2.50 g, 10.6 mmol, 3 eq) were 
subjected to general procedure 1. The crude product was purified by trituration 
(EtOH, 20 mL) and recrystallization (EtOH) providing olefin 160 as a light yellow 
solid (480 mg, 27%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 9.23 (s, 1H, H17, OH), 7.23 (m, 4H, CH=C), 
7.11 (m, 4H, CH=C), 6.65 (d, J = 8.8 Hz, 2H, CH=C), 6.44 (d, J = 8.8 Hz, 2H, 
CH=C), 2.25 (d, J = 6.9 Hz, 2H, H25, CH2-C=C), 1.55 (m, 5H, CH2-CH2), 1.30 (s, 9H, 
H16, C-(CH3)3), 1.06 (m, 4H, CH-CH2 and CH2-CH2), 0.75 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 176.2 (C14), 155.3, 149.1, 140.9, 140.5, 139.4, 
137.0, 132.9, 131.0, 130.9, 130.4, 129.9, 127.7, 121.3, 114.4, 41.8 (C25), 38.4 (C15), 
35.5 (C26), 32.7, 26.7 (C16), 25.8, 25.7 
 
IR: υmax/cm−1 (neat): 3403, 2923, 2848, 1723, 1611, 1512, 1267, 1196, 1163, 1015, 
903, 827 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
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(E)-4-(2-(4-Chlorophenyl)-3-cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)-
phenyl)prop-1-enyl)phenyl-2,2-dimethylpropanoate (162) 
 
 
 
Phenol 160 (350 mg, 0.689 mmol, 1 eq) was subjected to general procedure 2. The 
crude product was purified by flash column chromatography (gradient CH2Cl2/MeOH 
98:2 to 95:5) to yield amine 162 as a colorless oil (185 mg, 46%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.22 (d, 2H, J = 8.3 Hz, CH=C), 7.13 (d, 2H, 
J = 8.3 Hz, CH=C), 7.05 (d, 2H, J = 8.3 Hz, CH=C), 7.02 (d, 2H, J = 8.3 Hz, CH=C), 
6.74 (d, J = 8.8 Hz, 2H, CH=C), 6.57 (d, J = 8.8 Hz, 2H, CH=C), 3.94 (t, J = 5.9 Hz, 
2H, H17, CH2-O), 2.67 (t, J = 5.9 Hz, 2H, H32, CH2-N), 2.30 (app-s, 8H, H33 and H25, 
N-(CH3)2 and CH2-C=C), 1.59 (m, 5H, CH2-CH2), 1.36 (s, 9H, H16, C-(CH3)3), 1.14 
(m, 1H, H26, CH-CH2), 1.01 (m, 3H, CH2-CH2), 0.81 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 177.0, 156.8, 149.6, 141.0, 140.7, 139.4, 138.1, 
135.1, 131.5, 130.8, 130.5, 128.0, 121.0, 113.5, 65.6, 58.2, 45.8, 42.5, 39.1, 36.1, 
33.2, 27.1, 26.3 
Two carbons for peak at 33.2 ppm (confirmed by HSQC) 
One quaternary carbon missing 
 
IR: υmax/cm−1 (neat): 2923, 1744, 1608, 1506, 1241, 1199, 1116, 832  
 
MS (ESI): m/z = 574 [M(35Cl)+H]+, 576 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C36H45NO335Cl [M+H]+ 574.3088, found: 574.3083 
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(Z)-4-(2-(4-Chlorophenyl)-3-cyclohexyl-1-(4-(2-(dimethylamino)ethoxy) 
phenyl)-prop-1-enyl)phenol (114) 
 
 
 
Ester 162 (110 mg, 0.191 mmol, 1 eq) was subjected to general procedure 3. The 
crude solid was triturated with EtOH (1.2 mL) and collected by filtration to yield 
phenol 114 as a white solid (52.5 mg, 56%). 
 
1H-NMR (500MHz, CD3OD): δH = 7.13 (d, 2H, J = 8.3 Hz, ArCl, CH=C), 7.07 (d, 
2H, J = 8.3 Hz, ArCl, CH=C), 7.02 (d, 2H, J = 8.8 Hz, CH=C), 6.79-6.75 (m, 4H, 
CH=C), 6.61 (d, J = 8.8 Hz, 2H, CH=C), 3.97 (t, J = 5.4 Hz, 2H, H15, CH2-O), 2.69 
(t, J = 5.4 Hz, 2H, H16, CH2-N), 2.36 (d, J = 7.3 Hz, 2H, H25, CH2-C=C), 2.29 (s, 6H, 
H17, N-(CH3)2), 1.59 (m, 5H, CH2-CH2), 1.18 (m, 1H, H26, CH-CH2), 1.06 (m, 3H, 
CH2-CH2), 0.85 (m, 2H, CH2-CH2) 
 
13C-NMR (125MHz, CD3OD): δC = 158.3, 157.3, 143.2, 142.0, 138.7, 137.4, 136.0, 
132.8, 132.6, 132.5, 131.7, 128.9, 115.9, 114.6, 66.5, 59.2, 45.9, 43.6, 37.7, 34.7, 
27.6, 27.5 
 
IR: υmax/cm−1 (neat): 2933, 1611, 1507, 1447, 1278, 1238, 1168, 1092, 1014, 839, 
833, 781  
 
MS (ESI): m/z = 490 [M(35Cl)+H]+, 492 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C31H37NO235Cl [M+H]+ 490.2513, found: 
490.2526 
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(E)-4-(3-Cyclohexyl-1-(4-hydroxyphenyl)-2-(4-methoxyphenyl) 
prop-1-enyl)-phenyl-2,2-dimethylpropanoate (161) 
 
 
 
Ketones 135 (385 mg, 1.29 mmol, 1 eq) and 159 (900 mg, 3.87 mmol, 3 eq) were 
subjected to general procedure 1. The crude product was purified by trituration 
(EtOH, 7.0 mL) and recrystallization (EtOH) providing olefin 161 (slightly 
contaminated with (Z)-isomer) as a white solid (305 mg, 47%). 
 
1H-NMR (500MHz, (CD3)2SO): δH = 9.17 (s, 1H, H32, OH), 7.20 (d, J = 8.3 Hz, 2H, 
CH=C), 7.09 (d, J = 8.3 Hz, 2H, CH=C), 7.01 (d, J = 8.3 Hz, 2H, CH=C), 6.75 (d, 
J = 8.3 Hz, 2H, CH=C), 6.65 (d, J = 8.8 Hz, 2H, CH=C), 6.42 (d, J = 8.8 Hz, 2H, 
CH=C), 3.70 (s, 3H, H17, CH3-O), 2.22 (d, J = 6.8 Hz, 2H, H25, CH2-C=C), 1.56 (m, 
5H, CH2-CH2), 1.30 (s, 9H, H16, C-(CH3)3), 1.00 (m, 4H, CH-CH2 and CH2-CH2), 
0.75 (m, 2H, CH2-CH2) 
 
13C-NMR (125MHz, (CD3)2SO): δC = 176.3 (C14), 157.2, 155.1, 149.0, 141.1, 138.2, 
137.7, 134.0, 133.5, 131.0, 130.2, 130.1, 121.3, 114.4, 113.2, 54.8 (C17), 42.1 (C25), 
38.5 (C15), 35.6 (C26), 32.8, 26.7 (C16), 25.9, 25.8  
 
IR: υmax/cm−1 (neat): 3427, 2923, 2847, 1728, 1612, 1510, 1253, 1197, 1144, 1032, 
905, 829 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
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(E)-4-(3-Cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-(4-methoxy 
phenyl)prop-1-enyl)phenyl-2,2-dimethylpropanoate (163) 
 
 
 
Phenol 161 (200 mg, 0.398 mmol, 1 eq) was subjected to general procedure 2. The 
crude product was purified by flash column chromatography (gradient CH2Cl2/MeOH 
100:0 to 95:5) to yield amine 163 as a colorless oil (93.5 mg, 41%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.22 (d, J = 8.3 Hz, 2H, CH=C), 7.04 (d, 
J = 8.3 Hz, 2H, CH=C), 7.00 (d, J = 8.3 Hz, 2H, CH=C), 6.75 (d, J = 8.3 Hz, 2H, 
CH=C), 6.70 (d, J = 8.8 Hz, 2H, CH=C), 6.55 (d, J = 8.8 Hz, 2H, CH=C), 3.96 (t, 
J = 5.9 Hz, 2H, H32, CH2-O), 3.77 (s, 3H, H17, CH3-O), 2.70 (t, J = 5.9 Hz, 2H, H33, 
CH2-N), 2.33 (s, 6H, H34, N-(CH3)2), 2.29 (d, J = 7.4 Hz, 2H, H25, CH2-C=C), 1.59 
(m, 5H, CH2-CH2), 1.36 (s, 9H, H16, C-(CH3)3), 1.20 (m, 1H, H26, CH-CH2), 1.02 (m, 
3H, CH2-CH2), 0.81 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 177.1 (C14), 157.7, 156.4, 149.4, 141.3, 138.9, 
138.1, 135.8, 134.6, 131.6, 130.6, 130.5, 121.0, 113.4, 113.2, 65.4 (C32), 58.1 (C33), 
55.1 (C17), 45.6 (C34), 42.7 (C25), 39.1 (C15), 36.1 (C26), 33.4, 27.4, 27.1 (C16), 26.4  
 
IR: υmax/cm−1 (neat): 2924, 1756, 1605, 1510, 1279, 1243, 1199, 1117, 1033, 835 
 
MS (ESI): m/z = 569 [M+H]+ 
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(Z)-4-(3-Cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2- 
(4-methoxyphenyl)prop-1-enyl)phenol (115) 
 
 
 
Ester 163 (65 mg, 0.11 mmol, 1 eq) was subjected to general procedure 3. The crude 
solid was triturated with EtOH (1.5 mL) and collected by filtration to yield phenol 
115 as a white solid (22 mg, 40%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.00 (m, 4H, CH=C), 6.76 (m, 4H, CH=C), 
6.70 (d, J = 8.8 Hz, 2H, CH=C), 6.57 (d, J = 8.8 Hz, 2H, CH=C), 3.96 (t, J = 5.9 Hz, 
2H, H14, CH2-O), 3.73 (s, 3H, H17, CH3-O), 2.69 (t, J = 5.9 Hz, 2H, H15, CH2-N), 2.32 
(d, J = 6.9 Hz, 2H, H25, CH2-C=C), 2.29 (s, 6H, H16, N-(CH3)2), 1.61 (m, 5H, CH2-
CH2), 1.18 (m, 1H, H26, CH-CH2), 1.05 (m, 3H, CH2-CH2), 0.83 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CD3OD): δC = 157.2, 156.1, 155.7, 138.7, 137.3, 135.9, 134.3, 
134.2, 131.1, 130.3, 130.2, 114.9, 113.3, 113.2, 65.5 (C14), 57.7 (C15), 54.8 (C17), 
45.5 (C16), 42.2 (C25), 35.7 (C26), 32.8, 26.0, 25.9 
 
IR: υmax/cm−1 (neat): 2935, 2847, 1611, 1507, 1446, 1272, 1237, 1167, 1029, 832, 
798, 780 
 
MS (ESI): m/z = 486 [M+H]+ 
LCMS + HRMS (ESI): calculated for C32H40NO3 [M+H]+ 486.3008, found: 
486.3009 
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2-Cyclohexyl-1-(4-ethylphenyl)ethanol (167) 
 
 
 
To solution of aldehyde 164 (1.03 mL, 7.45 mmol, 1 eq) in THF (53 mL) was added 
(cyclohexyl)methylmagnesium bromide (166) (44.8 mL, 22.4 mmol, 3 eq, 0.5 M in 
THF) at 0 ºC. The reaction mixture was stirred at 0 ºC for 3 h and quenched by 
addition of a 1 M aqueous solution of HCl. The aqueous phase was extracted with 
Et2O (× 3) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude oil was purified by flash column chromatography (gradient 
PE/Et2O 90:10 to 70:30) to yield alcohol 167 as a colorless oil (1.37 g, 79%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.27 (d, J = 7.8 Hz, 2H, CH=C), 7.18 (d, 
J = 7.8 Hz, 2H, CH=C), 4.77 (m, 1H, H1, CH-OH), 2.65 (q, J = 7.3 Hz, 2H, H15, CH2-
CH3), 1.83 (m, 1H, H8, CH2-CH), 1.74-1.63 (m, 6H, CH2-CH2, CH-OH), 1.53 (m, 1H, 
H8, CH2-CH), 1.42 (m, 1H, H9, CH2-CH), 1.24 (t, J = 7.3 Hz, 3H, H16, CH2-CH3), 
1.26-1.14 (m, 3H, CH2-CH2), 1.02-0.88 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 143.5, 142.6, 127.9, 125.8, 71.9, 46.9, 34.2, 33.9, 
32.9, 28.5, 26.6, 26.3, 26.1, 15.6 
 
IR: υmax/cm−1 (neat): 3295, 2970, 2921, 2848, 1463, 1447, 1343, 1089, 1064, 1045, 
992, 827 
 
MS (CI): m/z = 232 [M]+• 
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2-Cyclohexyl-1-(4-ethylphenyl)ethanone (169)142 
 
 
 
To a solution of alcohol 167 (1.00 g, 4.30 mmol, 1.0 eq) and Et3N (2.95 mL, 
21.1 mmol, 4.9 eq) in CH2Cl2 (35 mL) at 0 ºC was added DMSO (9.0 mL) and 
SO3.pyridine (5.33 g, 15.1 mmol, 3.5 eq, 45% purity). The reaction mixture was 
stirred at room temperature for 1 h and diluted with EtOAc. The resulting solution 
was washed successively with H2O (× 3), a saturated aqueous solution of NaHCO3 
(× 1) and brine (× 1). The organic phase was dried over MgSO4, filtered and 
concentrated. The crude oil was purified by flash column chromatography (gradient 
PE/Et2O 98:2 to 95:5) to yield ketone 169 as a colorless oil (635 mg, 64%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.88 (d, J = 8.3 Hz, 2H, H3,7, CH=C), 7.28 (d, 
J = 8.3 Hz, 2H, H4,6, CH=C), 2.80 (d, J = 6.9 Hz, 2H, H8, CH2-CH), 2.71 (q, 
J = 7.3 Hz, 2H, H15, CH2-CH3), 1.97 (m, 1H, H9, CH2-CH), 1.77-1.64 (m, 5H, CH2-
CH2), 1.26 (t, J = 7.3 Hz, 3H, H16, CH2-CH3), 1.28-1.14 (m, 3H, CH2-CH2), 1.06-0.96 
(m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 200.0, 149.7, 135.2, 128.4, 128.0, 46.1, 34.7, 
33.5, 28.9, 26.3, 26.2, 15.2 
 
IR: υmax/cm−1 (neat): 2916, 2848, 1679, 1606, 1447, 1410, 1223, 1004, 959, 817 
 
MS (ESI): m/z = 231 [M+H]+ 
HRMS (ESI): calculated for C16H23O [M+H]+ 231.1749, found: 231.1740 
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2-Cyclohexyl-1-(4-isopropylphenyl)ethanol (168) 
 
 
 
To a solution of aldehyde 165 (1.26 mL, 8.33 mmol, 1 eq) in dry THF (60 mL) was 
added (cyclohexyl)methylmagnesium bromide (166) (50.0 mL, 25.0 mmol, 3 eq, 
0.5 M in THF) at 0 ºC. The reaction mixture was stirred at 0 ºC for 3 h and quenched 
by addition of a 1 M aqueous solution of HCl. The aqueous phase was extracted with 
Et2O (× 3) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude oil was purified by flash column chromatography (gradient 
PE/Et2O 85:15 to 70:30) to yield alcohol 168 as a colorless oil (1.61 g, 79%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.31 (d, J = 8.3 Hz, 2H, CH=C), 7.24 (d, 
J = 8.3 Hz, 2H, CH=C), 4.80 (m, 1H, H1, CH-OH), 2.94 (app-m, 1H, H15, CH-CH3), 
1.87 (m, 1H, H8, CH2-CH), 1.79-1.67 (m, 6H, CH2-CH2, CH-OH), 1.58-1.45 (m, 2H, 
H8 and H9, CH2-CH and CH2-CH), 1.29-1.23 (m, 9H, CH2-CH2, CH-(CH3)2), 1.06-
0.91 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 148.1, 142.8, 126.5, 125.8, 71.9, 46.9, 34.2, 34.0, 
33.8, 32.9, 26.6, 26.3, 26.1, 24.0 
 
IR: υmax/cm−1 (neat): 3293, 2922, 2849, 1461, 1447, 1415, 1048, 990, 827 
 
MS (CI): m/z = 246 [M]+• 
HRMS (CI): calculated for C17H30NO [M+NH4]+ 264.2327, found: 264.2333 
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2-Cyclohexyl-1-(4-isopropylphenyl)ethanone (170) 
 
 
 
To a solution of alcohol 168 (1.50 g, 6.09 mmol, 1.0 eq) and Et3N (4.16 mL, 
29.8 mmol, 4.9 eq) in CH2Cl2 (50 mL) at 0 ºC was added DMSO (13 mL) and 
SO3.pyridine (7.54 g, 21.3 mmol, 3.5 eq, 45% purity). The reaction mixture was 
stirred at room temperature for 1 h and diluted with EtOAc. The resulting solution 
was washed successively with H2O (× 3), a saturated aqueous solution of 
NaHCO3 (× 1) and brine (× 1). The organic phase was dried over MgSO4, filtered and 
concentrated. The crude oil was purified by flash column chromatography (gradient 
PE/Et2O 98:2 to 95:5) to yield ketone 170 as a colorless oil (1.03 g, 70%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.89 (d, J = 8.3 Hz, 2H, H3,7, CH=C), 7.30 (d, 
J = 8.3 Hz, 2H, H4,6, CH=C), 2.96 (app-m, 1H, H15, CH-CH3), 2.80 (d, J = 6.8 Hz, 
2H, H8, CH2-CH), 2.02-1.92 (m, 1H, H9, CH2-CH), 1.77-1.60 (m, 5H, CH2-CH2), 
1.33-1.10 (m, 9H, CH2-CH2, CH-(CH3)2), 1.06-0.96 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 199.9, 154.3, 135.4, 128.4, 126.6, 46.1, 34.6, 
34.2, 33.5, 26.3, 26.2, 23.7 
 
IR: υmax/cm−1 (neat): 2922, 2849, 1677, 1604, 1405, 1222, 1058, 1000, 820 
 
MS (ESI): m/z = 245 [M+H]+ 
HRMS (ESI): calculated for C17H25O [M+H]+ 245.1905, found: 245.1911 
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(E)-4-(3-Cyclohexyl-2-(4-ethylphenyl)-1-(4-hydroxyphenyl)prop-1-enyl) 
phenyl-2,2-dimethylpropanoate (171) 
 
 
 
Ketones 135 (320 mg, 1.07 mmol, 1 eq) and 169 (740 mg, 3.21 mmol, 3 eq) were 
subjected to general procedure 1. The crude solid was triturated with EtOH (6.0 mL) 
and collected by filtration. Recrystallization was unsuccessful and olefin 171 
(contaminated with (Z)-isomer) was isolated as a white solid (245 mg, 46%). This 
material was used with no further purification. 
 
1H-NMR (400MHz, (CD3)2SO): δH = 9.19 (s, 1H, H33, OH), 7.22 (d, J = 8.3 Hz, 2H, 
CH=C), 7.10 (d, J = 8.3 Hz, 2H, CH=C), 7.03 (app-s, 4H, CH=C), 6.66 (d, 
J = 8.3 Hz, 2H, CH=C), 6.42 (d, J = 8.3 Hz, 2H, CH=C), 2.56 (q, J = 7.3 Hz, 2H, H17, 
CH2-CH3), 2.25 (d, J = 6.8 Hz, 2H, H25, CH2-C=C), 1.62-1.50 (m, 5H, CH2-CH2), 
1.31 (s, 9H, H16, C-(CH3)3), 1.15 (t, J = 7.3 Hz, 3H, H32, CH2-CH3), 1.13 (m, 1H, H26, 
CH-CH2), 0.97-0.94 (m, 3H, CH2-CH2), 0.77-0.69 (m, 2H, CH2-CH2) 
 
IR: υmax/cm−1 (neat): 3456, 2928, 1726, 1615, 1513, 1265, 1213, 1135, 833 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
 
 
 
 
 
 
2 1
8
18
3
4
5
6
7HO
33 13
12
11
10
9
O 14
15
O
16
19 25
24
23
22
21
20
26
31
30
29
28
27
17
CH3
32
	   184	  
(E)-4-(3-Cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-(4-ethylphenyl) 
prop-1-enyl)phenyl-2,2-dimethylpropanoate (173) 
 
 
 
Phenol 171 (200 mg, 0.403 mmol, 1 eq) was subjected to general procedure 2. The 
crude product was purified by flash column chromatography (gradient CH2Cl2/MeOH 
98:2 to 95:5) to yield amine 173 as a colorless oil (83.5 mg, 34%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.23 (d, J = 8.8 Hz, 2H, CH=C), 7.04 (d, 
J = 8.8 Hz, 2H, CH=C), 6.98 (app-s, 4H, CH=C), 6.74 (d, J = 8.8 Hz, 2H, CH=C), 
6.53 (d, J = 8.8 Hz, 2H, CH=C), 3.96 (t, J = 5.9 Hz, 2H, H33, CH2-O), 2.70 (t, 
J = 5.9 Hz, 2H, H34, CH2-N), 2.58 (q, J = 7.3 Hz, 2H, H17, CH2-CH3), 2.33 (s, 6H, 
H35, N-(CH3)2), 2.29 (d, J = 7.4 Hz, 2H, H25, CH2-C=C), 1.63-1.54 (m, 5H, CH2-
CH2), 1.36 (s, 9H, H16, C-(CH3)3), 1.20 (t, J = 7.3 Hz, 3H, H32, CH2-CH3), 1.19 (m, 
1H, H26, CH2-CH), 1.03 (m, 3H, CH2-CH2), 0.84-0.78 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 177.1 (C14), 156.4, 149.4, 141.7, 141.3, 139.5, 
139.4, 138.2, 135.8, 131.6, 130.7, 129.3, 127.2, 121.0, 113.3, 65.4 (C33), 58.1 (C34), 
45.7 (C35), 42.8 (C25), 39.1 (C15), 36.0 (C26), 33.4, 28.4 (C17), 27.2 (C16), 26.4, 26.3, 
15.3 (C32)  
 
IR: υmax/cm−1 (CHCl3): 2923, 1753, 1608, 1608, 1507, 1279, 1242, 1198, 1115, 1031, 
833 
 
MS (ESI): m/z = 568 [M+H]+ 
HRMS (ESI): calculated for C38H50NO3 [M+H]+ 568.3791, found: 568.3771 
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(Z)-4-(3-Cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2- 
(4-ethylphenyl)prop-1-enyl)phenol (113) 
 
 
 
Ester 173 (65 mg, 0.12 mmol, 1 eq) was subjected to general procedure 3. The crude 
solid was triturated with EtOH (1.2 mL) and collected by filtration to yield phenol 
113 as a white solid (27 mg, 49%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.01 (d, J = 8.8 Hz, 2H, CH=C), 6.98 (app-s, 4H, 
CH=C), 6.78-6.75 (m, 4H, CH=C), 6.56 (d, J = 8.8 Hz, 2H, CH=C), 3.95 (t, 
J = 5.4 Hz, 2H, H14, CH2-O), 2.68 (t, J = 5.4 Hz, 2H, H15, CH2-N), 2.56 (q, 
J = 7.3 Hz, 2H, H17, CH2-CH3), 2.33 (d, J = 7.3 Hz, 2H, H25, CH2-C=C), 2.29 (s, 6H, 
H16, N-(CH3)2), 1.65-1.55 (m, 5H, CH2-CH2), 1.19 (t, J = 7.3 Hz, 3H, H32, CH2-CH3), 
1.19 (m, 1H, H26, CH2-CH), 1.07-1.01 (m, 3H, CH2-CH2), 0.86-0.78 (m, 2H, CH2-
CH2) 
 
13C-NMR (100MHz, CD3OD): δC = 157.9, 157.1, 143.0, 141.6, 140.7, 139.9, 137.9, 
136.5, 132.8, 131.8, 130.8, 128.3, 115.8, 114.4, 66.4 (C14), 59.2 (C15), 45.9 (C16), 
43.8 (C25), 37.6 (C26), 34.7, 29.5 (C17), 27.7, 27.6, 16.0 (C32)  
 
IR: υmax/cm−1 (neat): 2924, 2852, 1606, 1508, 1449, 1275, 1243, 1166, 1096, 1068, 
1049, 967, 835, 829 
 
MS (ESI): m/z = 484 [M+H]+ 
HRMS (ESI): calculated for C33H42NO2 [M+H]+ 484.3216, found: 484.3200 
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(E)-4-(3-Cyclohexyl-1-(4-hydroxyphenyl)-2-(4-isopropylphenyl) 
prop-1-enyl)-phenyl-2,2-dimethylpropanoate (172) 
 
 
 
Ketones 135 (407 mg, 1.36 mmol, 1 eq) and 170 (1.00 g, 4.09 mmol, 3 eq) were 
subjected to general procedure 1. The crude solid was triturated with EtOH (4.0 mL) 
and collected by filtration. Recrystallization was unsuccessful and olefin 172 
(contaminated with (Z)-isomer) was isolated as a white solid (115 mg, 17%). This 
material was used with no further purification. 
 
1H-NMR (400MHz, (CD3)2SO): δH = 9.17 (s, 1H, H33, OH), 7.20 (d, J = 8.3 Hz, 2H, 
CH=C), 7.10-7.00 (m, 6H, CH=C), 6.64 (d, J = 8.3 Hz, 2H, CH=C), 6.40 (d, 
J = 8.3 Hz, 2H, CH=C), 2.81 (app-m, 1H, H17, CH-CH3), 2.23 (d, J = 6.8 Hz, 2H, 
H25, CH2-C=C), 1.61-1.49 (m, 5H, CH2-CH2), 1.30 (s, 9H, H16, C-(CH3)3), 1.16 (d, 
J = 6.8 Hz, 6H, H32, CH-(CH3)2), 1.06 (m, 1H, H26, CH-CH2), 0.96-0.92 (m, 3H, 
CH2-CH2), 0.76 -0.70 (m, 2H, CH2-CH2) 
 
IR: υmax/cm−1 (neat): 3453, 2925, 1726, 1614, 1512, 1268, 1212, 1196, 1136, 836 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
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(E)-4-(3-Cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-(4-isopropyl-
phenyl)prop-1-enyl)phenyl-2,2-dimethylpropanoate (174) 
 
 
 
Phenol 172 (110 mg, 0.216 mmol, 1 eq) was subjected to general procedure 2. The 
crude product was purified by flash column chromatography (gradient CH2Cl2/MeOH 
98:2 to 95:5) to yield amine 174 as a colorless oil (28.4 mg, 23%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.23 (d, J = 8.3 Hz, 2H, CH=C), 7.04 (d, 
J = 8.3 Hz, 2H, CH=C), 6.99 (app-s, 4H, CH=C), 6.73 (d, J = 8.3 Hz, 2H, CH=C), 
6.52 (d, J = 8.3 Hz, 2H, CH=C), 3.93 (t, J = 5.9 Hz, 2H, H33, CH2-O), 2.83 (app-m, 
1H, H17, CH-CH3), 2.66 (t, J = 5.9 Hz, 2H, H34, CH2-N), 2.30 (app-s, 8H, H25 and 
H35, CH2-C=C and N-(CH3)2), 1.64-1.54 (m, 5H, CH2-CH2), 1.36 (s, 9H, H16, C-
(CH3)3), 1.28 (m, 1H, H26, CH2-CH), 1.21 (d, J = 6.8 Hz, 6H, H32, CH-(CH3)2), 1.03 
(m, 3H, CH2-CH2), 0.84-0.78 (m, 2H, CH2-CH2) 
 
13C-NMR (125MHz, CDCl3): δC = 177.1 (C14), 156.5, 149.4, 146.4, 141.3, 139.7, 
139.5, 138.2, 135.7, 131.6, 130.7, 129.3, 125.7, 120.9, 113.3, 65.6 (C33), 58.2 (C34), 
45.8 (C35), 42.8 (C25), 39.1 (C15), 36.0 (C26), 33.6 (C17), 33.4, 27.1 (C16), 26.4, 26.3, 
23.9 (C32) 
 
IR: υmax/cm−1 (CHCl3): 2924, 1754, 1608, 1508, 1483, 1280, 1242, 1198, 1164, 1117, 
1032, 834 
 
MS (ESI): m/z = 582 [M+H]+ 
HRMS (ESI): calculated for C39H52NO3 [M+H]+ 582.3947, found: 582.3958 
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(Z)-4-(3-Cyclohexyl-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2- 
(4-isopropyl-phenyl)prop-1-enyl)phenol (49) 
 
 
 
Ester 174 (100 mg, 0.172 mmol, 1 eq) was subjected to general procedure 3. The 
crude solid was triturated with EtOH (1.8 mL) and collected by filtration. The latter 
was then recrystallized from EtOH to yield phenol 49 (contaminated with 6.5% 
(NMR ratio) of undesired (E)-isomer) as a white solid (23.5 mg, 27%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.03-7.00 (m, 6H, CH=C), 6.77-6.75 (m, 4H, 
CH=C), 6.56 (d, J = 8.8 Hz, 2H, CH=C), 3.95 (t, J = 5.4 Hz, 2H, H14, CH2-O), 2.82 
(app-m, 1H, H17, CH-CH3), 2.68 (t, J = 5.4 Hz, 2H, H15, CH2-N), 2.33 (d, J = 6.8 Hz, 
2H, H25, CH2-C=C), 2.29 (s, 6H, H16, N-(CH3)2), 1.66-1.55 (m, 5H, CH2-CH2), 1.20 
(d, J = 6.8 Hz, 6H, H32, CH-(CH3)2), 1.19 (m, 1H, H26, CH2-CH), 1.05 (m, 3H, CH2-
CH2), 0.86-0.80 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CD3OD): δC = 157.9, 157.0, 147.7, 141.7, 140.8, 139.9, 137.9, 
136.6, 132.8, 131.9, 130.8, 126.8, 115.8, 114.4, 66.5 (C14), 59.2 (C15), 45.9 (C16), 
43.8 (C25), 37.6 (C26), 35.0 (C17), 34.7, 27.7, 27.6, 24.5 (C32) 
 
IR: υmax/cm−1 (neat): 2921, 2849, 1606, 1508, 1449, 1275, 1243, 1166, 1096, 1068, 
1049, 969, 835, 829 
 
MS (ESI): m/z = 498 [M+H]+ 
HRMS (ESI): calculated for C34H44NO2 [M+H]+ 498.3372, found: 498.3379 
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(E)-4-(3-Cyclohexyl-2-(4-ethylphenyl)-1-(4-(2-(piperidin-1-yl)ethoxy) 
phenyl)prop-1-enyl)phenyl-2,2-dimethylpropanoate (177) 
 
 
 
To a solution of phenol 171 (160 mg, 0.321 mmol, 1.0 eq) and hydrochloride salt of 
2-(piperidine)ethyl chloride (176) (119 mg, 0.643 mmol, 2.0 eq) in a mixture of 
acetone (4.1 mL) and H2O (0.30 mL) was added K2CO3 (147 mg, 1.06 mmol, 3.3 eq). 
The reaction mixture was then refluxed in the dark for 5 h. The solution was cooled 
to room temperature, dried over MgSO4, filtered and concentrated. The crude product 
was purified by flash column chromatography (gradient CH2Cl2/MeOH 98:2 to 95:5) 
to yield amine 177 as a colorless oil (120 mg, 62%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.23 (d, J = 8.3 Hz, 2H, CH=C), 7.04 (d, 
J = 8.3 Hz, 2H, CH=C), 6.98 (app-s, 4H, CH=C), 6.74 (d, J = 8.8 Hz, 2H, CH=C), 
6.52 (d, J = 8.8 Hz, 2H, CH=C), 4.00 (t, J = 5.9 Hz, 2H, H33, CH2-O), 2.61 (t, 
J = 5.9 Hz, 2H, H34, CH2-N), 2.58 (q, J = 7.3 Hz, 2H, H17, CH2-CH3), 2.52 (app-br s, 
4H, H35,39, N-(CH2)2), 2.29 (d, J = 7.3 Hz, 2H, H25, CH2-C=C), 1.63-1.54 (m, 9H, 
CH2-CH2), 1.44 (m, 2H, CH2-CH2), 1.36 (s, 9H, H16, C-(CH3)3), 1.20 (t, J = 7.3 Hz, 
3H, H32, CH2-CH3), 1.19 (m, 1H, H26, CH2-CH), 1.03 (m, 3H, CH2-CH2), 0.81-0.78 
(m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 177.1 (C14), 156.4, 149.4, 141.7, 141.3, 139.5, 
139.4, 138.2, 135.8, 131.6, 130.7, 129.3, 127.2, 121.0, 113.4, 65.3 (C33), 57.7 (C34), 
54.9 (C35,39), 42.8 (C25), 39.1 (C15), 36.0 (C26), 33.4, 28.4 (C17), 27.2 (C16), 26.4, 25.5, 
26.3, 23.9, 15.3 (C32) 
 
IR: υmax/cm−1 (CHCl3): 2922, 1753, 1507, 1279, 1242, 1198, 1164, 1115, 1031, 833 
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MS (ESI): m/z = 608 [M+H]+ 
HRMS (ESI): calculated for C41H54NO3 [M+H]+ 608.4104, found: 608.4095 
 
 
 
(Z)-4-(3-Cyclohexyl-2-(4-ethylphenyl)-1-(4-(2-(piperidin-1-yl) 
ethoxy)phenyl)prop-1-enyl)phenol (175) 
 
 
 
Ester 177 (100 mg, 0.172 mmol, 1 eq) was subjected to general procedure 3. The 
crude solid was triturated with EtOH (1.5 mL) and collected by filtration. The latter 
was then recrystallized from CH2Cl2/MeOH (95:5) to yield phenol 175 as a white 
solid (35.0 mg, 41%). 
 
1H-NMR (400MHz, mixture CD2Cl2/CD3OD): δH = 7.04 (d, J = 8.8 Hz, 2H, 
CH=C), 6.99 (app-s, 4H, CH=C), 6.80-6.76 (m, 4H, CH=C), 6.54 (d, J = 8.8 Hz, 2H, 
CH=C), 3.96 (t, J = 5.4 Hz, 2H, H14, CH2-O), 2.67 (t, J = 5.4 Hz, 2H, H15, CH2-N), 
2.56 (q, J = 7.8 Hz, 2H, H17, CH2-CH3), 2.47 (app-br s, 4H, H32,36, N-(CH2)2), 
2.30 (d, J = 6.8 Hz, 2H, H25, CH2-C=C), 1.63-1.53 (m, 9H, CH2-CH2), 1.43 (m, 2H, 
CH2-CH2), 1.18 (t, J = 7.8 Hz, 3H, H16, CH2-CH3), 1.17 (m, 1H, H26, CH2-CH), 1.03 
(m, 3H, CH2-CH2), 0.83-0.78 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, mixture CD2Cl2/CD3OD): δC = 157.1, 156.1, 142.4, 140.9, 
139.8, 139.5, 137.4, 136.1, 132.2, 131.3, 130.2, 127.7, 115.4, 113.9, 65.7 (C14), 
58.4 (C15), 55.4 (C32,36), 43.4 (C25), 36.8 (C26), 34.1, 29.0 (C17), 27.1, 27.0, 26.0, 24.5, 
15.6 (C16) 
 
IR: υmax/cm−1 (CH2Cl2/MeOH): 2923, 2850, 1607, 1509, 1448, 1240, 1171, 1038, 
834 
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MS (ESI): m/z = 524 [M+H]+ 
HRMS (ESI): calculated for C36H46NO2 [M+H]+ 524.3529, found: 524.3552 
 
 
 
(4-Hydroxyphenyl)(4-methoxyphenyl)methanone (192)143 
 
 
 
To a solution of 129 (5.00 g, 23.3 mmol, 1.0 eq) in acetone (125 mL) was added 
potassium carbonate (3.55 g, 25.7 mmol, 1.1 eq). After 10 min, iodomethane 
(1.60 mL, 25.7 mmol, 1.1 eq) was added and the reaction mixture refluxed for 16 h. 
After cooling to room temperature, the mixture was diluted with EtOAc and 
quenched by addition of a saturated aqueous solution of NH4Cl. The aqueous layer 
was extracted with EtOAc (× 2). The combined organic extracts were dried over 
MgSO4, filtered and concentrated. The crude solid was dry loaded on silica gel and 
purified by flash column chromatography (gradient CH2Cl2/EtOAc 95:5 to 85:15) to 
yield phenol 192 as a light yellow solid (2.30 g, 43%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 10.3 (br s, 1H, H15, OH), 7.67 (d, J = 8.8 Hz, 
2H, CH=C), 7.61 (d, J = 8.8 Hz, 2H, CH=C), 7.06 (d, J = 8.8 Hz, 2H, CH=C), 6.88 
(d, J = 8.8 Hz, 2H, CH=C), 3.84 (s, 3H, H14, O-CH3) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 193.0 (C1), 162.2, 161.4, 132.1, 131.6, 130.2, 
128.4, 115.0, 113.6, 55.4 (C14) 
 
IR: υmax/cm−1 (neat): 3243, 1626, 1589, 1569, 1513, 1432, 1310, 1262, 1222, 1163, 
1153, 1026, 929, 856, 772 
 
MS (ESI): m/z = 229 [M+H]+ 
HRMS (ESI): calculated for C14H13O3 [M+H]+ 229.0865, found: 229.0858  
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(4-(2-(Dimethylamino)ethoxy)phenyl)(4-methoxyphenyl)methanone (193) 
 
 
 
To a solution of phenol 192 (2.15 g, 9.42 mmol, 1 eq) and hydrochloride salt of 2-
(dimethylamino)ethyl chloride (120) (4.07 g, 28.3 mmol, 3 eq) in DMF (19 mL) was 
added K2CO3 (6.51 g, 47.1 mmol, 5 eq) and the reaction mixture heated at 110 ºC for 
5 h. After cooling to room temperature, the mixture was diluted with EtOAc and 
quenched by addition of H2O. The aqueous layer was extracted with EtOAc (× 4). 
The combined organic extracts were dried over MgSO4, filtered and concentrated. 
The crude solid was dry loaded on silica gel and purified by flash column 
chromatography (gradient CH2Cl2/MeOH 99:1 to 90:10) to yield amine 193 as a 
brown solid (1.74 g, 62%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.77 (m, 4H, H9,13, H3,7, CH=C), 6.96 (m, 4H, 
H4,6, H10,12, CH=C), 4.15 (t, J = 5.9 Hz, 2H, H15, CH2-O), 3.88 (s, 3H, H14, O-CH3), 
2.77 (t, J = 5.9 Hz, 2H, H16, CH2-N), 2.36 (s, 6H, H17, N-(CH3)2) 
 
13C-NMR (100MHz, CDCl3): δC = 194.4 (C1), 162.8, 162.1, 132.2, 130.9, 130.8, 
114.0, 113.5, 66.2 (C15), 58.1 (C16), 55.5 (C14), 45.9 (C17) 
Two carbons for peak at 132.2 ppm (confirmed by HSQC) 
 
IR: υmax/cm−1 (neat): 2942, 2821, 2764, 1640, 1603, 1505, 1418, 1252, 1152, 1031, 
853, 769 
 
MS (ESI): m/z = 300 [M+H]+ 
HRMS (ESI): calculated for C18H22NO3 [M+H]+ 300.1600, found: 300.1602  
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(E)-2-(4-(Hydrazono(4-methoxyphenyl)methyl) 
phenoxy)-N,N-dimethyl-ethanamine (194) 
 
 
 
To a solution of ketone 193 (1.60 g, 5.34 mmol, 1.0 eq) in absolute EtOH (22 mL) 
was added hydrazine monohydrate (5.20 mL, 107 mmol, 20 eq). The reaction mixture 
was refluxed for 24 h then cooled to room temperature. Filtration gave hydrazone 194 
as a 1:1.3 mixture of geometric isomers (1.34 g, 80%). Recrystallization from EtOH 
afforded 194 as a single isomer. 
 
1H-NMR (400MHz, CDCl3): δH = 7.39 (d, J = 8.8 Hz, 2H, CH=C), 7.21 (d, 
J = 8.8 Hz, 2H, CH=C), 7.03 (d, J = 8.8 Hz, 2H, CH=C), 6.83 (d, J = 8.8 Hz, 2H, 
CH=C), 5.32 (br s, 2H, H18, NH2), 4.07 (t, J = 5.9 Hz, 2H, H15, CH2-O), 3.87 (s, 3H, 
H14, O-CH3), 2.76 (t, J = 5.9 Hz, 2H, H16, CH2-N), 2.35 (s, 6H, H17, N-(CH3)2) 
 
13C-NMR (100MHz, CDCl3): δC = 159.8, 159.0, 149.3, 131.7, 130.2, 127.8, 125.0, 
114.7, 114.1, 66.0 (C15), 58.3 (C16), 55.3 (C14), 45.9 (C17) 
 
IR: υmax/cm−1 (neat): 3325, 3152, 2956, 2826, 2775, 1605, 1507, 1457, 1243, 1165, 
1035, 953, 839 
 
MS (ESI): m/z = 314 [M+H]+ 
HRMS (ESI): calculated for C18H24N3O2 [M+H]+ 314.1869, found: 314.1883  
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2-(4-(Diazo(4-methoxyphenyl)methyl)phenoxy)-N,N-dimethyl-ethanamine (186) 
 
 
 
To a suspension of hydrazone 194 (100 mg, 0.318 mmol, 1.0 eq) in Et2O (1.0 mL) 
were successively added anhydrous Na2SO4 (73.4 mg, 0.510 mmol, 1.6 eq), a few 
drops of a 10% ethanolic solution of KOH and yellow mercuric (I) oxide (166 mg, 
0.763 mmol, 2.4 eq). The reaction mixture was stirred at room temperature for 1 h in 
the dark. The solid was filtered off, washed with dry Et2O and dried under a N2 flow 
to give diazo 186 as a purple solid. The compound was used without further 
purification. 
 
IR: υmax/cm−1 (neat): 2942, 2823, 2773, 2030, 1608, 1510, 1245, 1179, 1033, 830 
 
 
 
1-Chloro-4-(3-cyclohexylprop-1-en-2-yl)benzene (187) 
 
 
 
To a suspension of triphenylmethylphosphonium bromide (195) (2.72 g, 7.60 mmol, 
2 eq) in dry Et2O (9.0 mL) was added potassium tert-butoxide (850 mg, 7.60 mmol, 
2 eq) at room temperature. The mixture was vigorously stirred for 30 min and a 
solution of ketone 158 (900 mg, 3.80 mmol, 1 eq) in dry Et2O (9.0 mL) was added 
dropwise. The yellow suspension was then stirred at room temperature for 4 h, 
filtered through Celite and the solid washed with Et2O. The solvent was concentrated 
in vacuo and the crude mixture was purified by flash column chromatography (PE 
100%) to yield alkene 187 as a colorless oil (880 mg, 99%). 
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1H-NMR (400MHz, CDCl3): δH = 7.33-7.27 (m, 4H, H3,4,6,7, CH=C), 5.25 (s, 1H, 
H15, CH=C), 5.02 (s, 1H, H15, CH=C), 2.36 (d, J = 6.9 Hz, 2H, H8, CH2-C=C), 1.68-
1.60 (m, 5H, CH2-CH2), 1.33-1.25 (m, 1H, H9, CH-CH2), 1.15-1.10 (m, 3H, CH2-
CH2), 0.93-0.86 (m, 2H, CH2-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 146.1, 139.9, 132.9, 128.4, 127.6, 114.0, 43.6, 
35.8, 33.2, 26.5, 26.2 
 
IR: υmax/cm−1 (neat): 2920, 2851, 1490, 1448, 1090, 1014, 834 
 
MS (EI): m/z = 234 [M(35Cl)]+•, 236 [M(37Cl)]+• 
HRMS (EI): calculated for C15H1935Cl [M]+• 234.1175, found: 234.1177 
 
 
 
2-(4-(2-(4-Chlorophenyl)-2-(cyclohexylmethyl)-1-(4-methoxyphenyl)-
cyclopropyl)phenoxy)-N,N-dimethylethanamine (191) 
 
 
 
Alkene 187 (375 mg, 1.60 mmol, 5 eq) was heated at 72 ºC for 15 min and crude 
diazo intermediate 186 (0.320 mmol, 1 eq) was added in one portion. The neat 
mixture was stirred at 72 ºC for 3.5 h, until the purple colour had completely 
disappeared. The reaction mixture was then cooled to room temperature and directly 
purified by flash column chromatography (CH2Cl2/MeOH 96:4) to yield 
cyclopropane 191 (racemic 1:1 mixture of diastereoisomers) as a light yellow 
oil (45.4 mg, 27% over two steps). 
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1H-NMR (400MHz, CDCl3): (1:1 mixture of diastereoisomers) δH = 7.37-7.34 (m, 
4H, CH=C), 7.10-7.08 (m, 8H, CH=C), 6.93-6.89 (m, 4H, CH=C), 6.87-6.83 (m, 4H, 
CH=C), 6.51-6.47 (m, 4H, CH=C), 4.06 (t, J = 5.9 Hz, 2H, H15, CH2-O), 3.89 (t, 
J = 5.9 Hz, 2H, H15, CH2-O), 3.78 (s, 3H, H33, O-CH3), 3.62 (s, 3H, H33, O-CH3), 
2.75 (t, J = 5.9 Hz, 2H, H16, CH2-N), 2.64 (t, J = 5.9 Hz, 2H, H16, CH2-N), 2.36 (s, 
6H, H17, N-(CH3)2), 2.29 (s, 6H, H17, N-(CH3)2), 2.19-2.16 (m, 4H), 1.91-1.88 (m, 
2H), 1.57-1.49 (m, 8H), 1.20-1.17 (m, 2H), 1.09-0.97 (m, 8H), 0.90-0.85 (m, 4H), 
0.83-0.79 (m, 2H) 
 
13C-NMR (100MHz, CDCl3): (1:1 mixture of diastereoisomers) δC = 157.8, 157.0, 
156.1, 140.3, 136.2, 136.0, 135.6, 135.4, 130.9, 130.8, 130.4, 130.3, 130.2, 127.8, 
114.3, 113.7, 113.0, 65.7, 65.4, 58.2, 58.1, 55.2, 54.9, 46.0, 45.7, 45.6, 39.3, 36.3, 
35.4, 34.5, 32.4, 26.5, 26.2, 26.0, 24.3 
 
IR: υmax/cm−1 (neat): 2924, 2851, 1608, 1510, 1493, 1450, 1244, 1174, 1034, 839 
 
MS (ESI): m/z = 518 [M(35Cl)+H]+, 520 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C33H41NO235Cl [M+H]+ 518.2826, found: 518.2838 
LCMS for purity - diastereoisomers well separated 
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1-(4-Methoxyphenyl)-2-[(3-methoxyphenyl)sulfanyl]ethan-1-one (206)113 
 
 
 
To a solution of KOH (4.80 g, 85.6 mmol, 1 eq, 85% purity) in EtOH (90 mL) and 
H2O (36 mL) at room temperature was added thiol 204 (10.5 mL, 85.6 mmol, 1 eq) in 
one portion. The mixture was then cooled to 0 ºC and a solution of α-bromoketone 
205 (19.6 g, 85.6 mmol, 1 eq) in EtOAc (30 mL) added dropwise. The reaction 
mixture was stirred at room temperature for 18 h, then concentrated in vacuo and the 
residue partitioned between H2O and EtOAc. The aqueous phase was extracted with 
EtOAc (× 2) and the combined organic extracts were washed successively with a 1 M 
aqueous solution of HCl, a saturated aqueous solution of NaHCO3, H2O and brine. 
The organic phase was dried over MgSO4, filtered and concentrated. The resulting 
yellow/brown oil was dry loaded on silica gel and purified by flash column 
chromatography (gradient PE/EtOAc 90:10 to 65:35) to yield 206 as an off white 
solid (20.0 g, 81%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 8.01 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 
7.19 (dd, J = 8.3 Hz, J = 8.3 Hz, 1H, H4, CH=C), 7.05 (d, J = 8.8 Hz, 2H, H12,14, 
CH=C), 6.90 (m, 2H, H7,3or5, CH=C), 6.73 (dd, J =  8.3 Hz, J = 2.4 Hz, 1H, H3or5, 
CH=C), 4.60 (s, 2H, H1, CH2-S), 3.84 and 3.72 (2 × s, 6H, H9,16, O-CH3) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 192.7, 163.3, 159.4, 136.9, 130.9, 129.7, 
128.1, 120.0, 113.9, 113.2, 111.4, 55.5, 55.0, 40.3 
 
IR: υmax/cm−1 (neat): 3014, 2947, 1666, 1592, 1513, 1483, 1425, 1258, 1173, 1139, 
1015, 838, 770 
 
MS (ESI): m/z = 289 [M+H]+ 
HRMS (ESI): calculated for C16H17O3S [M+H]+ 289.0898, found: 289.0901 
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6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophene (203)113 
 
 
 
To a 250 mL beaker fitted with a mechanical stirrer was placed 89.0 g of 
polyphosphoric acid. The acid was heated at 85 ºC and ketone 206 (15.0 g, 
52.0 mmol, 1 eq) added portionwise, maintaining the temperature below 94 ºC. The 
reaction mixture was then stirred at 90 ºC for 1 h then allowed to cool to 70 ºC. The 
viscous solution was poured into a rapidly stirred ice/H2O (300 mL) solution and the 
resulting precipitate collected by filtration and dried at air overnight. The solid was 
then slurried in refluxing acetone for 1 h, the solution cooled to room temperature and 
filtered. The resulting solid was washed with acetone and dried in vacuo affording 
203 as an amorphous grey solid (8.84 g, 63%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.63-7.59 (m, 3H, CH=C), 7.34 (s, 1H, H2, 
CH=C), 7.30 (d, J = 2.0 Hz, 1H, H7, CH=C), 6.98-6.93 (m, 3H, CH=C), 3.88 and 
3.58 (2 × s, 6H, H9,16, O-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 159.4, 157.2, 141.5, 140.6, 134.9, 127.4, 127.2, 
123.9, 117.7, 114.3, 104.9, 55.6, 55.4 
Two carbons for peak at 114.3 ppm (confirmed by HSQC) 
 
IR: υmax/cm−1 (neat): 2969, 2839, 1604, 1570, 1500, 1478, 1248, 1179, 1023, 829, 
816 
 
MS (EI): m/z = 270 [M]+• 
HRMS (EI): calculated for C16H14O2S [M]+• 270.0715, found: 270.0715 
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(4-Fluorophenyl)[6-methoxy-2-(4-methoxyphenyl)-1- 
benzothiophen-3-yl]methanone (208)119 
 
 
 
To a solution of para-fluorobenzoyl chloride (207) (375 µL, 3.11 mmol, 1.05 eq) in 
CH2Cl2 (15 mL) was added 203 (800 mg, 2.96 mmol, 1.00 eq). Aluminium 
chloride (2.96 g, 22.2 mmol, 7.50 eq) was then added portionwise and the reaction 
mixture stirred at room temperature for 18 h. The solution was quenched by addition 
of THF (10 mL), a 1 M aqueous solution of HCl (3.0 mL) and H2O (10 mL). The 
aqueous phase was extracted with CH2Cl2 (× 2) and the combined organic extracts 
were washed with H2O, dried over MgSO4, filtered and concentrated. The resulting 
green/yellow crude oil was dry loaded on silica gel and purified by flash column 
chromatography (gradient PE/EtOAc 95:5 to 90:10) to yield 208 as a pale yellow 
oil (825 mg, 69%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.78 (dd, J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, 
CH=C), 7.62 (d, J = 8.8 Hz, 1H, H4, CH=C), 7.33 (d, J = 2.4 Hz, 1H, H7, CH=C), 
7.28 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.00 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H, H5, 
CH=C), 6.93 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, H19,21, CH=C), 6.74 (d, J = 8.8 Hz, 
2H, H12,14, CH=C), 3.89 and 3.75 (2 × s, 6H, H9,23, O-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 192.8 (C16), 165.7 (d, JC-F = 256 Hz, C20), 159.9, 
157.8, 144.2, 140.1, 133.9, 133.7, 132.5 (d, JC-F = 8.7 Hz, C18,22), 130.5 (C11,15), 
129.9, 125.8, 124.1 (C4), 115.4 (d, JC-F = 22.5 Hz, C19,21), 115.0 (C5), 114.1 (C12,14), 
104.5 (C7), 55.6 and 55.2 (C9,23) 
 
IR: υmax/cm−1 (neat): 2977, 1737, 1648, 1595, 1250, 1226, 1150, 1029, 831 
 
MS (ESI): m/z = 393 [M+H]+ 
HRMS (ESI): calculated for C23H18FO3S [M+H]+ 393.0961, found: 393.0976 
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3-[(4-Fluorophenyl)carbonyl]-2-(4-hydroxyphenyl)-1-benzothiophen-6-ol 
(209)119 
 
 
 
To a solution of 208 (3.60 g, 9.17 mmol, 1 eq) in CH2Cl2 (90 mL) at -30 ºC was 
added BBr3 (36.7 mL, 36.7 mmol, 4 eq, 1 M in CH2Cl2) dropwise. The mixture was 
then warmed to 0 ºC and stirred at this temperature for 3 h. The reaction mixture was 
quenched by addition of MeOH and added to a saturated aqueous solution of 
NaHCO3. The aqueous phase was extracted with CH2Cl2 (× 4) and the combined 
organic extracts were washed with brine and concentrated. The crude solid was dry 
loaded on silica gel and purified by flash column chromatography (gradient 
PE/EtOAc 80:20 to 70:30) to yield 209 as a pale yellow foam (3.16 g, 95%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 9.84 and 9.78 (2 × s, 2H, H9,23, OH), 7.76 (dd, 
J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, CH=C), 7.44 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.39 (d, J = 2.4 Hz, 1H, H7, CH=C), 7.20 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, H19,21, 
CH=C), 7.17 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 6.92 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H, 
H5, CH=C), 6.68 (d, J = 8.8 Hz, 2H, H12,14, CH=C) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 192.1 (C16), 164.3 (d, JC-F = 255 Hz, C20), 
157.9, 155.4, 142.8, 139.2, 133.7, 132.3 (d, JC-F = 10.4 Hz, C18,22), 131.9, 
130.0 (C11,15), 128.8, 124.5, 124.4 (C4), 115.6 (d, JC-F = 22.5 Hz, C19,21), 
115.5 (C12,14), 115.3 (C5), 107.0 (C7) 
 
IR: υmax/cm−1 (neat): 3345, 1596, 1587, 1530, 1494, 1233, 1151, 1039, 836 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
  
5
6
7
8
3
4
S
1
2
HO
9 10
15 14
13
1211
OH
23
1617
22
21
20
19
18
F
O
	   202	  
3-[(4-Fluorophenyl)carbonyl]-2-(4-hydroxyphenyl)-7-iodo-1- 
benzothiophen-6-ol (202) 
 
 
 
To a solution of iodine (690 mg, 2.72 mmol, 3 eq) in benzene (86 mL) was added 
freshly distilled morpholine (715 µL, 8.15 mmol, 9 eq) and the resulting suspension 
was then stirred in the dark for 15 min. 209 (330 mg, 0.907 mmol, 1 eq) was added in 
one portion and the reaction mixture stirred for 14 h. The mixture was then quenched 
by addition of a 1 M aqueous solution of HCl and the aqueous phase was extracted 
with EtOAc (× 3). The combined organic extracts were washed with a saturated 
aqueous solution of Na2S2O3 and brine, then dried over MgSO4, filtered and 
concentrated. The crude was dry loaded on silica gel and purified by flash column 
chromatography (gradient CH2Cl2/Et2O 100:0 to 96:4) to yield 202 as a pale yellow 
foam (275 mg, 63%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 10.7 and 9.79 (2 × s, 2H, H9,23, OH), 7.74 (dd, 
J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, CH=C), 7.44 (d, J = 8.3 Hz, 1H, H4, CH=C), 
7.19-7.15 (m, 4H, H19,21,11,15, CH=C), 6.96 (d, J = 8.3 Hz, 1H, H5, CH=C), 6.66 (d, 
J = 8.3 Hz, 2H, H12,14, CH=C) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 192.1 (C16), 165.0 (d, JC-F = 251 Hz, C20), 
158.1, 155.2, 145.8, 142.6, 133.5, 132.4 (d, JC-F = 10.4 Hz, C18,22), 131.0, 130.2, 
130.1 (C11,15), 123.5 (C4), 123.1, 115.7 (d, JC-F = 22.5 Hz, C19,21), 115.5 (C12,14), 113.9 
(C5) 
One quaternary carbon missing 
 
IR: υmax/cm−1 (neat): 3209, 1638, 1587, 1536, 1497, 1452, 1342, 1264, 1234, 1148, 
1109, 1047, 817 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
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7-(4-Chlorophenyl)-3-[(4-fluorophenyl)carbonyl]-2- 
(4-hydroxyphenyl)-1-benzothiophen-6-ol (201) 
 
 
 
To a solution of iodide 202 (450 mg, 0.920 mmol, 1.0 eq) in a mixture of 
EtOH (3.0 mL) and H2O (3.0 mL) was added para-chlorophenylboronic acid (216) 
(158 mg, 1.01 mmol, 1.1 eq), Na2CO3 (370 mg, 3.50 mmol, 3.8 eq) and 
Pd/C (39.5 mg, 0.368 mmol, 0.40 eq, 10% on activated charcoal). The resulting 
suspension was then stirred under microwave irradiations at 150 ºC for 15 min. The 
reaction mixture was filtered through Celite and the filtrate washed with a 
1 M aqueous solution of HCl. The aqueous phase was extracted with EtOAc (× 4) and 
the combined organic extracts were washed with brine and concentrated. The crude 
was dry loaded on silica gel and purified by flash column chromatography 
(PE/EtOAc 80:20) to yield 201 as a yellow foam (379 mg, 87%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 9.92 and 9.76 (2 × s, 2H, H9,23, OH), 7.76 (dd, 
J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, CH=C), 7.63 and 7.58 (2 × d, J = 8.3 Hz, 4H, 
H25,26,28,29, CH=C), 7.42 (d, J = 8.3 Hz, 1H, H4, CH=C), 7.19 (dd, J = 8.8 Hz, JH-F 
= 8.8 Hz, 2H, H19,21, CH=C), 7.11-7.09 (m, 3H, H11,15 and H5, CH=C), 6.62 (d, 
J = 8.3 Hz, 2H, H12,14, CH=C) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 192.0 (C16), 164.9 (d, JC-F = 250 Hz, C20), 
157.9, 151.8, 142.9, 139.8, 135.2, 133.6, 132.4 (d, JC-F = 9.8 Hz, C18,22), 132.2, 132.1, 
131.3 and 128.5 (C25,26,28,29), 130.0 (C11,15), 129.3, 123.3, 122.9 (C4), 119.6, 
115.9 (C5), 115.7 (d, JC-F = 22.8 Hz, C19,21), 115.5 (C12,14) 
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IR: υmax/cm−1 (neat): 3295, 1628, 1584, 1534, 1487, 1382, 1227, 1151, 1015, 925, 
819, 755 
 
MS (ESI): m/z = did not provide spectra suitable for interpretation 
 
 
 
7-(4-Chlorophenyl)-2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl) 
ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol (50) 
 
 
 
To a suspension of NaH (27 mg, 0.67 mmol, 6.4 eq, 60% in mineral oil) in 
DMF (1.1 mL) was added 1-(2-hydroxyethyl)piperidine (217) (56 µL, 0.42 mmol, 
4.0 eq). The mixture was then stirred at room temperature for 5 min and a solution of 
201 (50 mg, 0.11 mmol, 1.0 eq) in DMF (0.20 mL) added in one portion. The 
reaction mixture was stirred at 50 ºC for 5 h and then quenched by addition of H2O. 
The aqueous phase was extracted with EtOAc (× 3) and the combined organic 
extracts were washed with brine and concentrated. The crude oil was dry loaded on 
silica gel and purified by flash column chromatography (gradient CH2Cl2/MeOH 99:1 
to 98:2 + 0.25% of NH4OH) to yield amine 50 as an amorphous yellow 
solid (18 mg, 30%). 
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1H-NMR (400MHz, (CD3)2SO): δH = 9.82 (app-br s, 2H, H9,23, OH), 7.68 (d, J = 8.8 
Hz, 2H, H18,22, CH=C), 7.63 and 7.57 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.26 
(d, J = 8.8 Hz, 1H, H4, CH=C), 7.14 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.05 (d, 
J = 8.8 Hz, 1H, H5, CH=C), 6.93 (d, J = 8.8 Hz, 2H, H19,21, CH=C), 6.64 (d, 
J = 8.8 Hz, 2H, H12,14, CH=C), 4.08 (t, J = 5.9 Hz, 2H, H30, O-CH2), 2.61 (t, 
J = 5.9 Hz, 2H, H31, N-CH2), 2.38 (app-br s, 4H, H32,36, N-CH2), 1.48-1.44 (m, 4H, 
H33,35, CH2-CH2), 1.35 (m, 2H, H34, CH2-CH2) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 192.4 (C16), 162.9, 157.9, 151.8, 140.5, 139.7, 
135.4, 132.5, 132.2, 131.8 (C18,22), 131.3 and 128.5 (C25,26,28,29), 130.2, 129.6 (C11,15), 
129.5, 123.5, 122.7 (C4), 119.7, 115.8 (C5), 115.7 (C12,14), 114.5 (C19,21), 66.0 (C30), 
57.1 (C31), 54.3 (C32,36), 25.5 (C33,35), 23.9 (C34) 
 
IR: υmax/cm−1 (neat): 2939, 1641, 1593, 1501, 1382, 1251, 1163, 1090, 924, 815 
 
MS (ESI): m/z = 584 [M(35Cl)+H]+, 586 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C34H31NO4S35Cl [M+H]+ 584.1662, 
found: 584.1647  
 
 
 
3,7-bis-[(4-Fluorophenyl)carbonyl]-2-(4-methoxyphenyl)-1- 
benzothiophen-6-ol (220) 
 
 
 
To a solution of para-fluorobenzoyl chloride (207) (184 µL, 1.55 mmol, 2.1 eq) in 
CH2Cl2 (3.8 mL) was added 203 (200 mg, 0.740 mmol, 1.0 eq). Aluminium 
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chloride (740 mg, 5.55 mmol, 7.5 eq) was then added portionwise and the reaction 
mixture stirred at room temperature for 6 h. An excess of para-fluorobenzoyl 
chloride (207) (184 µL, 1.55 mmol, 2.1 eq) was then added and the mixture stirred 
for an additional 12 h. The solution was quenched by addition of THF (2.7 mL), a 
1 M aqueous solution of HCl (1.0 mL) and H2O (2.7 mL). The aqueous phase was 
extracted with CH2Cl2 (× 2) and the combined organic extracts were washed with 
H2O, dried over MgSO4, filtered and concentrated. The crude was dry loaded on 
silica gel and purified by flash column chromatography (gradient PE/EtOAc 100:0 to 
85:15) to yield 220 as a yellow solid (260 mg, 70%). 
 
1H-NMR (400MHz, CDCl3): δH = 11.7 (s, 1H, H30, OH), 7.85 (d, J = 8.8 Hz, 1H, H4, 
CH=C), 7.74 (m, 4H, H18,22,24,28, CH=C), 7.22 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, 
CH=C), 7.13 (d, J = 8.8 Hz, 1H, H5, CH=C), 7.09 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 
6.91 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, CH=C), 6.68 (d, J = 8.3 Hz, 2H, H12,14, 
CH=C), 3.71 (s, 3H, H29, O-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 199.2 and 192.4 (C9,16), 166.9 and 164.4 (2 × d, 
JC-F = 256 Hz, JC-F = 255 Hz, C20,26), 162.1, 160.1, 144.3, 140.9, 134.2, 133.9, 133.6, 
133.5, 132.5 and 131.2 (2 × d, JC-F =  8.0 Hz, JC-F =  9.6 Hz, C18,22,24,28), 131.0 (C4), 
130.4 (C11,15), 129.3, 124.7, 117.7 (C5), 116.4 and 115.5 (2 × d, JC-F = 20.9 Hz, JC-F =  
20.9 Hz, C19,21,25,27), 114.1 (C12,14), 55.2 (C29) 
 
IR: υmax/cm−1 (neat): 2923, 1658,1610, 1596,1502, 1229, 1151, 811 
 
MS (ESI): m/z = 501 [M+H]+ 
HRMS (ESI): calculated for C29H19O4SF2 [M+H]+ 501.0972, found: 501.0963 
 
Melting point: 175-184 °C (EtOAc) 
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3,7-bis-[(4-Fluorophenyl)carbonyl]-2-(4-hydroxyphenyl)-1- 
benzothiophen-6-ol (219) 
 
 
 
To a solution of 220 (220 mg, 0.440 mmol, 1 eq) in CH2Cl2 (4.4 mL) at -30 ºC was 
added BBr3 (170 µL, 1.76 mmol, 4 eq) dropwise. The mixture was then warmed to 
0 ºC and stirred at this temperature for 3 h. The reaction mixture was quenched by 
addition of MeOH and added to a mixture of EtOAc and a saturated aqueous solution 
of NaHCO3. The aqueous phase was extracted with EtOAc (× 4) and the combined 
organic extracts were washed with brine and concentrated. The crude was purified by 
flash column chromatography (gradient PE/EtOAc 80:20 to 75:25) to yield 219 as a 
yellow foam (170 mg, 79%). 
 
1H-NMR (400MHz, CDCl3): δH = 11.7 (s, 1H, H29or30, OH), 7.84 (d, J = 8.8 Hz, 1H, 
H4, CH=C), 7.74 (m, 4H, H18,22,24,28, CH=C), 7.22 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, 
CH=C), 7.12 (d, J = 8.8 Hz, 1H, H5, CH=C), 7.04 (d, J = 8.3 Hz, 2H, H11-15, CH=C), 
6.92 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, CH=C), 6.60 (d, J = 8.3 Hz, 2H, H12,14, 
CH=C), 6.03 (br s, 1H, H29or30, OH) 
 
13C-NMR (100MHz, CDCl3): δC = 199.2 and 192.5 (C9,16), 165.8 and 165.6 (2 × d, 
JC-F = 255 Hz, JC-F = 255 Hz, C20,26), 162.1, 156.3, 144.3, 140.9, 134.2, 133.8, 133.5, 
132.6 and 131.2 (2 × d, JC-F = 8.7 Hz, JC-F = 10.4 Hz, C18,22,24,28), 131.0 (C4), 
130.6 (C11,15), 129.4, 124.9, 117.8 (C5), 116.4 and 115.5 (2 × d, JC-F = 22.5 Hz, JC-F 
= 22.5 Hz, C19,21,25,27), 115.6 (C12,14), 114.1 
 
IR: υmax/cm−1 (neat): 3347, 3023, 1595, 1504, 1360, 1260, 1225, 1152, 987, 828, 749 
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MS (ESI): m/z = 487 [M+H]+ 
HRMS (ESI): calculated for C28H17O4SF2 [M+H]+ 487.0816, found: 487.0813 
 
 
 
2-(4-Hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-7-{[4-
(piperidin-1-ylmethoxy)phenyl]carbonyl}-1-benzothiophen-6-ol (218) 
 
 
 
To a suspension of NaH (34 mg, 0.86 mmol, 7 eq, 60% in mineral oil) in 
DMF (1.4 mL) was added 1-(2-hydroxyethyl)piperidine (217) (66 µL, 0.49 mmol, 
4 eq). The mixture was then stirred at room temperature for 5 min and a solution of 
219 (60 mg, 0.12 mmol, 1 eq) in DMF (0.20 mL) was added in one portion. The 
reaction mixture was stirred at 50 ºC for 5 h and then quenched by addition of H2O. 
The aqueous phase was extracted with EtOAc (× 3) and the combined organic 
extracts were washed with brine and concentrated. The crude was purified three times 
by flash column chromatography (gradient CH2Cl2/MeOH 98:2 to 96:4 + 0.25% 
of NH4OH) to yield diamine 218 as a yellow solid (45 mg, 52%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 10.3 and 9.74 (2 × br s, 2H, H29,30, OH), 7.76 
and 7.68 (2 × d, J = 8.8 Hz, J = 8.8 Hz, 4H, H18,22,24,28, CH=C), 7.46 (d, J = 8.8 Hz, 
1H, H4, CH=C), 7.15 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.05 and 6.92 (2 × d, 
J = 8.8 Hz, J = 8.8 Hz, 4H, H19,21,25,27, CH=C), 7.04 (d, J = 8.8 Hz, 1H, H5, CH=C), 
6.65 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.16 and 4.08 (2 × t, J = 5.9 Hz, J = 5.9 Hz, 
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4H, H31,38, O-CH2), 2.67 and 2.61 (2 × t, J = 5.9 Hz, J = 5.9 Hz, 4H, H32,39, N-CH2), 
2.43 and 2.39 (2 × m, 8H, H33,37,40,44, N-CH2), 1.48 (m, 8H, H34,36,41,43, CH2-CH2), 
1.37 (m, 4H, H35,42, CH2-CH2) 
 
13C-NMR (100MHz, (CD3)2SO): δC = 193.3 and 192.3 (C9,16), 162.8, 162.5, 157.8, 
141.9, 138.4, 132.7, 131.8 and 131.7 (C18,22,24,28), 129.9, 129.7 (C11,15), 129.5, 129.3, 
125.8 (C4), 123.4, 118.4, 116.1 (C5), 115.6 (C12,14), 114.4 and 114.2 (C19,21,25,27), 
65.9 (C31,38), 57.1 and 57.0 (C32,39), 54.3 and 54.2 (C33,37,40,44), 25.5 and 
25.4 (C34,36,41,43), 23.8 (C35,42) 
Two carbons for both peaks at 23.8 ppm and 65.9 ppm (confirmed by HSQC) 
One quaternary carbon missing 
 
IR: υmax/cm−1 (neat): 3063, 2937, 1597, 1356, 1236, 1155, 900, 830 
 
MS (ESI): m/z = 353 [M+2H]+, 705 [M+H]+ 
LCMS + HRMS (ESI): calculated for C42H45N2O6S [M+H]+ 705.2998, 
found: 705.3015 
 
Melting point: 129-132 °C (MeOH) 
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7-[(3-Methylphenyl)carbonyl]-3-[(4-fluorophenyl)carbonyl]-2- 
(4-hydroxyphenyl)-1-benzothiophen-6-ol (223) 
 
 
 
To a solution of 3-methylbenzoyl chloride (221) (128 µL, 1.04 mmol, 3.0 eq) in 
CH2Cl2 (1.6 mL) was added 208 (126 mg, 0.346 mmol, 1.0 eq). Aluminium 
chloride (320 mg, 2.60 mmol, 7.5 eq) was then added portionwise and the reaction 
mixture stirred at room temperature for 18 h. The solution was quenched by addition 
of THF (1.1 mL), a 1 M aqueous solution of HCl (0.30 mL) and H2O (1.1 mL). The 
aqueous phase was extracted with CH2Cl2 (× 3) and the combined organic extracts 
were washed with H2O, dried over MgSO4, filtered and concentrated. The crude was 
dry loaded on silica gel and purified by flash column chromatography (gradient 
PE/EtOAc 90:10 to 80:20) to yield 222 that was contaminated with impurities 
inseparable by chromatography. The mixture was then used directly in the next step 
with no further purification.  
 
To a solution of impure 222 (0.346 mmol, 1.0 eq) in CH2Cl2 (3.3 mL) at -30 ºC was 
added BBr3 (130 µL, 1.38 mmol, 4.0 eq) dropwise. The mixture was then warmed to 
0 ºC and stirred at this temperature for 3 h. The reaction mixture was quenched by 
addition of MeOH and added to a mixture of EtOAc and a saturated aqueous solution 
of NaHCO3. The aqueous phase was extracted with EtOAc (× 4) and the combined 
organic extracts were washed with brine and concentrated. The crude was purified by 
flash column chromatography (gradient PE/EtOAc 80:20 to 70:30) to yield 223 as a 
yellow foam (124 mg, 42% over 2 steps). 
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1H-NMR (400MHz, CDCl3): δH = 12.0 (s, 1H, H29or30, OH), 7.83 (d, J = 8.8 Hz, 1H, 
H4, CH=C), 7.73 (dd, J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, CH=C), 7.49-7.41 (m, 4H, 
H24,25,26,28, CH=C), 7.12 (d, J = 8.8 Hz, 1H, H5, CH=C), 7.02 (d, J = 8.3 Hz, 2H, 
H11,15, CH=C), 6.91 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, H19,21, CH=C), 6.59 (d, 
J = 8.3 Hz, 2H, H12,14, CH=C), 5.28 (br s, 1H, H29or30, OH), 2.44 (s, 3H, H31, Ar-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 200.9 and 192.6 (C9,16), 164.5 (app-s, C20), 
162.4, 156.1, 144.5, 141.3, 139.1, 138.1, 133.7, 133.6, 133.4 and 129.0 and 128.5 and 
125.3 (C24,25,26,28), 132.6 (d, JC-F = 8.7 Hz, C18,22), 130.9 (C4), 130.6 (C11,15), 129.3, 
125.0, 117.7 (C5), 115.6 (d, JC-F = 22.5 Hz, C19,21), 115.5 (C12,14), 114.2, 21.4 (C31) 
 
IR: υmax/cm−1 (neat): 3363, 1595, 1499, 1460, 1335, 1230, 1196, 1173, 1153, 990, 
831, 752 
 
MS (ESI): m/z = 483 [M+H]+ 
HRMS (ESI): calculated for C29H20O4SF [M+H]+ 483.1066, found: 483.1057 
 
 
 
7-[(3-Methylphenyl)carbonyl]-2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl) 
ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol (224) 
 
 
 
To a suspension of NaH (25 mg, 0.62 mmol, 5 eq, 60% in mineral oil) in 
DMF (1.4 mL) was added 1-(2-hydroxyethyl)piperidine (217) (33 µL, 0.25 mmol, 
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2 eq). The mixture was then stirred at room temperature for 5 min and a solution of 
223 (60 mg, 0.12 mmol, 1 eq) in DMF (0.20 mL) was added in one portion. The 
reaction mixture was stirred at 50 ºC for 5 h and then quenched by addition of H2O. 
The aqueous phase was extracted with EtOAc (× 3) and the combined organic 
extracts were washed with brine and concentrated. The crude oil was dry loaded on 
silica gel and purified by flash column chromatography (gradient CH2Cl2/MeOH 99:1 
to 95:5 + 0.25% of NH4OH) to yield amine 224 as an amorphous yellow 
solid (27 mg, 37%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 10.4 and 9.74 (2 × br s, 2H, H29,30, OH), 
7.68 (d, J = 9.3 Hz, 2H, H18,22, CH=C), 7.59 (s, 1H, H28, CH=C), 7.54 (d, J = 7.8 Hz, 
1H, H24or26, CH=C), 7.51 (d, J = 8.8 Hz, 1H, H4, CH=C), 7.45 (d, J = 7.3 Hz, 1H, 
H24or26, CH=C), 7.40 (dd, J = 7.8 Hz, J = 7.3 Hz, 1H, H25, CH=C), 7.17 (d, J = 8.8 Hz, 
2H, H11,15, CH=C), 7.05 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.93 (d, J = 9.3 Hz, 2H, 
H19,21, CH=C), 6.66 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.08 (t, J = 5.4 Hz, 2H, H32, 
O-CH2), 2.62 (t, J = 5.4 Hz, 2H, H33, N-CH2), 2.39-2.36 (m, 7H, H31,34,38, N-CH2, Ar-
CH3), 1.48-1.45 (m, 4H, H35,37, CH2-CH2), 1.37-1.35 (m, 2H, H36, CH2-CH2) 
 
13C-NMR (125MHz, (CD3)2SO): δC = 195.2 and 192.4 (C9,16), 172.4, 162.8, 
157.9, 142.3, 138.8, 138.2, 137.7, 133.4 and 126.3 (C24,26), 132.9, 131.9 (C18,22), 
129.8 (C11,15), 129.6, 129.3, 129.1 (C28), 128.3 (C25), 126.7 (C4), 123.5, 117.9, 
116.3 (C5), 115.7 (C12,14), 114.5 (C19,21), 65.9 (C32), 57.1 (C33), 54.3 (C34,38), 
25.5 (C35,37), 23.8 (C36), 20.8 (C31) 
 
IR: υmax/cm−1 (neat): 1653, 1594, 1503, 1429, 1387, 1287, 1248, 1164, 1030, 939, 
841, 761 
 
MS (ESI): m/z = 592 [M+H]+ 
LCMS + HRMS (ESI): calculated for C36H34NO5S [M+H]+ 592.2158, found: 
592.2156 
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7-[(3,5-Dimethylphenyl)carbonyl]-3-[(4-fluorophenyl)carbonyl]-2- 
(4-hydroxyphenyl)-1-benzothiophen-6-ol (227) 
 
 
 
To a solution of 3,5-dimethylbenzoyl chloride (225) (220 µL, 1.56 mmol, 3.0 eq) in 
CH2Cl2 (2.5 mL) was added 208 (190 mg, 0.521 mmol, 1.0 eq). Aluminium 
chloride (490 mg, 3.91 mmol, 7.5 eq) was then added portionwise and the reaction 
mixture stirred at room temperature for 18 h. The solution was quenched by addition 
of THF (1.7 mL), a 1 M aqueous solution of HCl (0.50 mL) and H2O (1.7 mL). The 
aqueous phase was extracted with CH2Cl2 (× 2) and the combined organic extracts 
were washed with H2O, dried over MgSO4, filtered and concentrated. The crude was 
dry loaded on silica gel and purified by flash column chromatography (gradient 
PE/EtOAc 100:0 to 90:10) to yield 226 that was contaminated with impurities 
inseparable by chromatography. The mixture was then used directly in the next step 
with no further purification.  
 
To a solution of impure 226 (0.521 mmol, 1.0 eq) in CH2Cl2 (5.0 mL) at -30 ºC was 
added BBr3 (200 µL, 2.08 mmol, 4.0 eq) dropwise. The mixture was then warmed to 
0 ºC and stirred at this temperature for 3 h. The reaction mixture was quenched by 
addition of MeOH and added to a mixture of EtOAc and a saturated aqueous solution 
of NaHCO3. The aqueous phase was extracted with EtOAc (× 4) and the combined 
organic extracts were washed with brine and concentrated. The crude was purified by 
flash column chromatography (gradient PE/EtOAc 80:20 to 70:30) to yield 227 as a 
yellow foam (161 mg, 46% over 2 steps). 
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1H-NMR (400MHz, CDCl3): δH = 12.0 (s, 1 H, H29or30, OH), 7.81 (d, J = 8.8 Hz, 1H, 
H4, CH=C), 7.73 (dd, J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, CH=C), 7.28 (s, 2H, H24,28, 
CH=C), 7.26 (s, 1H, H26, CH=C), 7.11 (d, J = 8.8 Hz, 1H, H5, CH=C), 7.02 (d, 
J = 8.3 Hz, 2H, H11,15, CH=C), 6.92 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, H19,21, 
CH=C), 6.59 (d, J = 8.3 Hz, 2H, H12,14, CH=C), 5.26 (br s, 1H, H29or30, OH), 2.38 (s, 
6H, H31,32, Ar-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 201.1 and 192.8 (C9,16), 165.8 (d, JC-F 
= 253 Hz, C20), 162.3, 156.2, 144.6, 141.4, 138.8, 138.1, 134.2 (C26), 133.7, 133.6, 
132.6 (d, JC-F = 10.4 Hz, C18,22), 130.7 (C4), 130.6 (C11,15), 129.3, 125.7 (C24,28), 
125.0, 117.7 (C5), 115.6 (d, JC-F = 22.5 Hz, C19,21), 115.5 (C12,14), 114.3, 21.3 (C31,32) 
 
IR: υmax/cm−1 (neat): 3366, 3018, 2921, 1595, 1502, 1463, 1339, 1266, 1204, 1153, 
1037, 986, 830, 754 
 
MS (ESI): m/z = 497 [M+H]+ 
HRMS (ESI): calculated for C30H22O4SF [M+H]+ 497.1223, found: 497.1209 
 
 
 
7-[(3,5-Dimethylphenyl)carbonyl]-2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl) 
ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol (228) 
 
 
 
To a suspension of NaH (25 mg, 0.61 mmol, 5 eq, 60% in mineral oil) in 
DMF (1.4 mL) was added 1-(2-hydroxyethyl)piperidine (217) (32 µL, 0.24 mmol, 
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2 eq). The mixture was then stirred at room temperature for 5 min and a solution of 
227 (60 mg, 0.12 mmol, 1 eq) in DMF (0.20 mL) was added in one portion. The 
reaction mixture was stirred at 50 ºC for 5 h and then quenched by addition of H2O. 
The aqueous phase was extracted with EtOAc (× 3) and the combined organic 
extracts were washed with brine and concentrated. The crude oil was dry loaded on 
silica gel and purified by flash column chromatography (gradient CH2Cl2/MeOH 99:1 
to 95:5 + 0.25% of NH4OH) to yield amine 228 as an amorphous yellow 
solid (25 mg, 35%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 10.4 and 9.75 (2 × br s, 2H, H29,30, OH), 7.68 
(d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.50 (d, J = 8.8 Hz, 1H, H4, CH=C), 7.37 (s, 2H, 
H24,28, CH=C), 7.27 (s, 1H, H26, CH=C), 7.17 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 
7.04 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.92 (d, J = 8.8 Hz, 2H, H19,21, CH=C), 6.66 (d, 
J = 8.3 Hz, 2H, H12,14, CH=C), 4.08 (app-br t, 2H, H33, O-CH2), 2.62 (app-br t, 2H, 
H34, N-CH2), 2.39 (app-br s, 4H, H35,39, N-CH2), 2.32 (s, 6H, H31,32, Ar-CH3), 1.46 
(app-br s, 4H, H36,38, CH2-CH2), 1.36 (app-br s, 2H, H37, CH2-CH2) 
 
13C-NMR (125MHz, (CD3)2SO): δC = 201.1 and 192.8 (C9,16), 162.8, 157.9, 154.8, 
142.2, 138.7, 138.3, 137.5, 134.2 (C26), 132.8, 131.9 (C18,22), 129.8 (C11,15), 129.6, 
129.3, 126.5 (C24,28,4), 123.5, 118.1, 116.3 (C5), 115.7 (C12,14), 114.5 (C19,21), 
65.9 (C33), 57.1 (C34), 54.3 (C35,39), 25.5 (C36,38), 23.8 (C37), 20.7 (C31,32) 
Three carbons for the peak at 126.5ppm (confirmed by HSQC) 
 
IR: υmax/cm−1 (neat): 1655, 1595, 1504, 1429, 1384, 1361, 1244, 1163, 1140, 1035, 
939, 842, 763 
 
MS (ESI): m/z = 606 [M+H]+ 
LCMS + HRMS (ESI): calculated for C37H36NO5S [M+H]+ 606.2314, 
found: 606.2287 
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7-(4-Chlorophenyl)-2-(4-hydroxyphenyl)-3-({4-[2-(morpholin-4-yl) 
ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol (229) 
 
 
 
To a suspension of NaH (25 mg, 0.61 mmol, 6.4 eq, 60% in mineral oil) in 
DMF (1.0 mL) was added 1-(2-hydroxyethyl)morpholine (231) (46 µL, 0.38 mmol, 
4.0 eq). The mixture was then stirred at room temperature for 5 min and a solution of 
201 (45 mg, 0.095 mmol, 1.0 eq) in DMF (0.20 mL) added in one portion. The 
reaction mixture was stirred at 50 ºC for 5 h and then quenched by addition of H2O. 
The aqueous phase was extracted with EtOAc (× 3) and the combined organic 
extracts were washed with brine and concentrated. The crude oil was dry loaded on 
silica gel and purified by flash column chromatography (gradient CH2Cl2/MeOH 
100:0 to 98:2 + 0.25% of NH4OH) to yield 229 as an amorphous yellow 
solid (19 mg, 34%). 
 
1H-NMR (400MHz, (CD3)2SO): δH = 9.84 (app-br s, 2H, H9,23, OH), 7.68 (d, 
J = 8.8 Hz, 2 H, H18,22, CH=C), 7.63 and 7.57 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, 
CH=C), 7.26 (d, J = 8.8 Hz, 1H, H4, CH=C), 7.14 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 
7.05 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.94 (d, J = 8.8 Hz, 2H, H19,21, CH=C), 6.64 (d, 
J = 8.8 Hz, 2H, H12,14, CH=C), 4.10 (t, J = 5.9 Hz, 2H, H30, O-CH2), 3.55 (dd, 
J = 4.9 Hz, J = 4.4 Hz, 4H, H33,34, O-CH2), 2.65 (t, J = 5.9 Hz, 2H, H31, N-CH2), 
2.43 (app-br s, 4H, H32,35, N-CH2) 
 
13C-NMR (100MHz, CD3OD): δC = 194.0 (C16), 163.1, 157.9, 151.5, 143.1, 140.6, 
135.4, 133.2, 133.1, 132.1 (C18,22), 131.1 and 128.3 (C25,26,28,29), 130.3, 130.2, 
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130.0 (C11,15), 124.5, 122.8 (C4), 120.3, 115.3 (C5), 115.1 (C12,14), 114.0 (C19,21), 
66.2 (C30), 65.2 (C33,34), 57.0 (C31), 53.7 (C32,35)  
 
IR: υmax/cm−1 (neat): 3280, 2929, 1639, 1593, 1502, 1382, 1253, 1164, 1111, 921, 
814 
 
MS (ESI): m/z = 586 [M(35Cl)+H]+, 588 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C33H29NO5S35Cl [M+H]+ 586.1455, 
found: 586.1453  
 
 
 
tert-Butyl-4-(2-hydroxyethyl)piperazine-1-carboxylate (233)144 
 
 
 
To a solution of 1-(2-hydroxyethyl)piperazine (232) (2.00 g, 15.4 mmol, 1.1 eq) in 
CH2Cl2 (20.0 mL) was successively added triethylamine (2.85 mL, 20.5 mmol, 
1.4 eq) and di-tert-butyl dicarbonate (3.11 g, 14.3 mmol, 1.0 eq). The reaction 
mixture was then stirred at room temperature for 16 h, diluted with CH2Cl2 and 
washed with a 1 M aqueous solution of Na2CO3. The organic phase was dried over 
MgSO4, filtered and concentrated to yield 233 as a colorless oil (3.20 g, 90%). This 
material was used directly in the next step with no further purification. The 
spectroscopic data were identical to that in the literature.144 
 
1H-NMR (400MHz, CDCl3): δH = 3.55 (t, 2H, J = 5.4 Hz, CH2-OH), 3.35-3.33 (br 
m, 4H, CH2-N), 3.08 (br s, 1H, CH2-OH), 2.45 (t, 2H, J = 5.4 Hz, CH2-N), 2.37-
2.34 (br m, 4H, CH2-N), 1.36 (s, 9H, C-(CH3)3) 
 
13C-NMR (100MHz, CDCl3): δC = 154.5, 79.7, 59.3, 57.4, 52.5, 43.5, 28.2 
 
HO N
N O
O
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tert-Butyl-4-[2-(4-{[7-(4-chlorophenyl)-6-hydroxy-2-(4-hydroxyphenyl)-1-
benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperazine-1-carboxylate (234) 
 
 
 
To a suspension of NaH (54 mg, 1.4 mmol, 6.4 eq, 60% in mineral oil) in 
DMF (2.2 mL) was added alcohol 233 (0.19 g, 0.84 mmol, 4.0 eq). The mixture was 
then stirred at room temperature for 5 min and a solution of 201 (0.10 g, 0.21 mmol, 
1.0 eq) in DMF (0.30 mL) added in one portion. The reaction mixture was stirred at 
50 ºC for 14 h and then quenched by addition of H2O. The aqueous phase was 
extracted with EtOAc (× 4) and the combined organic extracts were washed with 
brine and concentrated. The crude oil was dry loaded on silica gel and purified by 
flash column chromatography (gradient CH2Cl2/MeOH 100:0 to 98:2 + 0.25% of 
NH4OH) to yield 234 as a yellow foam (70 mg, 49%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.66 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.57 and 
7.45 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.38 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.10 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 6.98 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.76 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.57 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.04 (t, 
J = 5.4 Hz, 2H, H30, O-CH2), 3.39 (app-br s, 4H, N-CH2), 2.70 (t, J = 5.4 Hz, 2H, 
H31, N-CH2), 2.43 (app-br s, 4H, N-CH2), 1.44 (s, 9H, H38, O-C(CH3)3) 
 
13C-NMR (100MHz, CD3OD): δC = 195.3 (C16), 164.5, 159.2, 156.4, 152.9, 144.4, 
142.0, 136.8, 134.6, 134.5, 133.5 (C18,22), 132.5 and 129.7 (C25,26,28,29), 131.7, 131.6, 
131.4 (C11,15), 125.9, 124.2 (C4), 121.7, 116.7 (C5), 116.5 (C12,14), 115.4 (C19,21), 
81.3 (C37), 66.8 (C30), 58.0 (C31), 54.3 and 44.0 (C32,33,34,35), 28.7 (C38) 
Very weak signal for carbons at 44.0 ppm 
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IR: υmax/cm−1 (MeOH): 3307, 2979, 2936, 1660, 1596, 1503, 1462, 1423, 1252, 
1167, 1016, 828 
 
MS (ESI): m/z = 685 [M(35Cl)+H]+, 687 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C38H38N2O6S35Cl [M+H]+ 685.2139, 
found: 685.2155  
 
 
 
7-(4-Chlorophenyl)-2-(4-hydroxyphenyl)-3-({4-[2-(piperazin-1-yl)ethoxy]phenyl} 
carbonyl)-1-benzothiophen-6-ol, trifluoroacetic acid salt (230) 
 
 
 
A solution of carbamate 234 (58 mg, 0.085 mmol, 1 eq) in a mixture of 
CH2Cl2 (0.90 mL) and TFA (0.10 mL) was stirred at room temperature for 1 h. 
TFA (50 µL) was then added and the mixture stirred for a further 1.5 h. The reaction 
mixture was concentrated in vacuo and the residue dry loaded on silica gel and 
purified by flash column chromatography (gradient CH2Cl2/MeOH 100:0 to 92.5:7.5 
+ 0.25% of NH4OH) to yield 230 as a yellow solid (50 mg, 100%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.66 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.55 and 
7.44 (2 × d, J = 8.3 Hz, 4H, H25,26,28,29, CH=C), 7.37 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.09 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 6.99 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.76 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.58 (d, J = 8.3 Hz, 2H, H12,14, CH=C), 4.06 (t, 
J = 5.4 Hz, 2H, H30, O-CH2), 3.20 (m, 4H, N-CH2), 2.84-2.78 (m, 6H, N-CH2) 
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13C-NMR (100MHz, CD3OD): δH = 194.0 (C16), 163.0, 161.2 (q, JC-F = 34.7 Hz, 
CF3-COO), 157.8, 151.5, 143.1, 140.6, 135.4, 133.2, 133.1, 132.2 (C18,22), 131.1 
and 128.3 (C25,26,28,29), 130.4, 130.2, 130.0 (C11,15), 124.5, 122.8 (C4), 120.3, 116.8 (q, 
JC-F = 295 Hz, CF3-COO), 115.4 (C5), 115.2 (C12,14), 114.0 (C19,21), 65.5 (C30), 56.1, 
49.7, 43.2 
 
IR: υmax/cm−1 (neat): 3061, 1666, 1594, 1436, 1256, 1172, 1126, 1013, 837, 799, 723 
 
MS (ESI): m/z = 585 [M(35Cl)+H-TFA]+, 587 [M(37Cl)+H-TFA]+ 
LCMS + HRMS (ESI): calculated for C33H30N2O4S35Cl [M+H-TFA]+ 585.1615, 
found: 585.1627  
 
 
 
2-(4-Methylpiperazin-1-yl)ethan-1-ol (235)124 
 
 
 
To a solution of 1-(2-hydroxyethyl)piperazine (232) (940 µL, 7.68 mmol, 1.0 eq) in 
THF (60 mL) was added a solution of formaldehyde (6.20 g, 76.8 mmol, 10 eq, 37% 
in H2O) followed by NaBH3CN (2.40 g, 38.4 mmol, 5.0 eq). The reaction mixture 
was then stirred at 50 ºC for 14 h, cooled to room temperature and quenched by 
addition of H2O. The aqueous phase was extracted with CH2Cl2 (× 3) and the 
combined organic extracts were dried over MgSO4, filtered and concentrated. The 
residue was purified by flash column chromatography (gradient CH2Cl2/MeOH 100:0 
to 90:10) to yield alcohol 235 as a colorless oil (1.10 g, 100%). 
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1H-NMR (400MHz, CDCl3): δH = 3.65 (t, J = 5.4 Hz, 2H, H2, O-CH2), 3.27-3.21 (m, 
2H, N-CH2), 2.93-2.83 (m, 4H, N-CH2), 2.74 (s, 3H, H8, N-CH3), 2.65-2.60 (m, 4H, 
N-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 59.0, 58.1, 58.0 (C2), 48.2 (C8), 46.9  
Very weak signal for the carbon at 48.2 ppm (confirmed by HSQC)  
 
IR: υmax/cm−1 (neat): 3428, 2958, 2836, 1463, 1158, 1121, 1049, 855, 749 
 
MS (ESI): m/z = 145 [M+H]+ 
HRMS (ESI): calculated for C7H17N2O [M+H]+ 145.1341, found: 145.1336  
 
 
 
7-(4-Chlorophenyl)-2-(4-hydroxyphenyl)-3-({4-[2-(4-methylpiperazin-1-yl) 
ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol (236) 
 
 
 
To a suspension of NaH (11 mg, 0.27 mmol, 6.4 eq, 60% in mineral oil) in 
DMF (0.50 mL) was added alcohol 235 (25 mg, 0.17 mmol, 4.0 eq). The mixture was 
then stirred at room temperature for 5 min and a solution of 201 (20 mg, 0.042 mmol, 
1.0 eq) in DMF (0.10 mL) added in one portion. The reaction mixture was stirred at 
80 ºC under microwave irradiations for 3 h and alcohol 235 (4.0 eq) followed by 
NaH (4.0 eq) were added. The mixture was then stirred under the same conditions for 
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a further 14 h, cooled to room temperature and quenched by addition of H2O. The 
aqueous phase was extracted with EtOAc (× 4) and the combined organic extracts 
were washed with brine and concentrated. The crude was dry loaded on silica gel and 
purified by flash column chromatography (gradient CH2Cl2/MeOH 100:0 to 96:4 + 
0.25% of NH4OH) to yield 236 as a yellow foam (12 mg, 69%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.68 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.58 and 
7.47 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.40 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.12 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 6.99 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.80 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.58 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.09 (t, 
J = 5.4 Hz, 2H, H30, O-CH2), 2.75 (t, J = 5.4 Hz, 2H, H31, N-CH2), 2.65-2.40 (app-br 
m, 8H, H32,33,34,35, N-CH2), 2.26 (s, 3H, H36, N-CH3) 
 
13C-NMR (100MHz, CD3OD): δC = 195.4 (C16), 164.5, 159.3, 153.0, 144.5, 142.0, 
136.9, 134.6, 134.5, 133.6 (C18,22), 132.5 and 129.7 (C25,26,28,29), 131.7, 131.6, 
131.4 (C11,15), 125.9, 124.2 (C4), 121.7, 116.7 (C5), 116.5 (C12,14), 115.4 (C19,21), 
66.8 (C30), 57.8 (C31), 55.5, 54.0, 46.0 (C36) 
 
IR: υmax/cm−1 (neat): 3193, 2931, 2804, 1593, 1502, 1460, 1251, 1163, 1089, 1011, 
815 
 
MS (ESI): m/z = 599 [M(35Cl)+H]+, 601 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C34H32N2O4S35Cl [M+H]+ 599.1771, 
found: 599.1770  
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1-{4-[2-(4-{[7-(4-Chlorophenyl)-6-hydroxy-2-(4-hydroxyphenyl)-1-
benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperazin-1-yl}ethan-1-one (238) 
 
 
 
To a solution of 230 (25 mg, 0.036 mmol, 1.0 eq) in DMF (0.50 mL) was added 
diisopropylethylamine (3.3 µL, 0.047 mmol, 1.3 eq) dropwise. The reaction mixture 
was then stirred at room temperature for 30 min, acetyl chloride (237) (6.2 µL, 
0.036 mmol, 1.0 eq) was added and the resulting solution stirred for 14 h. The crude 
mixture was directly purified by flash column chromatography (gradient 
CH2Cl2/MeOH 100:0 to 98:2 + 0.25% of NH4OH) to yield amide 238 as a yellow 
solid (15 mg, 66%).  
 
1H-NMR (400MHz, CD3OD): δH = 7.70 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.59 and 
7.48 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.40 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.13 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 6.99 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.82 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.59 (d, J = 8.3 Hz, 2H, H12,14, CH=C), 4.11 (t, 
J = 5.4 Hz, 2H, H30, O-CH2), 3.58 (dd, J = 5.4 Hz, J = 4.9 Hz, 2H, N-CH2), 3.51 (dd, 
J = 5.4 Hz, J = 4.9 Hz, 2H, N-CH2), 2.77 (t, J = 5.4 Hz, 2H, H31, N-CH2), 2.55 (dd, 
J = 5.4 Hz, J = 4.9 Hz, 2H, N-CH2), 2.50 (dd, J = 5.4 Hz, J = 4.9 Hz,  2H, N-CH2), 
2.07 (s, 3H, H37, O=C-CH3), 
 
13C-NMR (100MHz, CD3OD): δC = 195.4 (C16), 171.6, 164.6, 159.4, 153.0, 144.5, 
142.1, 136.9, 134.6, 134.5, 133.6 (C18,22), 132.5 and 129.7 (C25,26,28,29), 131.8, 131.6, 
131.4 (C11,15), 129.9, 124.2 (C4), 121.7, 116.7 (C5), 116.5 (C12,14), 115.4 (C19,21), 
66.9 (C30), 57.9 (C31), 54.6, 54.2, 47.2, 42.4, 21.1 (C37) 
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IR: υmax/cm−1 (neat): 3195, 2929, 1593, 1502, 1462, 1381, 1250, 1163, 1089, 999, 
815 
 
MS (ESI): m/z = 627 [M(35Cl)+H]+, 629 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C33H30N2O4S35Cl [M+H]+ 627.1720, 
found: 627.1699  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   225	  
(–)-(2R,3S)-Diethyl-2-azido-3-hydroxybutanedioate (245)126 
 
 
 
To a solution of (–)-diethyl tartrate (243) (6.00 g, 29.1 mmol, 1.0 eq) in 
CH2Cl2 (150 mL) was added Et3N (8.10 mL, 58.2 mmol, 2.0 eq). The solution was 
cooled to -5 ºC and SOCl2 (3.18 mL, 43.6 mmol, 1.5 eq) in CH2Cl2 (2.50 mL) was 
added dropwise maintaining the temperature below 0 ºC. After stirring at 0 ºC for 
30 min, the reaction mixture was quenched by addition of ice/H2O. The aqueous layer 
was extracted with Et2O (× 3) and the combined organic extracts were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo to yield the cyclic sulfite 
244 as a yellow oil that was used directly in the next step with no further purification. 
The crude cyclic sulfite 244 was dissolved in DMF (300 mL) and sodium 
azide (3.78 g, 58.2 mmol, 2.0 eq) added in one portion. The reaction mixture was 
then stirred at room temperature for 16 h and H2O added. The aqueous layer was 
extracted with Et2O (× 4) and the combined organic extracts were washed with H2O, 
brine, dried over MgSO4, filtered and concentrated. The residue was purified by flash 
column chromatography (gradient PE/EtOAc 90:10 to 70:30) to yield azide 245 as a 
yellow oil (4.38 g, 64% over 2 steps). The spectroscopic data were identical to that in 
the literature.126 
 
1H-NMR (400MHz, CDCl3): δH = 4.62 (dd, J = 5.4 Hz, J = 2.9 Hz, 1H), 4.31-
4.23 (m, 5H), 3.41 (d, J = 5.4 Hz, 1H, OH), 1.28 (t, J = 7.3 Hz, 3H), 1.27 (t, 
J = 7.3 Hz, 3H) 
 
13C-NMR (100MHz, CDCl3): δC = 170.7, 166.9, 72.0, 64.3, 62.6, 62.3, 14.0, 13.9 
 
IR: υmax/cm−1 (CHCl3): 3480, 2986, 2114, 1737, 1200, 1110, 1026, 861 
 
MS (CI): m/z = 249 [M+NH4]+ 
HRMS (CI): calculated for C8H17N4O5 [M+NH4]+ 249.1199, found: 249.1196 
 
Specific rotation: [α]D25 = -39.4 (c 1.0, EtOH) 
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(–)-(S)-2-Azido-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (247)126 
 
 
 
To a solution of diester 245 (4.25 g, 18.4 mmol, 1.0 eq) in EtOH (60 mL) was added 
lithium chloride (780 mg, 18.4 mmol, 1.0 eq), the mixture cooled to -10 ºC and 
sodium borohydride (4.18 g, 110 mmol, 6.0 eq) added portionwise over a 30 min 
period. The reaction mixture was allowed to warm to room temperature and stirred 
for 14 h. The resultant white paste was then cooled to -10 ºC and a 1 M aqueous 
solution of HCl was carefully added to adjust the pH to 4. The clear solution was 
concentrated to dryness and the residue dry loaded and filtered through silica 
gel (gradient EtOAc/MeOH 90:10 to 85:15) to yield the azidotriol 246 that was used 
directly in the next step with no further purification.  
To a solution of triol 246 (18.4 mmol, 1.0 eq) in acetone (43 mL) was added 2,2-
dimethoxypropane (23.5 mL, 184 mmol, 10 eq) followed by para-toluene sulfonic 
acid monohydrate (350 mg, 1.84 mmol, 0.10 eq) and the reaction mixture heated at 
55 ºC for 2 h. The solution was then cooled to room temperature and stirred with a 
saturated aqueous solution of NH4Cl for 1 h. The aqueous layer was extracted with 
Et2O (× 3) and the combined organic extracts were washed with a saturated aqueous 
solution of NaHCO3, dried over MgSO4, filtered and concentrated. Purification by 
flash column chromatography (PE/EtOAc 80:20) yielded primary alcohol 247 as a 
yellow oil (2.39 g, 69% over 3 steps). The spectroscopic data were identical to that in 
the literature.126 
 
1H-NMR (400MHz, CDCl3): δH = 4.13-4.05 (m, 2H), 3.94-3.90 (dd, J = 8.3 Hz, 
J  = 5.4 Hz, 1H), 3.87-3.82 (m, 1H), 3.70-3.64 (m, 1H), 3.62-3.58 (m, 1H), 2.40 (t, 
J = 5.4 Hz, 1H, OH), 1.44 (s, 3H), 1.34 (s, 3H) 
 
13C-NMR (100MHz, CDCl3): δC = 109.7, 75.4, 66.5, 64.5, 62.6, 26.3, 25.0 
 
IR: υmax/cm−1 (neat): 3434, 2988, 2938, 2886, 2096, 1374, 1256, 1212, 1156, 1047, 
842, 757 
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MS (CI): m/z = 188 [M+H]+ 
HRMS (CI): calculated for C7H14N3O3 [M+H]+ 188.1035, found: 188.1036 
 
Specific rotation: [α]D25 = -6.7 (c 0.96, CHCl3) 
 
 
 
(+)-(S)-4-((S)-1-Azido-2-(methoxymethoxy)ethyl)-2,2-dimethyl-1,3-dioxolane 
(248)126 
 
 
 
To a solution of alcohol 247 (2.00 g, 10.7 mmol, 1 eq) and DIPEA (7.44 mL, 
42.7 mmol, 4 eq) in CH2Cl2 (27 mL) at 0 ºC was added MOMCl (3.24 mL, 42.7 
mmol, 4 eq) dropwise. The reaction mixture was then stirred at room temperature for 
16 h, cooled to 0 ºC, diluted with CH2Cl2 and washed with H2O. The aqueous layer 
was extracted with CH2Cl2 (× 3) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. The residue was purified by flash column 
chromatography (PE/EtOAc 95:5) to yield azide 248 as a colorless oil (2.00 g, 81%). 
The spectroscopic data were identical to that in the literature.126 
 
1H-NMR (400MHz, CDCl3): δH = 4.65 (s, 2H), 4.09-4.03 (m, 2H), 3.94-3.90 (m, 
1H), 3.79-3.77 (m, 1H), 3.66-3.61 (m, 2H), 3.39 (s, 3H), 1.44 (s, 3H), 1.34 (s, 3H) 
 
13C-NMR (100MHz, CDCl3): δC = 109.7, 96.6, 74.8, 67.3, 66.5, 62.9, 55.4, 26.5, 
25.1 
 
IR: υmax/cm−1 (neat): 2990, 2938, 2891, 2096, 1458, 1372, 1258, 1213, 1152, 1112, 
1035, 919, 843 
 
MS (CI): m/z = 249 [M+NH4]+ 
HRMS (CI): calculated for C9H21N4O4 [M+NH4]+ 249.1563, found: 249.1562 
 
Specific rotation: [α]D25 = +18.6 (c 1.2, CHCl3) 
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(+)-(S)-1-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2-(methoxymethoxy)-ethanamine 
(242)126 
 
 
 
To a solution of azide 248 (1.00 g, 4.32 mmol, 1 eq) in MeOH (9.0 mL) was added 
Pd/C (230 mg, 0.216 mmol, 0.05 eq, 10% on charcoal). The reaction mixture was 
then stirred under an atmosphere of H2 for 1.5 h, filtered through Celite and 
concentrated in vacuo to afford amine 242 as a colorless oil (860 mg, 97%). The 
spectroscopic data were identical to that in the literature.126 
 
1H-NMR (400MHz, CDCl3): δH = 4.66 (s, 2H), 4.61 (br s, 2H), 4.19-4.14 (m, 1H), 
4.11-4.07 (m, 1H), 4.00-3.97 (m, 1H), 3.74 (dd, J = 10.3 Hz, J = 3.4 Hz, 1H), 
3.63 (dd, J = 10.3 Hz, J = 5.9 Hz, 1H), 3.38 (s, 3H), 3.23-3.21 (m, 1H), 1.43 (s, 3H), 
1.34 (s, 3H) 
 
13C-NMR (100MHz, CDCl3): δC = 109.2, 96.7, 75.5, 67.8, 66.3, 55.4, 53.2, 26.5, 
25.1 
 
IR: υmax/cm−1 (neat): 3300, 2988, 2937, 2889, 1456, 1374, 1213, 1152, 1043, 935, 
854 
 
MS (ESI): m/z = 206 [M+H]+ 
HRMS (ESI): calculated for C9H20NO4 [M+H]+ 206.1392, found: 206.1389 
 
Specific rotation: [α]D25 = +1.2 (c 1.0, CHCl3) 
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2-[(tert-Butyldimethylsilyl)oxy]ethan-1-ol130 
 
 
 
To a suspension of NaH (1.29 g, 32.2 mmol, 1 eq, 60% in mineral oil) in 
THF (60 mL) at 0 ºC was added ethylene glycol (249) (2.00 g, 32.2 mmol, 1 eq) and 
the mixture stirred for 45 min. TBSCl (4.85 g, 32.2 mmol, 1 eq) was then added and 
the reaction mixture stirred at room temperature for 16 h, diluted with Et2O and 
quenched by addition of H2O. The aqueous phase was extracted with Et2O (× 3) and 
the combined organic extracts were dried over MgSO4, filtered and concentrated. The 
resulting crude oil was purified by flash column chromatography (PE/Et2O 8:2) to 
yield mono-TBS protected ethylene glycol as a colorless oil (4.60 g, 81%). The 
spectroscopic data were identical to that in the literature.130 
 
 
 
2-[(tert-Butyldimethylsilyl)oxy]acetaldehyde (250)145 
 
 
 
To a solution of mono-TBS protected ethylene glycol (1.50 g, 8.51 mmol, 1.0 eq) and 
Et3N (5.80 mL, 41.7 mmol, 4.9 eq) in CH2Cl2 (70 mL) at 0 ºC was added DMSO (18 
mL) and SO3.pyridine (10.5 g, 29.8 mmol, 3.5 eq, 45% purity). The reaction mixture 
was stirred at room temperature for 1.5 h and then quenched by addition of H2O. The 
organic layer was washed successively with H2O (× 2), a saturated aqueous solution 
of NaHCO3 (× 1) and brine (× 1). The organic phase was then dried over MgSO4, 
filtered and concentrated. The resulting crude aldehyde 250 was isolated as a light 
orange oil (1.45 g) and used in the next step with no further purification. 
 
 
 
HO O Si
O
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(6S)-6-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]-11,11,12,12-tetramethyl-2,4,10-
trioxa-7-aza-11-silatridecane (251) 
 
 
 
To a solution of aldehyde 250 (465 mg, 2.66 mmol, 1.0 eq, crude mixture) in DCE 
(14 mL) was added amine 242 (600 mg, 2.92 mmol, 1.1 eq). The mixture was then 
stirred at room temperature for 15 min and NaB(OAc)3H (790 mg, 3.72 mmol, 
1.4 eq) added in one portion. The reaction mixture was stirred for a further 3.5 h and 
quenched by addition of a saturated aqueous solution of NaHCO3. The aqueous phase 
was extracted with CH2Cl2 (× 4) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. The resulting crude oil was dry loaded on silica gel 
and purified by flash column chromatography (gradient CH2Cl2/MeOH 100:0 
to 97:3) to yield secondary amine 251 as a light yellow oil (660 mg, 68% over 3 
steps). 
 
1H-NMR (400MHz, CDCl3): δH = 4.63-4.58 (m, 2H), 4.10-3.98 (m, 2H), 3.91-
3.82 (m, 1H), 3.68-3.53 (m, 4H), 3.34 (s, 3H, OCH3), 2.91-2.71 (m, 2H), 2.66-
2.61 (m, 1H), 1.72 (br s, 1H, NH), 1.38 and 1.31 (2 × s, 6H, C-(CH3)2), 0.99 (s, 9H, 
C-(CH3)3), 0.20 (s, 6H, Si-(CH3)2)  
 
13C-NMR (100MHz, CDCl3): δC = 108.8, 96.6, 76.0, 67.2, 65.9, 62.8, 59.8, 55.2, 
49.9, 26.7, 25.9, 25.3, 18.2, -5.4 
 
MS (ESI): m/z = 364 [M+H]+ 
HRMS (ESI): calculated for C17H38NO5Si [M+H]+ 364.2519, found: 364.2505 
 
Specific rotation: [α]D25 = +14.4 (c 1.2, CHCl3) 
 
 
 
HN
O
O
O
O Si
O
	   231	  
tert-Butyl-N-{2-[(tert-butyldimethylsilyl)oxy]ethyl}-N-[(1S)-1-[(4S)-2,2-dimethyl-
1,3-dioxolan-4-yl]-2-(methoxymethoxy)ethyl]carbamate (251(b)) 
 
 
 
To a solution of amine 251 (500 mg, 1.38 mmol, 1.0 eq) in CH2Cl2 (4.0 mL) was 
successively added triethylamine (210 µL, 1.51 mmol, 1.1 eq) and di-tert-butyl 
dicarbonate (330 mg, 1.51 mmol, 1.1 eq). The reaction mixture was then stirred at 
room temperature for 16 h, diluted with CH2Cl2 and washed with H2O. The aqueous 
phase was extracted with CH2Cl2 (× 3) and the combined organic extracts were dried 
over MgSO4, filtered and concentrated. The crude oil was dry loaded on silica gel and 
purified by flash column chromatography (gradient PE/Et2O 85:15 to 80:20) to yield 
the corresponding carbamate 251(b) as a colorless oil (430 mg, 69%). 
 
1H-NMR (400MHz, at 50 ºC, CDCl3): δH = 4.63-4.57 (m, 2H), 4.31 (m, 1H), 4.02-
3.99 (m, 1H), 3.88-3.84 (m, 2H), 3.80-3.74 (m, 2H), 3.72-3.68 (m, 2H), 3.35 (app-br 
s, 5H), 1.46 (s, 9H, C-(CH3)3, Boc), 1.42 and 1.33 (2 × s, 6H, C-(CH3)2), 0.90 (s, 9H, 
C-(CH3)3, TBS), 0.07 (s, 6H, Si-(CH3)2)  
 
13C-NMR (100MHz, at 50 ºC, CDCl3): δC = 155.7, 109.7, 96.5, 80.0, 75.3, 67.4, 
66.2, 61.7, 59.5, 55.3, 48.8, 28.5, 26.9, 26.0, 25.6, 18.4, -5.3 
 
MS (ESI): m/z = 464 [M+H]+, 486 [M+Na]+ 
HRMS (ESI): calculated for C22H46NO7Si [M+H]+ 464.3044, found: 464.3029 
 
 
 
 
 
N
O
O
O
O Si
O
O
O
	   232	  
tert-Butyl-N-[(1S)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-
(methoxymethoxy)ethyl]-N-(2-hydroxyethyl)carbamate (241) 
 
 
 
Tetrabutylammonium fluoride (1.60 mL, 1.60 mmol, 2 eq, 1 M in THF) was added 
dropwise to a solution of silyl ether 251(b) (370 mg, 0.800 mmol, 1 eq) in 
THF (8.0 mL) at 0 °C. The reaction mixture was stirred at room temperature for 
30 min, diluted with EtOAc and then washed with a saturated aqueous solution of 
NaHCO3. The aqueous layer was extracted with EtOAc (× 3) and the combined 
organic extracts were dried over MgSO4, filtered and concentrated. The crude oil was 
purified by flash column chromatography (PE/EtOAc 60:40) to yield alcohol 241 as a 
colorless oil (240 mg, 86%). 
 
1H-NMR (400MHz, CDCl3): δH = 4.68-4.63 (m, 2H), 4.45 (br s, 1H, OH), 4.26-
4.20 (m, 1H), 4.03-3.99 (m, 1H), 3.82-3.61 (m, 7H), 3.35 (s, 3H, OCH3), 3.21-3.13 
(m, 1H), 1.48 (app-m, 12H, C-(CH3)3), 1.32 (s, 3H, C-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 110.0, 96.3, 81.0, 80.3, 74.9, 74.7, 66.9, 65.6, 
62.6, 62.2, 55.5, 28.4, 26.8, 25.5 
 
MS (ESI): m/z = 372 [M+Na]+ 
HRMS (ESI): calculated for C16H31NO7Na [M+Na]+ 372.1998, found: 372.1984 
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(4-Fluorophenyl)[7-iodo-6-methoxy-2-(4-methoxyphenyl)-1- 
benzothiophen-3-yl]methanone (255) 
 
 
 
To a solution of 208 (155 mg, 0.395 mmol, 1.0 eq) in AcOH (6.0 mL) was added 
NIS (116 mg, 0.513 mmol, 1.3 eq). The reaction mixture was then stirred in darkness 
for 72 h and quenched by addition of H2O. The aqueous phase was extracted with 
EtOAc (× 3) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude was dry loaded on silica gel and purified by flash column 
chromatography (gradient PE/EtOAc 95:5 to 90:10) to yield iodide 255 as a yellow 
foam (200 mg, 98%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.77 (dd, J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, 
CH=C), 7.70 (d, J = 8.8 Hz, 1H, H4, CH=C), 7.30 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 
6.94-6.90 (m, 3H, H5,19,21, CH=C), 6.74 (d, J = 8.3 Hz, 2H, H12,14, CH=C), 3.95 and 
3.74 (2 × s, 6H, H9,23, O-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 192.6 (C16), 165.6 (d, JC-F = 255 Hz, C20), 160.1, 
156.4, 147.1, 144.7, 133.7, 133.0, 132.5 (d, JC-F = 8.7 Hz, C18,22), 130.7, 
130.5 (C11,15), 125.3, 124.2 (C4), 115.5 (d, JC-F = 22.5 Hz, C19,21), 114.1 (C12,14), 
109.7 (C5), 57.2 and 55.3 (C9,23) 
One quaternary carbon missing 
 
IR: υmax/cm−1 (CHCl3): 2940, 2840, 1648, 1596, 1530, 1460, 1434, 1253, 1180, 1152, 
1051  
 
MS (ESI): m/z = 518 [M+H]+ 
HRMS (ESI): calculated for C23H17FIO3S [M+H]+ 518.9927, found: 518.9915 
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[7-(4-Chlorophenyl)-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophen-3-yl]- 
(4-fluorophenyl)methanone (254) 
 
 
 
To a solution of iodide 255 (95 mg, 0.18 mmol, 1.0 eq) in a mixture of 
EtOH (0.60 mL), H2O (0.60 mL) and toluene (a few drops) was added para-
chlorophenylboronic acid (216) (32 mg, 0.20 mmol, 1.1 eq), Na2CO3 (74 mg, 
0.70 mmol, 3.8 eq) and Pd/C (8.0 mg, 0.073 mmol, 0.40 eq, 10% on activated 
charcoal). The resulting suspension was stirred under microwave irradiation at 150 ºC 
for 15 min. The reaction mixture was then filtered through Celite and the filtrate 
washed with a 1 M aqueous solution of HCl. The aqueous phase was extracted with 
EtOAc (× 3) and the combined organic extracts were washed with brine, dried over 
MgSO4, filtered and concentrated. The crude material was dry loaded on silica gel 
and purified by flash column chromatography (PE/EtOAc 95:5) to yield 254 as a 
yellow foam (74 mg, 80%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.85 (dd, J = 8.8 Hz, JH-F = 5.4 Hz, 2H, H18,22, 
CH=C), 7.75 (d, J = 8.8 Hz, 1H, H4, CH=C), 7.59 and 7.52 (2 × d, J = 8.8 Hz, 4H, 
H25,26,28,29, CH=C), 7.28 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.17 (d, J = 8.8 Hz, 1H, 
H5, CH=C), 6.97 (dd, J = 8.8 Hz, JH-F = 8.8 Hz, 2H, H19,21, CH=C), 6.74 (d, 
J = 8.8 Hz, 2H, H12,14, CH=C), 3.87 and 3.75 (2 × s, 6H, H9,23, O-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 192.6 (C16), 165.6 (d, JC-F = 255 Hz, C20), 159.9, 
153.7, 145.2, 141.0, 134.8, 134.0, 133.8, 133.7, 132.5 (d, JC-F = 8.0 Hz, C18,22), 
131.0 and 128.8 (C25,26,28,29), 130.4 (C11,15), 129.9, 125.5, 123.4 (C4), 122.5, 115.4 (d, 
JC-F = 22.5 Hz, C19,21), 114.0 (C12,14), 111.1 (C5), 56.5 and 55.2 (C9,23) 
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IR: υmax/cm−1 (CHCl3): 1648, 1596, 1501, 1471, 1255, 1178, 1153, 1052, 826 
 
MS (ESI): m/z = 503 [M(35Cl)+H]+, 505 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C29H21FO3S35Cl [M+H]+ 503.0884, found: 503.0882  
 
 
 
[7-(4-Chlorophenyl)-6-methoxy-2-(4-methoxyphenyl)-1- 
benzothiophen-3-yl][4-(2,2-diethoxyethoxy)phenyl]methanone (253) 
 
 
 
To a suspension of NaH (67.0 mg, 1.67 mmol, 4 eq, 60% in mineral oil) in 
DMF (4.2 mL) was added acetal 256 (220 mg, 1.67 mmol, 4 eq). The mixture was 
then stirred at room temperature for 5 min and a solution of 254 (210 mg, 
0.418 mmol, 1 eq) in DMF (0.50 mL) added in one portion. After stirring at 50 ºC for 
16 h, the reaction mixture was quenched by addition of H2O. The aqueous phase was 
extracted with EtOAc (× 4) and the combined organic extracts were washed with 
brine, dried over MgSO4, filtered and concentrated. The crude was dry loaded on 
silica gel and purified by flash column chromatography (gradient PE/EtOAc 95:5 to 
85:15) to yield 253 as a yellow foam (205 mg, 79%). 
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1H-NMR (400MHz, CDCl3): δH = 7.79 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.62 (d, 
J = 8.8 Hz, 1H, H4, CH=C), 7.55 and 7.48 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 
7.30 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.10 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.79 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.71 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.79 (t, 
J = 5.4 Hz, 1H, H31, O-CH-O), 3.99 (d, J = 5.4 Hz, 2H, H30, O-CH2), 3.82 (s, 3H, 
H9or23, O-CH3), 3.75-3.59 (m, 7H, H9or23,32,34, O-CH3, O-CH2), 1.23 (t, J = 7.4 Hz, 6H, 
H33,35, CH2-CH3) 
 
13C-NMR (100MHz, CDCl3): δC = 193.0 (C16), 162.7, 159.8, 153.6, 143.5, 141.0, 
134.9, 134.3, 133.7, 132.3 (C18,22), 131.1 and 128.8 (C25,26,28,29), 130.6, 130.5, 
130.2 (C11,15), 125.8, 123.4 (C4), 122.6, 115.3 (C19,21), 114.0 (C12,14), 111.1 (C5), 
100.3 (C31), 68.6 (C30), 62.9 (C32,34), 56.6 and 55.2 (C9,23), 15.3 (C33,35)  
 
IR: υmax/cm−1 (CHCl3): 2976, 1648, 1598, 1502, 1468, 1256, 1177, 1136, 1053, 827 
 
MS (ESI): m/z = 617 [M(35Cl)+H]+, 619 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C35H34O6S35Cl [M+H]+ 617.1765, found: 617.1752 
 
 
 
2-(4-{[7-(4-Chlorophenyl)-6-methoxy-2-(4-methoxyphenyl)-1- 
benzothiophen-3-yl]carbonyl}phenoxy)acetaldehyde (257) 
 
 
 
To a solution of diethyl acetal 253 (220 mg, 0.360 mmol, 1.0 eq) in CHCl3 (1.8 mL) 
was added TFA (280 µL, 3.60 mmol, 10 eq). The reaction mixture was then stirred at 
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room temperature for 16 h, diluted with CHCl3 and quenched by addition of H2O. The 
aqueous phase was extracted with CHCl3 (× 3) and the combined organic extracts 
were dried over MgSO4, filtered and concentrated. The crude aldehyde 257 was 
isolated as a yellow foam and directly used in the next step without purification. 
 
 
 
(5S)-1-(4-{[7-(4-Chlorophenyl)-6-methoxy-2-(4-methoxyphenyl)-1-
benzothiophen-3-yl]carbonyl}phenyl)-5-[(4S)-2,2-dimethyl-1,3- 
dioxolan-4-yl]-1,7,9-trioxa-4-azadecane (258) 
 
 
 
To a solution of aldehyde 257 (0.360 mmol, 1.0 eq, crude mixture) in DCE (2.2 mL) 
was added amine 242 (80.0 mg, 0.396 mmol, 1.1 eq). The mixture was then stirred at 
room temperature for 15 min and NaB(OAc)3H (106 mg, 0.504 mmol, 1.4 eq) added 
in one portion. The reaction mixture was stirred for a further 2 h and purified by flash 
column chromatography (gradient PE/EtOAc 70:30 to 35:65) to yield 258 as a yellow 
oil (220 mg, 84% over 3 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.82 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.63 (d, 
J = 8.8 Hz, 1H, H4, CH=C), 7.58 and 7.51 (2 × d, J = 8.3 Hz, 4H, H25,26,28,29, CH=C), 
7.33 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.12 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.79 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.75 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.67-
4.64 (app-m, 2H, H35, O-CH2), 4.16-4.05 (m, 4H), 3.98-3.91 (m, 1H), 3.85 (s, 3H, O-
CH3), 3.76 (s, 3H, O-CH3), 3.74-3.70 (dd, J = 10.3 Hz, J = 3.4 Hz, 1H), 3.67-
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3.63 (dd, J = 10.3 Hz, J = 4.4 Hz, 1H), 3.38 (s, 3H, O-CH3), 3.20-3.14 (m, 1H), 2.99-
2.93 (m, 1H), 2.83-2.79 (m, 1H), 1.99 (br s, 1H, H32, NH-C), 1.43 and 1.39 (2 × s, 6H, 
H40,41, C-(CH3)2) 
 
13C-NMR (100MHz, CDCl3): δC = 193.0 (C16), 163.0, 159.8, 153.5, 143.3, 141.0, 
134.9, 134.3, 133.7, 132.3 (C18,22), 131.1 and 128.8 (C25,26,28,29), 130.5, 130.4, 
130.1 (C11,15), 125.8, 123.4 (C4), 122.5, 114.1 and 114.0 (C12,14,19,21), 111.0 (C5), 
108.9, 96.7 (C35), 75.9, 68.1, 67.1, 65.9, 59.9, 56.5 and 55.3 and 55.2 (C9,23,36), 46.7, 
26.7 and 25.2 (C40,41) 
 
IR: υmax/cm−1 (CHCl3): 2934, 1651, 1598, 1504, 1471, 1381, 1256, 1166, 1048, 830 
 
MS (ESI): m/z = 732 [M(35Cl)+H]+, 734 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C40H43NO8S35Cl [M+H]+ 732.2398, found: 732.2412 
 
Specific rotation: [α]D25 = +9.9 (c 1.2, CHCl3) 
 
 
 
(2S,3S)-3-{[2-(4-{[7-(4-Chlorophenyl)-6-hydroxy-2-(4-hydroxyphenyl)-1- 
benzothiophen-3-yl]carbonyl}phenoxy)ethyl]amino}butane-1,2,4-triol (240) 
 
 
 
To a solution of 258 (70 mg, 0.096 mmol, 1 eq) in CH2Cl2 (2.2 mL) at -20 ºC was 
added BBr3 (0.48 mL, 0.48 mmol, 5 eq, 1 M in CH2Cl2) dropwise. The mixture was 
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then slowly warmed to 0 ºC over a 30 min period and stirred at this temperature for 
3 h. The reaction mixture was quenched by addition of MeOH, stirred for 15 min and 
concentrated in vacuo. The residue was then co-evaporated with MeOH (× 3) and the 
resulting crude solid dry loaded on silica gel and purified by flash column 
chromatography (gradient CH2Cl2/MeOH 95:5 to 90:10 + 0.25% NH4OH) to yield 
240 as an amorphous yellow solid (49 mg, 82%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.73 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.58 and 
7.48 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.41 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.12 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.02 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.93 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.60 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.34 (t, 
J = 4.9 Hz, 2H, H30, O-CH2), 4.07-4.03 (m, 1H, H37, HO-CH), 3.98-3.88 (m, 2H, H34, 
HO-CH2), 3.77-3.73 (dd, J = 11.2 Hz, J = 4.9 Hz, 1H, H38, HO-CH2), 3.67-3.61 (m, 
3H, H31,38, HN-CH2 and HO-CH2), 3.54-3.50 (m, 1H, H33, HN-CH) 
 
13C-NMR (100MHz, CD3OD): δC = 195.4 (C16), 163.5, 159.2, 152.9, 144.6, 142.0, 
136.8, 134.6, 134.5, 133.5 (C18,22), 132.5 and 129.7 (C25,26,28,29), 131.5, 131.4 (C11,15), 
129.1, 125.9, 124.1 (C4), 121.7, 116.8 (C5), 116.5 (C12,14), 115.6 (C19,21), 68.9 (C37), 
64.7 (C30), 64.4 (C38), 63.6 (C33), 57.9 (C34), 46.4 (C31) 
 
IR: υmax/cm−1 (MeOH): 3356, 3132, 3033, 2805, 1632, 1596, 1401, 1254, 1170, 830 
 
MS (ESI): m/z = 620 [M(35Cl)+H]+, 622 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C33H31NO7S35Cl [M+H]+ 620.1510, 
found: 620.1505 
 
Specific rotation: [α]D25 = -4.3 (c 0.49, MeOH) 
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Ethyl-1,4-dibenzyl-3-oxopiperazine-2-carboxylate (263)135 
 
 
 
To a solution of N,N’-dibenzylethylenediamine (261) (14.2 mL, 60.0 mmol, 2 eq) in 
acetonitrile (90 mL) was added diethyl bromomalonate (262) (5.20 mL, 30.0 mmol, 
1 eq) and the reaction mixture was stirred at reflux for 6 h, then cooled to room 
temperature and concentrated in vacuo. The residue was diluted with a 1 M aqueous 
solution of NaOH and Et2O.  The aqueous layer was extracted with Et2O (× 3) and 
the combined organic extracts were dried over MgSO4, filtered and concentrated. The 
orange residue was purified by flash column chromatography (PE/EtOAc 75:25) to 
yield 263 as a pale yellow oil (9.00 g, 85%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.33-7.25 (m, 10H, Ar-H), 4.74 and 4.47 (2 × d, 
AB system, J = 14.7 Hz, 2H, CH2-Ph), 4.29 (q, J = 7.3 Hz, 2H, CH2-CH3), 4.09 (s, 
1H, CH-COOEt), 3.75 and 3.59 (2 × d, AB system, J = 13.7 Hz, 2H, CH2-Ph), 3.27-
3.09 (m, 3H, BnN-CH2), 2.54-2.48 (m, 1H, BnN-CH2), 1.34 (t, J = 7.3 Hz, 3H, CH2-
CH3), 
 
13C-NMR (100MHz, CDCl3): δC = 168.5, 163.8, 136.3, 136.0, 128.8, 128.4, 128.2, 
127.8, 127.4, 127.3, 68.5, 61.2, 58.6, 49.6, 45.3, 44.7, 14.0 
 
IR: υmax/cm−1 (neat): 2981, 2930, 1734, 1649, 1494, 1453, 1354, 1179, 1154, 1028, 
748 
 
MS (ESI): m/z = 353 [M+H]+ 
HRMS (ESI): calculated for C21H25N2O3 [M+H]+ 353.1865, found: 353.1850 
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Ethyl-4-benzyl-3-oxopiperazine-2-carboxylate (264)135 
 
 
 
To a solution of benzyl amine 263 (7.50 g, 21.3 mmol, 1 eq) in absolute 
EtOH (75 mL) was added Pd/C (450 mg, 0.426 mmol, 0.02 eq, 10% on activated 
charcoal). The reaction mixture was stirred under an atmosphere of H2 for 44 h, 
filtered through Celite and concentrated in vacuo. The residue was purified by flash 
column chromatography (gradient CH2Cl2/MeOH 99:1 to 98:2) to yield amine 264 as 
a pale yellow oil (2.80 g, 50%) and 3.23 g (43%) of recovered starting material. 
 
1H-NMR (400MHz, CDCl3): δH = 7.31-7.25 (m, 5H, Ar-H), 4.72-4.49 (2 × d, AB 
system, J = 14.6 Hz, 2H, CH2-Ph), 4.28 (m, 3H, CH2-CH3 and CH-COOEt), 3.26-
3.14 (m, 3H, N-CH2), 3.00-2.94 (m, 1H, N-CH2), 2.30 (br s, 1H, NH), 1.33 (t, 
J = 7.3 Hz, 3H, CH2-CH3), 
 
13C-NMR (100MHz, CDCl3): δC = 169.7, 164.0, 136.2, 128.6, 128.0, 127.5, 62.4, 
61.8, 50.0, 46.9, 40.4, 14.0 
 
IR: υmax/cm−1 (neat): 3318, 2981, 2939, 1731, 1643, 1495, 1453, 1301, 1236, 1183, 
1027, 736 
 
MS (ESI): m/z = 263 [M+H]+ 
HRMS (ESI): calculated for C14H19N2O3 [M+H]+ 263.1396, found: 263.1396 
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(4-Benzylpiperazin-2-yl)methanol (265)135 
 
 
 
To a stirred solution of LAH (13.1 mL, 26.2 mmol, 2.8 eq, 2 M in THF) in 
THF (5.0 mL) was added dropwise a solution of ester 264 (2.50 g, 9.36 mmol, 1.0 eq) 
in THF (37 mL). The reaction mixture was then stirred at room temperature for 1.5 h 
and sequentially quenched with H2O (1.0 mL), a 2 M aqueous solution of 
NaOH (3.0 mL) and H2O (1.0 mL). The resulting suspension was stirred for 30 min, 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (CH2Cl2/MeOH 90:10 + 0.5% NH4OH) to yield amino alcohol 265 
as a pale brown oil (1.38 g, 71%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.33-7.25 (m, 5H, Ar-H), 3.56-3.43 (m, 4H, CH2-
Ph and CH2-OH), 3.20 (app-br s, 2H, NH and OH), 3.01-2.97 (m, 1H, N-CH2), 2.94-
2.86 (m, 2H, N-CH2 and CH-CH2OH), 2.75-2.73 (m, 2H, N-CH2), 2.11 (ddd, 
J = 11.2 Hz, J = 11.2 Hz, J = 3.4 Hz, 1H, N-CH2), 1.87 (dd, J = 10.8 Hz, J = 10.8 Hz, 
1H, N-CH2) 
 
13C-NMR (100MHz, CDCl3): δC = 137.7, 129.1, 128.1, 127.0, 64.0, 63.4, 56.1, 55.7, 
53.6, 44.9 
 
IR: υmax/cm−1 (CHCl3): 3264, 2938, 2818, 1497, 1454, 1329, 1135, 1054, 1028, 842, 
747 
 
MS (ESI): m/z = 207 [M+H]+ 
HRMS (ESI): calculated for C12H19N2O [M+H]+ 207.1497, found: 207.1498 
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1-Benzyl-3-{[(tert-butyldimethylsilyl)oxy]methyl}piperazine (267) 
 
 
 
To a solution of alcohol 265 (400 mg, 1.94 mmol, 1.0 eq) in CH2Cl2 (4.0 mL) was 
successively added imidazole (265 mg, 3.88 mmol, 2.0 eq) and TBSCl (320 mg, 
2.13 mmol, 1.1 eq). The reaction mixture was then stirred at room temperature for 
16 h, diluted with CH2Cl2 and quenched by addition of a saturated aqueous solution 
of NaHCO3. The aqueous layer was extracted with CH2Cl2 (× 4) and the combined 
organic extracts were washed with H2O, dried over MgSO4, filtered and concentrated. 
The residue was purified by flash column chromatography (CH2Cl2/MeOH 96:4 
+ 0.25% NH4OH) to yield 267 as a pale yellow oil (585 mg, 94%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.29-7.22 (m, 5H, Ar-H), 3.54-3.43 (m, 4H, CH2-
Ph and CH2-OTBS), 2.98-2.93 (m, 1H, N-CH2), 2.91-2.85 (m, 2H, N-CH2 and CH-
CH2OTBS), 2.74-2.69 (m, 2H, N-CH2), 2.06 (ddd, J = 11.3 Hz, J = 11.3 Hz, 
J = 3.4 Hz, 1H, N-CH2), 1.94 (br s, 1H, NH), 1.77 (dd, J = 10.8 Hz, J = 10.8 Hz, 1H, 
N-CH2), 0.86 (s, 9H, C-(CH3)3) , 0.02 (s, 6H, Si-(CH3)2) 
 
13C-NMR (100MHz, CDCl3): δC = 138.2, 129.2, 128.2, 127.0, 65.6, 63.5, 56.5, 56.0, 
54.0, 45.4, 25.9, 18.3, -5.4 
 
IR: υmax/cm−1 (CHCl3): 2928, 2858, 2807, 1460, 1251, 1124, 1083, 834, 774 
 
MS (ESI): m/z = 321 [M+H]+ 
HRMS (ESI): calculated for C18H33N2OSi [M+H]+ 321.2362, found: 321.2354 
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4-Benzyl-2-{[(tert-butyldimethylsilyl)oxy]methyl}-1-[2-(4-{[7-(4-chlorophenyl)-6-
methoxy-2-(4-methoxyphenyl)-1-benzothiophen-3-yl]carbonyl}phenoxy) 
ethyl]piperazine (268) 
 
 
 
To a solution of aldehyde 257 (0.13 mmol, 1.0 eq, crude mixture) in DCE (0.70 mL) 
was added amine 267 (44 mg, 0.14 mmol, 1.1 eq). The mixture was then stirred at 
room temperature for 15 min and NaB(OAc)3H (37 mg, 0.17 mmol, 1.4 eq) was 
added in one portion. The reaction mixture was stirred for a further 2 h and purified 
by flash column chromatography (gradient PE/EtOAc 65:35 to 50:50) to yield 268 as 
a yellow oil (72 mg, 69% over 3 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.75 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.56 (d, 
J = 8.8 Hz, 1H, H4, CH=C), 7.52 and 7.44 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 
7.28-7.22 (m, 7H, H39,40,41,42,43,11,15, Ar-H and CH=C), 7.05 (d, J = 8.8 Hz, 1H, H5, 
CH=C), 6.72 (d, J = 8.8 Hz, 2H, H19,21, CH=C), 6.68 (d, J = 8.8 Hz, 2H, H12,14, 
CH=C), 4.04-4.02 (m, 2H), 3.78 (app-s, 4H, H9or23, O-CH3), 3.69 (s, 3H, H9or23, O-
CH3), 3.54-3.50 (m, 1H), 3.46 (app-s, 2H, H37, CH2-Ph), 3.17-3.11 (m, 1H), 2.90-
2.81 (m, 2H), 2.74-2.71 (m, 1H), 2.66-2.55 (m, 3H), 2.25-2.20 (m, 1H), 2.07-2.01 (m, 
1H), 0.86 (s, 9H, H46, C-(CH3)3) , 0.02 (s, 6H, H44, Si-(CH3)2) 
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13C-NMR (100MHz, CDCl3): δC = 193.0 (C16), 163.0, 159.7, 153.5, 143.3, 140.9, 
137.7, 134.9, 134.3, 133.7, 132.3 (C18,22), 131.1 and 129.2 (C25,26,28,29), 130.6, 130.3 
and 128.7 and 128.2 and 127.0 (C11,15,39,40,41,42,43), 130.1, 125.8, 123.4 (C4), 122.5, 
114.1 and 114.0 (C12,14,19,21), 111.0 (C5), 66.2, 63.4, 63.0, 61.1, 56.5 and 55.2 (C9,23), 
55.8, 52.8, 52.7, 52.0, 25.8 (C46), 18.1 (C45), -5.5 (C44) 
 
IR: υmax/cm−1 (CHCl3): 2935, 1650, 1598, 1502, 1468, 1255, 1165, 1093, 1052, 832 
 
MS (ESI): m/z = 847 [M(35Cl)+H]+, 849 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C49H56N2O5SiS35Cl [M+H]+ 847.3368, found: 847.3369 
 
 
 
3-[(4-{2-[4-Benzyl-2-(hydroxymethyl)piperazin-1-yl]ethoxy}phenyl)carbonyl]-7-
(4-chlorophenyl)-2-(4-hydroxyphenyl)-1-benzothiophen-6-ol (269) 
 
 
 
To a solution of 268 (30 mg, 0.035 mmol, 1.0 eq) in CH2Cl2 (1.0 mL) at -20 ºC was 
added BBr3 (0.13 mL, 0.13 mmol, 3.5 eq, 1 M in CH2Cl2) dropwise. The mixture was 
then slowly warmed to 0 ºC over a 30 min period and stirred at this temperature for 
3 h. The reaction mixture was quenched by addition of MeOH, stirred for 15 min, 
concentrated in vacuo and then co-evaporated with MeOH (× 3). The resulting crude 
solid was dry loaded on silica gel and purified by flash column chromatography 
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(gradient CH2Cl2/MeOH 99:1 to 97:3 + 0.25% NH4OH) to yield alcohol 269 as a pale 
yellow oil (17 mg, 68%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.69 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.59 and 
7.48 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.39 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.30-7.22 (m, 5H, H39,40,41,42,43, Ar-H), 7.12 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 
6.99 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.80 (d, J = 8.8 Hz, 2H, H19,21, CH=C), 6.58 (d, 
J = 8.8 Hz, 2H, H12,14, CH=C), 4.08 (app-br s, 2H, H30, CH2-O), 3.67 (dd, 
J = 11.2 Hz, J = 3.4 Hz, 1H, H36, CH2-OH), 3.58 (dd, J = 11.2 Hz, J = 5.4 Hz, 1H, 
H36, CH2-OH), 3.49 (app-s, 2H, H37, CH2-Ph), 3.20-3.13 (m, 1H), 2.92-2.89 (m, 1H), 
2.83-2.76 (m, 2H), 2.67-2.64 (m, 1H), 2.58-2.53 (m, 2H, H35, CH-CH2OH), 2.24-2.11 
(m, 2 H) 
 
13C-NMR (100MHz, CD3OD): δC = 195.4, 164.6, 159.3, 153.0, 144.4, 142.0, 138.3, 
136.8, 134.6, 134.5, 133.6, 132.5, 131.7, 131.4, 130.7, 129.7, 129.4, 128.5, 125.9, 
124.2, 121.7, 116.8, 116.6, 115.4, 67.0, 64.0, 62.8, 62.1, 57.0, 53.5, 53.4, 52.9 
One quaternary carbon missing 
 
IR: υmax/cm−1 (MeOH): 3261, 2941, 2832, 1639, 1596, 1505, 1384, 1259, 1166, 
1015, 828 
 
MS (ESI): m/z = 705 [M(35Cl)+H]+, 707 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C41H38N2O5S35Cl [M+H]+ 705.2190, 
found: 705.2195 
 
 
 
 
 
 
 
 
 
 
	   247	  
7-(4-Chlorophenyl)-3-[(4-{2-[2-(hydroxymethyl)piperazin-1-yl]ethoxy}phenyl) 
carbonyl]-2-(4-hydroxyphenyl)-1-benzothiophen-6-ol (259) 
 
 
 
To a solution of benzyl amine 269 (30 mg, 0.043 mmol, 1.0 eq) in MeOH (1.0 mL) 
was successively added Pd/C (2.4 mg, 0.0021 mmol, 0.05 eq, 10% on activated 
charcoal) and TFA (3.6 µL, 0.047 mmol, 1.1 eq). The reaction mixture was then 
stirred under an atmosphere of H2 for 2 h, filtered through Celite and concentrated in 
vacuo. The residue was dry loaded on silica gel and purified by flash column 
chromatography (gradient CH2Cl2/MeOH 90:10 to 85:15 + 0.25% of NH4OH) to 
yield amino alcohol 259 as an amorphous yellow solid (15 mg, 56%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.69 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.59 and 
7.48 (2 × d, J = 8.3 Hz, 4H, H25,26,28,29, CH=C), 7.40 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.12 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 6.99 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.81 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.59 (d, J = 8.3 Hz, 2H, H12,14, CH=C), 4.08 (app-br t, 
2H, H30, CH2-O), 3.70-3.61 (m, 2H), 3.22-3.14 (m, 1H), 3.04-3.00 (m, 1H), 2.94-
2.88 (m, 2H), 2.85-2.75 (m, 2H), 2.71-2.66 (m, 1H), 2.51-2.46 (m, 2H) 
 
13C-NMR (125MHz, CD3OD): δC = 195.5, 164.6, 159.4, 153.0, 144.5, 142.1, 136.9, 
134.7, 134.6, 133.6 (C18,22), 132.5 and 129.7 (C25,26,28,29), 131.8, 131.7, 131.4 (C11,15), 
125.9, 124.2 (C4), 121.7, 116.8 (C5), 116.6 (C12,14), 115.4 (C19,21), 67.0 (C30), 62.3, 
62.2 (C35), 53.7, 53.1, 48.8, 45.9 
Peak at 48.8 ppm below solvent peak but identified with DEPT experiment 
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IR: υmax/cm−1 (MeOH): 3163, 1595, 1503, 1385, 1262, 1169, 1027, 828 
 
MS (ESI): m/z = 615 [M(35Cl)+H]+, 617 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C34H32N2O5S35Cl [M+H]+ 615.1720, 
found: 615.1749 
 
 
 
5-Benzyl-hexahydro-1H-[1,3]oxazolo[3,4]piperazin-1-one (270)146 
 
 
 
To a stirred solution of diethyl carbonate (3.17 mL, 26.2 mmol, 10 eq) in absolute 
EtOH (5.3 mL) was added NaH (210 mg, 5.24 mmol, 2.0 eq). This was then added 
dropwise to a solution of amino alcohol 265 (540 mg, 2.62 mmol, 1.0 eq) in absolute 
EtOH (21 mL) and the reaction mixture stirred at reflux for 6 h, before being cooled 
to room temperature and quenched by dropwise addition of AcOH (2.0 mL). The 
resulting solution was then concentrated to dryness and the residue partitioned 
between CH2Cl2 and a 1 M aqueous solution of HCl. The aqueous layer was extracted 
with CH2Cl2 (× 3) and the combined organic extracts were dried over MgSO4, filtered 
and concentrated. The residue was dry loaded on silica gel and purified by flash 
column chromatography (gradient PE/EtOAc 60:40 to 15:85) to yield 
oxazolidinone 270 as a colorless oil (610 mg, 100%). 
 
1H-NMR (400MHz, CDCl3): δH = 7.38-7.28 (m, 5H, Ar-H), 4.40-4.34 (app-m, 1H, 
CH2-O), 3.92-3.85 (m, 2H, CH2-O and CH-CH2O), 3.82-3.78 (m, 1H, N-CH2), 3.65-
3.51 (2 × d, AB system, J = 13.2 Hz, 2H, CH2-Ph), 3.18-3.11 (m, 1H, N-CH2), 2.92-
2.81 (m, 2H, N-CH2), 2.13 (ddd, J = 11.7 Hz, J = 11.7 Hz, J = 3.9 Hz, 1H, N-CH2), 
1.96 (dd, J = 10.8 Hz, J = 10.8 Hz, 1H, N-CH2) 
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13C-NMR (100MHz, CDCl3): δC = 156.9, 137.2, 128.9, 128.3, 127.4, 65.4, 62.7, 
56.7, 53.1, 51.8, 41.0 
 
IR: υmax/cm−1 (neat): 2921, 2814, 1745, 1447, 1425, 1352, 1240, 1060, 997, 758 
 
MS (ESI): m/z = 233 [M+H]+ 
HRMS (ESI): calculated for C13H17N2O2 [M+H]+ 233.1290, found: 233.1284 
 
 
 
Hexahydro-1H-[1,3]oxazolo[3,4]piperazin-1-one (271)147 
 
 
 
To a solution of benzyl amine 270 (300 mg, 1.29 mmol, 1 eq) in a mixture of 
MeOH (3.0 mL) and AcOH (3.0 mL) was added Pd/C (70.5 mg, 0.0645 mmol, 
0.05 eq, 10% on activated charcoal). The reaction mixture was then stirred under an 
atmosphere of H2 for 72 h, filtered through Celite and concentrated in vacuo. The 
resulting crude amine 271, contaminated with traces of AcOH, was directly used in 
the next step with no further purification. 
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5-[2-(4-{[7-(4-Chlorophenyl)-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophen-
3-yl]carbonyl}phenoxy)ethyl]-hexahydro-1H-[1,3]oxazolo[3,4]piperazin-1-one 
(272) 
 
 
 
To a solution of aldehyde 257 (0.260 mmol, 1.0 eq, crude mixture) in DCE (1.6 mL) 
was added amine 271 (41.3 mg, 0.286 mmol, 1.1 eq). The resulting suspension was 
gently heated till both starting materials dissolved, cooled to room temperature and 
stirred for 15 min. NaB(OAc)3H (77.0 mg, 0.364 mmol, 1.4 eq) was then added in 
one portion and the reaction mixture stirred for a further 2.5 h and purified by flash 
column chromatography (gradient PE/EtOAc 50:50 to 0:100) to yield 272 as a pale 
yellow oil (100 mg, 58% over 4 steps). 
 
1H-NMR (400MHz, CDCl3): δH = 7.79 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.60 (d, 
J = 8.8 Hz, 1H, H4, CH=C), 7.55 and 7.47 (2 × d, J = 8.3 Hz, 4H, H25,26,28,29, CH=C), 
7.29 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 7.09 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.76 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.71 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.36 (dd, 
J = 7.8 Hz, J = 7.8 Hz, 1H, H35, O-CH2), 4.07 (t, J = 5.4 Hz, 2H, H30, O-CH2), 3.91-
3.83 (m, 2H, H35,36, CH2-O and CH-CH2O), 3.81 (s, 3H, H9or23, O-CH3), 3.79-
3.73 (m, 1H, N-CH2), 3.71 (s, 3H, H9or23, O-CH3), 3.10 (ddd, J = 11.7 Hz, 
J = 11.7 Hz, J = 3.4 Hz, 1H, N-CH2), 2.99-2.96 (m, 1H, N-CH2), 2.86-2.81 (m, 3H, 
H31, N-CH2 and N-CH2), 2.22 (ddd, J = 11.7 Hz, J = 11.7 Hz, J = 3.4 Hz, 1H, N-
CH2), 2.11 (dd, J = 10.8 Hz, J = 10.8 Hz, 1 H, N-CH2) 
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13C-NMR (100MHz, CDCl3): δC = 192.9 (C16), 162.6, 159.7, 156.8, 153.5, 143.3, 
140.9, 134.8, 134.2, 133.7, 132.3 (C18,22), 131.0 and 128.7 (C25,26,28,29), 130.5, 130.4, 
130.1 (C11,15), 125.8, 123.3 (C4), 122.5, 114.1 and 113.9 (C12,14,19,21), 111.0 (C5), 
66.0 (C30), 65.3 (C35), 57.4, 56.8, 56.5 and 55.2 (C9,23), 53.0 (C36), 52.1, 40.9 
 
IR: υmax/cm−1 (CHCl3): 2939, 2842, 1751, 1650, 1596, 1501, 1470, 1253, 1165, 1049, 
1032, 730 
 
MS (ESI): m/z = 669 [M(35Cl)+H]+, 671 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C37H34N2O6S35Cl [M+H]+ 669.1826, found: 669.1824 
 
 
 
5-[2-(4-{[7-(4-Chlorophenyl)-6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-
3-yl]carbonyl}phenoxy)ethyl]-hexahydro-1H-[1,3]oxazolo[3,4]piperazin-1-one 
(273) 
 
 
 
To a solution of 272 (57 mg, 0.085 mmol, 1 eq) in CH2Cl2 (2.3 mL) at -20 ºC was 
added BBr3 (0.34 mL, 0.34 mmol, 4 eq, 1 M in CH2Cl2) dropwise. The mixture was 
then slowly warmed to 0 ºC over a 30 min period and stirred at this temperature for 
3 h. The reaction mixture was quenched by addition of MeOH, stirred for 15 min, 
concentrated in vacuo and then co-evaporated with MeOH (× 3). The resulting crude 
solid was dry loaded on silica gel and purified by flash column chromatography 
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(gradient CH2Cl2/MeOH 98:2 to 96:4 + 0.25% NH4OH) to yield 273 as a pale 
yellow oil (39 mg, 71%). 
 
1H-NMR (400MHz, mixture CD3OD/CDCl3): δH = 7.72 (d, J = 8.8 Hz, 2H, H18,22, 
CH=C), 7.58 and 7.44 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.42 (d, J = 8.8 Hz, 
1H, H4, CH=C), 7.13 (d, J = 8.3 Hz, 2H, H11,15, CH=C), 6.99 (d, J = 8.8 Hz, 1H, H5, 
CH=C), 6.76 (d, J = 8.8 Hz, 2H, H19,21, CH=C), 6.59 (d, J = 8.3 Hz, 2H, H12,14, 
CH=C), 4.38 (dd, J = 8.3 Hz, J = 8.3 Hz, 1H, H35, O-CH2), 4.07 (t, J = 5.4 Hz, 2H, 
H30, O-CH2), 3.94-3.84 (m, 2H, H35,36, CH2-O and CH-CH2O), 3.68 (m, 1H, N-CH2), 
3.09 (ddd, J = 11.7 Hz, J = 11.7 Hz, J = 3.4 Hz, 1H, N-CH2), 3.00 (dd, J = 11.7 Hz, 
J = 3.4 Hz, 1H, N-CH2), 2.88-2.79 (m, 3H, H31, N-CH2 and N-CH2), 2.17 (ddd, 
J = 11.7 Hz, J = 11.7 Hz, J = 3.4 Hz, 1H, N-CH2), 2.07 (dd, J = 10.8 Hz, J = 10.8 Hz, 
1H, N-CH2) 
 
13C-NMR (100MHz, mixture CD3OD/CDCl3): δC = 195.1 (C16), 163.8, 158.6, 
158.4, 152.2, 144.3, 141.6, 136.0, 134.2, 134.1, 133.2 (C18,22), 131.9 and 
129.4 (C25,26,28,29), 131.2, 131.0 (C11,15), 125.5, 123.8 (C4), 121.1, 116.3 (C5), 
116.1 (C12,14), 114.9 (C19,21), 66.7 and 66.5 (C30,35), 57.8, 57.4, 53.9 (C36), 52.7, 41.5 
One quaternary carbon missing 
 
IR: υmax/cm−1 (MeOH/CHCl3): 3287, 2943, 1731, 1595, 1503, 1458, 1383, 1260, 
1167, 1041, 829 
 
MS (ESI): m/z = 641 [M(35Cl)+H]+, 643 [M(37Cl)+H]+ 
HRMS (ESI): calculated for C35H30N2O6S35Cl [M+H]+ 641.1513, found: 641.1511 
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7-(4-Chlorophenyl)-3-[(4-{2-[3-(hydroxymethyl)piperazin-1-yl]ethoxy}phenyl) 
carbonyl]-2-(4-hydroxyphenyl)-1-benzothiophen-6-ol (260) 
 
 
 
To a solution of oxazolidinone 273 (30 mg, 0.047 mmol, 1 eq) in MeOH (0.20 mL) 
was added a 2 N aqueous solution of NaOH (0.20 mL). The reaction mixture was then 
stirred at 80 ºC for 4 h, cooled to room temperature and neutralized by addition of a 
1 M aqueous solution of HCl. The aqueous layer was extracted with EtOAc (× 3) and 
the combined organic extracts were concentrated in vacuo. The residue was dry 
loaded on silica gel and purified by flash column chromatography (CH2Cl2/MeOH 
90:10 to 86:14 + 0.25% NH4OH) to yield amino alcohol 260 as an amorphous yellow 
solid (25 mg, 87%). 
 
1H-NMR (400MHz, CD3OD): δH = 7.69 (d, J = 8.8 Hz, 2H, H18,22, CH=C), 7.58 and 
7.47 (2 × d, J = 8.8 Hz, 4H, H25,26,28,29, CH=C), 7.39 (d, J = 8.8 Hz, 1H, H4, CH=C), 
7.12 (d, J = 8.8 Hz, 2H, H11,15, CH=C), 6.99 (d, J = 8.8 Hz, 1H, H5, CH=C), 6.80 (d, 
J = 8.8 Hz, 2H, H19,21, CH=C), 6.59 (d, J = 8.8 Hz, 2H, H12,14, CH=C), 4.09 (t, 
J = 5.5 Hz, 2H, H30, O-CH2), 3.69 (dd, J = 11.7 Hz, J = 4.4 Hz, 1H, H35, CH2-OH), 
3.59 (dd, J = 11.7 Hz, J = 6.4 Hz, 1H, H35, CH2-OH), 3.25-3.18 (m, 2H, H36, CH-
CH2O and N-CH2), 3.09-3.01 (m, 3H, N-CH2), 2.81 (t, J = 5.5 Hz, 2H, H31, O-CH2), 
2.43 (m, 1H, N-CH2), 2.29 (dd, J = 10.8 Hz, J = 10.8 Hz, 1H, N-CH2) 
 
13C-NMR (100MHz, CD3OD): δC = 195.4 (C16), 164.5, 159.3, 152.9, 144.4, 142.0, 
136.8, 134.6, 134.5, 133.6 (C18,22), 132.5 and 129.7 (C25,26,28,29), 131.8, 131.6, 
5
6
7 8
3
4
S
1
2
HO
9 10
15 14
13
1211
OH
23
1617
22
21
20
19
18
O
O
24
25
26
27
28
29
Cl
30
31
N
3736
HN
34
33 32
35
OH
38
	   254	  
131.4 (C11,15), 126.0, 124.2 (C4), 121.7, 116.7 (C5), 116.5 (C12,14), 115.4 (C19,21), 
67.0 (C30), 61.7 (C35), 57.9 (C36), 57.7 (C31), 54.2, 51.7, 44.7 
 
IR: υmax/cm−1 (MeOH): 3320, 2958, 1636, 1600, 1572, 1506, 1385, 1262, 1169, 
1044, 830 
 
MS (ESI): m/z = 615 [M(35Cl)+H]+, 617 [M(37Cl)+H]+ 
LCMS + HRMS (ESI): calculated for C34H32N2O5S35Cl [M+H]+ 615.1720, 
found: 615.1714 
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